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I. INTRODUCTION 
I.1 Chemical and biological significance of oximes 
I.1.1 The chemistry of oximes 
Oximes represent a distinct group of organic compounds that belong to the family of 
imines. They can be described with the formula RR′C=NOH, where R is an organic side-chain 
(alkyl or aryl), and R′ may stand for hydrogen or another organic group so that the compound 
is an aldoxime or a ketoxime, respectively. Further, R′ can appear as an amine, and in that case, 
the moiety is an amidoxime 1,2. As an overview, Fig. 1 illustrates the chemical structures. 
 
Figure 1. Chemical structures of oximes and amidoximes 3. (R=alkyl, aryl) 
 
The synthetic preparation of oximes from their corresponding parent compounds has been 
extensively studied and discussed in the literature 3,4. Amidoximes are typically obtained from 
nitriles using hydroxylamine salt in water or alcohol 5–7. Alternatively, hydrazide imides, 
thioamides, amidines 8, and, in some cases, imino ethers 9 can also be promising reactants for 
their preparation.  
Similarly to amidoximes, the synthesis of ketoximes and aldoximes is typically achieved 
by using a hydroxylamine analog that, in this case, is reacted with an aldehyde or a ketone 10–
12. Following this preparative strategy, oxime or oxime ether analogs of various types of oxo-
function possessing substrates may be conveniently obtained in typically good yields 13,14. 
Besides, the nitrosation of aliphatic molecules 15 or the reduction of nitro compounds 16 can be 
alternatives for the preparation of ketoximes and aldoximes. 
In some instances, oxime synthesis may be carried out under solvent-free conditions 17–
19. However, it is important to note that the wide-scale applicability of these procedures might 
be limited since most reports exclusively involve simple, liquid-state reactants that taken 
together, may question the procedures’ extensibility towards solid-state, complex substrates. 
Oximes are of great importance in the chemical industry and research. As for the former, 
the mass-scale production of ε-caprolactam represents an illustrative example. This derivative 
serves as a precursor in the preparation of nylon-6, and its synthesis commonly relies on the 
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acid-catalyzed Beckmann-rearrangement of cyclohexanone oxime. Importance of the oxime 
substrate may well be illustrated by the fact that, for example, in 2016, the world’s caprolactam 
consumption had reached as much as ca. 5.5 × 106 t 20. This example fits well to a broader 
perspective: oximes and their O-substituted analogs are attractive synthons in the preparation 
of various nitrogen-containing species, including amines, hydroxylamines, amino alcohols, 
nitriles, lactams and 3- to 7-membered ring nitrogen heterocycles 21–23. Thus, in their intact 
form or as synthetic precursors, they indeed find their use among various fields of application. 
It should be noted that oximes can occur in forms of geometric isomers where the 
stereochemical configuration can significantly influence a compound’s chemical, physical, and 
biological properties 24,25. Therefore, a remarkable scientific interest is appearing towards the 
development of regioselective synthetic procedures 26,27, and towards the employment of 
specific chromatographic techniques that can effectively separate the corresponding E/Z-
isomers from their mixtures 28,29. 
I.1.2 Natural occurrence and bioactivities of oximes 
Despite the fact that synthetic analogs spectacularly outnumber them, many natural 
oximes also exist. In plants, oximes are predominantly derivatives of amino acids 30,31. Most 
plant oximes and their typically O-methylated oxime ethers 32 possess relatively simple 
chemical structures, which usually reflect the structure of their precursor amino acids. 
Regarding their physiological role, it appears that they participate in both general and 
specialized plant metabolism, facilitating a set of biochemical processes influencing plant 
growth and development 30,33. 
Besides plants, without attempting to be comprehensive, fungi 34, bacteria 35, marine 
sponges 36–38, and insects (e.g., millipedes (Harpaphe haydeniana)) 39 may also contain natural 
oxime derivatives. Moreover, even some mammals are known to be producing them. 
Interestingly, the sternal gland secretion of male koalas (Phascolarctos cinereus) contains 
volatile nitrile and oxime derivatives 40. This oily gland plays a vital role in koalas’ 
communication and is only produced by males that use it for scent marking on trees within their 
territorial range. Although the composition of the gland reflects versatile information, the 
specific relevance of individual oxime components has not yet been clarified in this regard 41. 
Oximes are therefore widely present in the various Kingdoms of Nature, which might 
indicate a remarkable biological potential of this moiety. In this context, not surprisingly, 
synthetic oximes and oxime ethers are subjects of intensive research, and bioactive analogs are 
utilized for various purposes. Just to mention a few examples, synthetic oxime derivatives are 
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widely used in the agricultural sector as plant growth regulators 42, insecticides (e. g. Aldicarb) 
43, herbicides 44, fungicides 45 or even anti-viral agents 46,47. Besides, oximes are highly 
important for the health sector as well. Previously, derivatives such as pralidoxime 48, 
obidoxime, HI-6, or TMB-4 became well-known nerve agent antidotes available for clinical 
use 49,50. Most recently, the first-in-class luso-inotropic steroid istaroxime has been granted Fast 
Track Designation by the FDA 51, and by the time of writing this Ph.D. thesis, it is undergoing 
a phase II clinical trial for the treatment of for acute decompensated heart failure with persistent 
hypotension 52. Besides, there is much evidence on various oxime derivatives exerting e. g. 
antitumor 53, antioxidant 54, anti-inflammatory 55 or antibacterial 56 properties. 
We have valuable examples available on the bioactivities of natural oximes too. Alkaloids 
derived from marine sponges (e. g. from species of the Agelas genus) are potent inhibitors of 
molecular fouling organisms 57. Furthermore, derivatives from the corticioid fungi 
Boreostereum vibrans, including the first natural oxime esters isolated, were reported to exert 
pancreatic lipase inhibitory activity and to exhibit cytotoxicity against various human cancer 
cell lines with IC50 values comparable to that of cisplatin 
58.  
I.2 ECDYSTEROIDS 
I.2.1 Chemistry and occurrence in nature 
In this present Ph.D. research work, we selected our substrates for semi-synthetic 
transformations among the derivatives of two bioactive compound families containing an enone 
moiety in their structure, such as ecdysteroids and protoflavonoids. Among these, ecdysteroids 
represent a unique group of steroids, extensively studied for their versatile chemical and 
biological properties. Our research group has long been studying the chemistry and 
pharmacology of natural and semi-synthetic ecdysteroid derivatives 59–64. 
Ecdysteroids are best known as hormones regulating the molting and metamorphosis of 
arthropods 65. They were discovered rather late, in 1954, by german chemists Karlson and 
Butenandt, who successfully isolated α-ecdysone (now commonly referred to as ecdysone) 
from silkworm pupae 66. Subsequently, the search for bioactive compounds in Podocarpus 
nakaii had led to the discovery of 3 novel analogs, ponasterone A, B, and C, which revealed the 
existence of the so-called phytoecdysteroids 67. Subsequent intensive research on these 
compounds in the Plant Kingdom resulted in the discovery of a wide diversity of novel 
structures so that currently, 517 natural ecdysteroids are registered in the continuously updated 
online ecdysteroid database  68. Research efforts had also revealed that certain derivatives could 
occur both in flora and fauna, and in general, plants appear to contain these compounds in 
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several orders of magnitude higher amounts than arthropods 69,70. In this regard, the insect 
hormone 20-hydroxyecdysone (1; 20E; β-ecdysone) was found in the vast majority of 
ecdysteroid-containing plants, and it typically also dominates these plants’ ecdysteroid 
composition. 20E is therefore by far the most abundant natural ecdysteroid 60 (Figure 2). 
 
 
Figure 2. Chemical structure of 20E (1) with carbon atom numbering indicated. 
 
Regarding structural properties, ecdysteroids are biosynthesized from cholesterol and 
thus, most derivatives possess a skeleton that contains 27-29 carbon atoms. Besides, C19-C24 
derivatives also exist (e.g., poststerone, rubrosterone), probably as products of sterol side-chain 
cleavage. A common structural feature of ecdysteroids is the 7-en-6-one chromophore moiety 
in the B-ring, responsible for their UV absorption with λmax at ca. 243 nm in methanol. Most 
ecdysteroids are relatively hydrophilic compounds due to the 3-8 hydroxyl groups in their 
structure, predominantly at positions C-2β, C-3β, C-14α, C-20R, and C-22R. Each ecdysteroids 
contain β-orientated methyl groups at C-10 and C-13. Junctions of rings A and B are commonly 
cis, while junctions of C and D rings are generally trans 71. 
I.2.2 Pharmacological effects and possible uses 
Ecdysteroids exert strong hormonal effects on insects. However, their use as 
environmentally sound insecticides has not so far been successful, mostly due to their relatively 
high polarity that prevents absorption through the insect cuticle. Above their effect on insects, 
it is of interest that ecdysteroids also exert a number of bioactivities in mammals, including 
humans 72. The effect of ecdysteroids in mammals greatly differs from that on insects. In 
mammals, that apparently lack a dedicated ecdysteroid receptor, these compounds display an 
almost negligible acute toxicity, and their effect is generally considered mild 73. 
During this Ph.D. work, we focused on the preparation and investigation of potentially 
antitumor, chemo-sensitizing derivatives, therefore, after a brief summary of the most 
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fundamental bioactivities of these compounds, their antitumor effects and related structure-
activity relationships will be presented more in detail (section I.2.3). 
Anabolic effect. Ecdysteroids exert a non-hormonal anabolic activity, which has been 
compared by several authors to that of anabolic steroids. In this regard, certain 
phytoecdysteroids were shown to increase protein synthesis in skeletal muscle cells 74, and pure 
20E treatment (5 mg/kg body weight) was demonstrated to enhance the muscle fiber size in 
either the normal and regenerating muscles of male Wistar rats 59,75. All literature reports 
underline that ecdysteroids’ are free from the adverse effects of androgenic steroids. Although 
there had been only a few human trials on low numbers of volunteers 73,76, this led to the 
blooming of an unregulated worldwide market of ecdysteroid-containing dietary supplements 
73,77. Considering that they indeed seem to influence sports performance 76, in 2019, the World 
Anti-Doping Agency (WADA) added ecdysteroid-containing substances to the 2020 list of 
monitored agents 78. 
Adaptogenic effect. Extracts of certain ecdysteroid-containing plant species (Tinospora 
cordifolia, Leuzea carthamoides, Achyranthes aspera) are reported to exert adaptogenic 
activity, i.e., the ability to assist non-specific stress-response. These properties have long been 
recognized by various systems of traditional medicine wherein parts of these plants are used as 
ingredients to prepare medicinal consumables. Although the observations are typically 
associated with the plants’ ecdysteroid-content, a proper scientific confirmation is still not 
available in this regard 79.  
Antidiabetic activity. In traditional medicine, certain ecdysteroid-containing plant 
species (e. g. Ajuga iva) are processed to prepare antidiabetics from their extracts. Considering 
this, ecdysteroid content in these species were examined for their effects on the glucose 
metabolism of mammals. 20E (1) was found active from various aspects. On rodent in vivo 
models, pure 20E (1) could reduce hyperglycemia and could enhance glucose utilization by 
tissues 59,72. Additionally, 20E (1) treatment was found to decrease gluconeogenesis and could 
induce the Akt2 phosphorylation of H4IIE cells. Furthermore, upon fed to high-fat diet mice, it 
could decrease the body weight gain and body fat mass of the animals 80. 
Further bioactivities Beyond the highlighted features and the anticancer activities 
described in section I.2.3., ecdysteroids have been reported to exert various other bioactivities 
59. In this regard, their possible multi-purpose dermatological use seems particularly promising, 
considering the several patents on the use of ecdysteroid-containing formulations to prevent 
hair-loss or to stimulate cell defense mechanisms against UV-irradiation 81,82. 
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I.2.3 Anticancer activities 
Since the discovery of ecdysteroids, numerous papers were published on their potential 
anticancer activities, although, more concordant data are only available since the 1990s 83.  
During this decade, seven polyporusterone analogs were isolated from the fruit body of the 
fungus Polyporus umbellatus which showed dose-dependent, moderate to weak (IC50 ca. 30–
100 µM) cytotoxicity on leukemia cells 84. Furthermore, certain ecdysteroid derivatives (e. g., 
cyasterone) were found to have the potential to inhibit the Epstein−Barr virus early antigen 
induction (EBV-EA) by the tumor promoter 85. However, the slowly unfolding picture of their 
possible antitumor effect was somewhat nuanced by the fact that muristerone A and 
ponasterone A showed anti-apoptotic effects on colon tumors 86. 
Following these studies, our research group made a significant contribution to the field 
by discovering the potential of less polar ecdysteroids to sensitize cancer cells to 
chemotherapeutics (i.e., “chemo-sensitizing” activity) 87. This activity of particularly 
ecdysteroid diacetonides was confirmed in combination with various chemotherapeutic agents, 
both on multi-drug resistant (MDR) and drug-susceptible cancer cells, with notably higher 
selectivity towards the former 88,89. This MDR selectivity, i.e., potent sensitizing activity on 
ABCB1 transporter (P-glycoprotein; P-gp) over-expressing cell lines, is an interesting aspect 
of the bioactivity of these compounds because they were found only rather mild inhibitors of 
the efflux pump. Through the preparation and bioactivity testing of over a hundred derivatives, 
we have identified numerous structure-activity relationships (SARs); the most important are 
summarized in Fig. 3.  
 
 
Figure 3. SARs of ecdysteroids’ chemo-sensitization illustrated on a 20E 2,3;20,22-dioxolane 
analog 90.  
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Considering the characteristics displayed, the followings should be highlighted: 1) 
introduction of apolar substituents (e. g. acetonides) on the ecdysteroid diols, particularly on 
the 2,3-moiety, is required for chemo-sensitization 90,  and 2) direct inhibitory effect on drug 
efflux by P-gp, that may be considered as a disadvantageous side-effect of these compounds, 
can be eliminated by the oxidative cleavage of the sterol side-chain 89. 
Besides the above, the antitumor properties of an ecdysteroid may significantly be 
modified by introducing heteroatoms to its chemical backbone. In this regard, we observed 
notable differences in the pharmacological response of the parental 20E 2,3;20,22-diacetonide 
and its synthetically prepared difluorinated analog. Fluor-substitution at the C-14 and C-25 
positions increased P-gp inhibition, as well as the strength of synergism with doxorubicin  both 
on the P-gp-transfected MDR cell line and on its non-MDR counterpart 91.  
In the context of the first two sections (I.1.1 and I.1.2) of the introduction, the carbonyl 
moiety/moieties at C-6 and, in some side-chain shortened derivatives, at C-20 of ecdysteroids 
allows simple semi-synthetic preparation of their oxime analogs. Previously, Galyautdinov et 
al. reported the synthesis of some ecdysteroid oximes; however, to the best of our knowledge, 
no pharmacological studies were so far performed on such derivatives 92. 
I.3 Nano-formulation through self-assembling pro-drug conjugates 
Very frequently, in vitro antitumor activity on cell cultures cannot be translated to in vivo 
efficacy. The reason is often related to pharmacokinetic limitations that may simply prevent the 
agent from reaching the site of action at a minimum required concentration. Nowadays, 
medicinal nanotechnology provides several solutions to overcome this obstacle, among which 
the synthesis of self-assembling drug conjugates represents a simple, yet efficient approach 93.  
In the previous section, we have shown that the presence of the 2,3-acetonide function on 
an ecdysteroid is necessary for the antitumor effect; however, unfortunately, this moiety is one 
of the chemically most sensitive part of these molecules, especially in an acidic environment. 
Therefore, the idea of obtaining the self-assembling bioconjugates of an antitumor ecdysteroid 
can not only serve as a relevant targeting strategy to improve the in vivo pharmacokinetic 
properties of the drug but might contribute to the chemical stability of these molecules as well, 
e.g., by ensuring that the 2,3-acetonide pharmacophore remains intact in the intravenous matrix. 
I.3.1 The theory of using self-assembling drug conjugates in anticancer treatment 
In the course of this Ph.D. study, we utilized a variation of this technique that used 
squalene for nano-formulation to obtain the drug conjugates and, subsequently, the 
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corresponding self-assembled nanoparticles (NPs) of an antitumor ecdysteroid oxime. 
Therefore, in the current section, we aim to give a brief overview on the theoretical background 
of the methodology, while in section I.3.2, we will focus exclusively on the introduction of 
squalene-based bioconjugates. 
The phrase “self-assembly” represents a spontaneously occurring process mediated by 
secondary intermolecular interactions (e. g., hydrophobic, van der Waals interactions) that 
results in the formation of an ordered nanostructure from molecular building blocks. Although 
numerous procedures exist to prepare self-assembled NPs, amphiphilicity of the substrates is 
usually a crucial factor that determines the chemical and pharmacological properties of the 
supramolecular products 93,94. 
Self-assembling drug conjugates may be prepared through the covalent coupling of two 
functional units: a (chemo)therapeutic agent and a biocompatible lipid moiety that acts as the 
inducer of self-assembly. In some cases, the linkage of these molecular units through a so-called 
linker function may further improve the in vivo release of the drug 95.  In general, the related 
synthetic procedure consists of the formation of chemical bonds that are hydrolyzable in a 
biological environment (e. g., esters), while for this reason, NPs obtained from drug conjugates, 
once administered into the organism, will typically act as pro-drugs 96.  
The drug delivery mechanism of NPs usually differs from that of molecular agents, and 
supramolecular structural attributes typically result in improved tumor-targeting properties for 
NPs in either a direct or indirect way (e. g., by taking advantage of the Enhanced Permeability 
and Retention or rather EPR effect 97). Moreover, it is important to note that by the proper nano-
formulation of the drug, we might have the ability to influence its physicochemical properties, 
including its chemical stability or solubility in a favorable way. Such parameters can be well 
predicted employing colloid chemical characterization, wherein the mean diameter and the 
surface charge are of decisive importance in the further fate of nano assemblies 98. 
I.3.2 Self-assembling drug conjugates of squalene 
Numerous self-assembly inducers exist that can form stable nanoparticles in serum 
without the need to use any additional surfactants. Among the substances available for the 
purpose, squalene is a subject of remarkable scientific interest 93. This triterpene is mostly 
known as a precursor in the cholesterol biosynthesis, which as a natural lipid, occurs in a wide 
range of organisms, including that of humans 99,100. 
The idea of using squalene as a self-assembly inducer relies on its biocompatibility and 
relative inertness that, altogether, make this compound an attractive synthon for the preparation 
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of bioconjugates. Although squalene is devoid of a proper anchor point for the chemical linkage 
of a drug, its terminal double-bond can be easily and regioselectively converted to a variety of 
functional groups that can later serve this purpose. In this regard, a typical synthetic procedure 
starts with the conversion of squalene to 1,1′,2-trisnorsqualene aldehyde that, as a key 
intermediate, can be further transformed into alcohol, amine or carboxylic acid, according to 
the task. The general overview of this preparative strategy is depicted in Fig. 4 99,101. 
 
Figure 4. Schematic overview of the possible synthetic functionalization of squalene to obtain 
analogs possessing different terminal functional groups 99. 
NPs of squalene bioconjugates can be conveniently prepared by nanoprecipitation in an 
aqueous medium. It was recently demonstrated that following intravenous administration, these 
particles do not remain intact in the bloodstream but get dissolved by lipoproteins, particularly 
low-density lipoproteins (LDL) in humans that will transport them, and this allows targeting 
cancer cells displaying high expression and activity of LDL receptors 102. Although the method 
represents a relatively new platform for drug delivery, the technique's efficacy had already been 
successfully demonstrated with versatile bioactive molecules, including anticancer agents 103, 
antibiotics 104, and neuroprotective compounds 105. 
I.4 PROTOFLAVONOIDS   
I.4.1 Chemistry and occurrence in nature 
In this Ph.D. study, besides ecdysteroids, the second substrate group of our investigation 
was the protoflavonoids. The chemical and biological diversity of these compounds have been 
previously reviewed by our research group 106. 
Briefly, protoflavonoids represent a unique, naturally occurring group of flavonoids, 
possessing a non-aromatic B-ring and a hydroxyl moiety at C-1ʹ. According to their widely 
accepted nomenclature, their trivial names are derived from the corresponding 4ʹ-
hydroxyflavones, wherein the addition of “proto-” prefix indicates the presence of the 4ʹ-
hydroxyl group, while the use of “-one” ending represents that the moiety is oxidized to an oxo 
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group. The protoflavone B-ring can appear in various forms; it may be a symmetric dienone p-
quinol that may be partially or fully saturated, as illustrated by some examples of natural 
derivatives in Fig. 5 106. 
Up to now, the natural occurrence of protoflavones was found almost exclusively in 
certain genera of ferns 107 though their 2,3-saturated structural analogs, such as protoflavanones, 
were found in other plants as well (Piper carniconnectivum 108, Ongokea gore 109). Their 
biosynthesis was suggested to take place through the oxidation of 4ʹ-hydroxyflavones. 
Subsequently, these already non-aromatic derivatives can be reduced to analogs with differently 
saturated B-rings whose 4ʹ-oxo groups may also be reduced to a 4ʹ-OH group 106.  
 
Figure 5. Selected examples of natural protoflavones with different levels of saturation in 
their B-ring. Trivial names of the compounds shown are a) protoapigenone, b) 
protogenkwanine, c) 5’,6’-dihydroprotogenkwanin, d) tetrahydroprotoapigenone. 
I.4.2 Bioactivities of protoflavonoids 
Protoflavones are bioactive compounds, and many analogs are known for their potent 
anticancer effect that is currently by far their most deeply investigated pharmacological 
property. Numerous derivatives showed strong cytotoxicity on a wide range of cancer cell lines, 
while many can selectively kill certain types of resistant cancer cells that had been adapted to 
chemotherapeutics 110,111. Up to now, the most extensively studied protoflavone is the oxidized 
analog of apigenin, protoapigenone (Figure 5, a). This compound was identified as a potent 
antitumor agent on various in vitro and in vivo tumor models 112–116. Concerning the mechanism 
of action, there are several pharmacological pathways reported to be involved in the antitumor 
activity. It appears that the symmetric dienone p-quinol structure that is required for a potent 
antitumor action, allows these compounds to participate in redox reactions that induce oxidative 
stress within the cancer cells through the generation of reactive oxygen species (ROS) 117,118. 
Additionally, protoapigenone interferes with crucial DNA-damage response mechanisms by 
inhibiting the ataxia-telangiectasia and Rad3-related protein (ATR)-dependent phosphorylation 
of checkpoint kinase 1, which confers this compound a chemo-sensitizing property towards 
DNA-damaging chemotherapeutics, such as cisplatin 119. This mechanism is of high interest 
since ATR has become an emerging antitumor target, and several related clinical studies are 
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currently ongoing 120. 
Besides the above, there are some pieces of evidence suggesting that the possible use of 
protoflavones might exceed their antitumor potential. In this regard, our group identified 
protoapigenone 1ʹ-O-propargyl ether as the first non-planar flavonoid to express high inhibitory 
activity on xanthine oxidase (XO), the key enzyme in the development of gout 121. Also, 
protoapigenone was shown to exert antiviral activity on Epstein-Barr virus by inhibiting the 
expression of lytic proteins, hence preventing the proliferation of the virus 122. These suggest 
that the unique 3D structure of protoflavones among flavonoids, that is a direct consequence of 
the sp3 configuration of C-2, may result in a versatile pharmacology of this compound class. 
However, any attempts to explore this are seriously limited by the potent cytotoxicity of the p-
quinol dienone pharmacophore. 
I.4.3 Synthetic preparation and SARs of protoflavonoids 
Over the years, total- 123 and semi-synthetic 114 procedures were developed to obtain 
protoflavones as potent bioactive analogs of protoapigenone, and this enabled their preparation 
in large quantities and contributed to the exploration of their pharmacological properties, 
predominantly concerning their anticancer activities. 
During the course of previous studies on protoflavonoids, it was found that, 1) the 
presence of a symmetric non-substituted dienone p-quinol in the B-ring is crucial for a strong 
cytotoxic effect 124, 2) the observed activity can be further increased through the introduction 
of a non-branching, alkyl side-chain of 3 or 4 carbon atoms at the 1ʹ-OH or 3) significantly 
decreased through the addition of a branching (e. g. isopropyl) substituent at the same position 
114. It is important to note that the presence of 1’-OH alkyl substituents can significantly 
improve the chemical stability of the B-ring over that of the non-substituted p-quinol 114. 
As discussed above, protoflavones may also exert bioactivities that are not related to 
cancer. Protoapigenone 1ʹ-O-propargyl ether, a synthetic analog with potent XO-inhibitory 
activity, is a good example to this, even though this compound is also cytotoxic, therefore it 
would likely not be applicable as a therapeutic XO inhibitor. This justifies semi-synthetic 
strategies that point towards possibly decreased cytotoxicity. In this regard, the regioselective 
preparation of protoflavone oximes on the carbonyl group of their B-ring was an attractive 
strategy to obtain new, potentially bioactive compounds; prior to this Ph.D. study, no such 
derivatives have been reported.  
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II. OBJECTIVES 
 Oximes and their derivatives have remarkable significance both in chemistry and 
biology. Our scientific interest has recently turned towards the semi-synthetic preparation and 
investigation of such compounds from the derivatives of two, naturally occurring, bioactive 
compound groups, ecdysteroids and protoflavonoids. In this context, the primary aim of this 
Ph.D. study was to further extend the chemical diversity of these unique compound classes 
through the semi-synthetic preparation of new bioactive analogs, and to investigate the 
relevance of the oxime moiety in their chemical and pharmacological space. Therefore, we 
established the following objectives for this work. 
ECDYSTEROIDS 
1. Preparation of oxime derivatives from antitumor ecdysteroids. We aimed to transform 
20E 2,3;20,22-diacetonide into its corresponding 6-oximes and oxime ethers, and subsequently 
to prepare lactam derivatives from the obtained oximes through Beckmann-rearrangement. 
Additionally, to further increase the chemical diversity of the products, we planned to subject 
a second substrate, poststerone 2,3-acetonide for oximation at its 20-carbonyl moiety. 
2. The preparation of self-assembled NPs from an ecdysteroid oxime. We planned to select 
one of our synthetically obtained ecdysteroid derivatives possessing advantageous chemical 
and/or biological properties to prepare squalenoylated pro-drug nanoparticles. 
3. Biological evaluation of the semi-synthetic ecdysteroids. The synthesized products were 
planned to be investigated for their in vitro anticancer properties in research collaborations. 
PROTOFLAVONOIDS 
4. Preparation of B-ring modified protoflavone derivatives including oximes. For the aim 
to extend the chemical–pharmacological space of protoflavones towards non-cytotoxic 
derivatives, we planned to prepare semi-synthetic analogs of protoapigenone. To achieve this, 
we aimed to perform the flow chemical hydrogenation or deuteration of the B-ring, and/or the 
preparation of 4ʹ-oxime derivatives. 
5. Biological evaluation of the synthetically obtained protoflavones. We aimed to study the 
pharmacological properties of the obtained protoflavones from various perspectives within the 
frameworks of scientific research co-operations. We planned to investigate the compounds’ 
cytotoxic, ATR inhibitory and antiviral (anti-human immunodeficiency viral (anti-HIV) and 
anti-EBV) activities. 
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III. MATERIALS AND METHODS 
Solvents and reagents were purchased from Sigma (Merck KGaA, Darmstadt, Germany) 
and were used without any further purification. The applied chromatographic instruments and 
columns are summarized in Table 1. 
Table 1. Functional build-up of chromatographic instruments applied for different purposes 
during the course of this Ph.D. work. 
Instrument Functional units 
Flash chromatograph 
(Teledyne ISCO, Lincoln, NE, 
USA; preparative purposes) 
Combiflash Rf+ instrument equipped with diode array 
and evaporative light scattering detection (DAD‐ELSD). 
We used it with commercially available prefilled 
“RediSep” columns. 
HPLC instrument used for 
analytical purposes 
(Jasco, Hachioji, Tokyo, Japan) 
A dual-pump Jasco HPLC instrument equipped with an 
“MD-2010 Plus” PDA detector. Columns: Phenomenex 
(Torrence, CA, USA) 250 x 4.6 mm 5 µm stationary 
phases (C18, C8) 
HPLC instrument used for 
semi-prep. purposes 
(Agilent Inc., Santa Clara, CA, 
USA) 
Agilent “1100 series” pump attached with a Jasco “UV-
2070 Plus” single-wavelength UV detector. Columns: 
Phenomenex 250 x 10 mm 5 µm stationary phases (C18, 
C8) 
HPLC instrument used for 
preparative purposes 
(Gilson Inc., Middleton , WI, USA) 
Armen “Spot Prep II -250” preparative chromatographic 
system equipped with four individual solvent pumps and 
a dual-wavelength UV detector. Columns: Phenomenex 
250 x 21.2 mm 5 µm stationary phases (C18, C8) 
III.1 ECDYSTEROIDS 
III.1.1 Source of natural ecdysteroids 1 and 2, later used as substrates in synthesis 
III.1.1.1 Natural ecdysteroid 1 readily available from a commercial source 
20-hydroxyecdysone (20E, 1) was purchased from Shaanxi KingSci Biotechnology Co., 
Ltd (China) in a purity of 90%. By applying recrystallization from ethyl acetate – methanol 
(2:1, v/v), we afforded 20E (1) in an RP-HPLC purity of 97.8%. 
III.1.1.2 Preparation of poststerone (2) via oxidative side-chain cleavage 
An aliquot of 1 g of 20E (1) was dissolved in 80 ml of methanol. One molar equivalent 
of PIDA was added, and the solution was stirred for 45 minutes at RT. Following this, the 
reaction mixture was neutralized with 5% aq. NaHCO3-solution and then, the solvent was 
evaporated under reduced pressure on a rotary evaporator. The products’ dry residue was re-
dissolved in methanol and silica gel (~6 g) was added to the solution. The solvent was 
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evaporated to prepare the sample for dry loading flash chromatographic separation that 
eventually yielded pure poststerone (2) (0.55 g, 72.9%; for details of chromatographic 
purification, see Table 2). 
Table 2. List of chromatographic methods that were utilized for the purification of the prepared 
ecdysteroids and squalene analogs discussed in relation to this dissertation. “X g silica (plain) / 
C18” columns refer to commercially available “RediSep” (Teledyne ISCO, USA) flash 
chromatographic columns; “XB-C18”: Kinetex 5 µm XB-C18 100A 250 x 21.2 mm HPLC 
column (Phenomenex Inc, USA); “XDB-C8”: Agilent Eclipse Zorbax 5 µm XDB-C8 250 x 9.4 
mm HPLC column (Agilent Technologies, USA). In each case, the yield refers to the isolated 
yield% of the pure (HPLC peak area% ≥ 95 at the λmax, or at the PDA chromatogram recorded 
between 210-410 nm) compound. Numbers depicted as “(x)” indicate the corresponding step of 
the chromatographic purification. All solvent ratios refer to v/v. 
cpd. x (yield) column flow rate purification detection 
2 (72.9%) 80 g silica 60 ml/min 
CH2Cl2 : CH3OH 
85:15 (40 min) 
254 nm 
3 (51%) 80 g silica 60 ml/min 
CH2Cl2 : CH3OH (A:B) 
03% B (60 min) 
254 nm 
4 (71%) 80 g silica 60 ml/min 
CH2Cl2 : CH3OH (A:B) 
03% B (60 min) 
254 nm 
5 (31%), 
6 (38%) 
XB-C18 15 ml/min 53% aq. CH3CN 254 nm 
7 (28.3%), 
13 (43.3%) 
4 g silica 18 ml/min 
CH2Cl2 : CH3OH (A: B) 
45100% B (35 min) 
254 nm 
8 (15.2%), 
9 (2.8%), 
14 (33.3%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) CH2Cl2 : CH3OH (A:B) 
45100% B (35 min) 
(2) 75% aq. CH3CN 
254 nm 
10 (15.5%), 
11 (1.6%), 
15 (2%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) CH2Cl2 : CH3OH (A:B) 
35100% B (40 min) 
(2) 77% aq. CH3CN 
254 nm 
12 (38.9%), 
16 (8.3%), 
17 (2.5%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) CH2Cl2 : CH3OH (A:B) 
10100% B (45 min); 100% B 
(2) 80% aq. CH3CN 
254 nm 
18 (8%) XB-C18 15 ml/min 75% aq. CH3OH 254 nm 
19 (69.7%) XDB-C8 3 ml/min 35% aq. CH3CN 243 nm 
20 (12%) 30 g C18 35 ml/min 
water : CH3CN (A:B) 
4055% B (45 min) 
254 nm 
21a (71%) 80 g silica 60 ml/min 
n-hexane : CH2Cl2 (A:B) 
50% B 
210 nm, 
254 nm 
22 (25%) 24 g silica 35 ml/min 
n-hexane : EtOAc (A:B) 
3.55% B (60 min) 
210 nm, 
254 nm 
23 (62%) 
24 (65%) 
24 g silica 35 ml/min 
n-hexane : EtOAc (A:B) 
525% B (60 min) 
210 nm, 
254 nm 
25 (73%) 
26 (76%) 
4 g silica 18 ml/min 
n-hexane : EtOAc (A:B) 
25% B 
210 nm, 
254 nm 
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III.1.2 Preparation of ecdysteroid acetonides 3 and 4 as starting materials for further 
transformations 
Acetonide formation of ecdysteroids 1 and 2 was performed by dissolving 10 g of the 
corresponding substrate in acetone, in a concentration of 1 g/100 ml (1000 ml). To this solution, 
10 g of phosphomolybdic acid was added, and the mixture was stirred or sonicated for 20 
minutes at RT. Following this, the mixture was neutralized with 10% aq. NaHCO3-solution and 
then, acetone was evaporated on a rotary evaporator. Products were extracted from their 
aqueous residue using ethyl acetate (3 x 100 ml), and the collected organic fractions were 
combined and dried over Na2SO4. The solution was then filtered, and the solvent was 
evaporated under reduced pressure. The obtained residue was subjected to flash 
chromatographic purification (see Table 2) that afforded 20E 2,3;20,22-diacetonide 3 (5.95 g, 
51%), or poststerone 2,3-acetonide 4, (7.88 g, 71%). 
III.1.3 Preparation of oxime, oxime ether and lactam derivatives from ecdysteroid 
acetonides [I, II] [1] 
III.1.3.1 Synthesis of 6-oxime derivatives 5-6 from 20E 2,3;20,22-diacetonide [I] 
A 1 g aliquot of compound 3 (1.78 mmol) was dissolved in 10 ml of pyridine, and 1 g of 
hydroxylamine hydrochloride was added to the solution. The mixture was stirred at 70 °C for 
three days. Following this, pyridine was evaporated on a rotary evaporator, water (50 ml) was 
added to the dry residue, and extraction was carried out using ethyl acetate (3 x 50 ml). The 
collected organic fractions were combined and dried over Na2SO4. Subsequently, the solution 
was filtered and evaporated to dryness under reduced pressure. Purification of products was 
carried out by means of preparative RP-HPLC (see Table 2) to obtain ecdysteroid (6E)-oxime 
5 (0.31 g, 31%) and (6Z)-oxime 6 (0.38 g, 38%) as pure, amorphous, white solids. 
III.1.3.2 Synthesis of 6-oxime ether derivatives 7-17 from 20E 2,3;20,22-diacetonide [I] 
A 200 mg aliquot of 20E 2,3;20,22-diacetonide (3, 0.35 mmol) was dissolved in 8 ml of 
pyridine and 200 mg of the alkoxyamine hydrochloride corresponding to the target oxime ether 
was added. The reaction was stirred at 70 °C for 24 hours, and subsequently, it was cooled to 0 
°C and neutralized with a methanolic solution of KOH. After this, the solvent was evaporated 
on a rotary evaporator, water (50 ml) was added to the dry residue, and extraction was 
performed with ethyl acetate (3 x 50 ml). All organic fractions were combined, dried over 
Na2SO4, and filtered. Then, the solution was evaporated on a rotary evaporator, and the residue 
[1] Reference to own publication related to the thesis 
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was subjected to flash chromatography to obtain oxime ether isomer mixtures, and subsequent 
semi-preparative RP-HPLC (see Table 2) to afford pure isomers 7-17. 
III.1.3.3 Synthesis of ecdysteroid lactam 18 from compound 5 [I] 
A 150 mg aliquot of ecdysteroid oxime 5 (0.27 mmol) was dissolved in 10 ml of acetone. 
Then, 29 mg Na2CO3 (0.27 mmol, 1 equiv.) and 104.3 mg of p-toluenesulfonyl chloride (TsCl, 
0.54 mmol, 2 equiv.) were added to the solution, and the mixture was stirred for 6 hours at RT. 
Following this, the solution was cooled to 0 °C, water (50 ml) was added under stirring, and 
extraction was performed using ethyl acetate (3 x 50 ml). The collected organic fractions were 
combined, dried over Na2SO4, and filtered. Then, the solvent was evaporated under reduced 
pressure, and the residue was purified by preparative RP-HPLC (see Table 2) to afford 
ecdysteroid lactam 18 (11 mg, 8%). 
III.1.3.4 Synthesis of (20E)-oxime derivative 19 from poststerone 2,3-acetonide [II] 
A 42.2 mg (0.10 mmol) aliquot of compound 4 was dissolved in 5 ml of pyridine. Then, 
10.9 mg (0.16 mmol; 1.5 equiv.) of hydroxylamine hydrochloride was added, and the reaction 
was stirred for 25 minutes at RT. Subsequently, the mixture was cooled to 0 °C, and neutralized 
with an ethyl alcoholic solution of KOH (8.8 mg; 0.16 mmol). The solution was evaporated 
under reduced pressure, water (30 ml) was added to its dry residue, and the products were 
extracted with ethyl acetate (4 x 30 ml). The collected organic fractions were combined, dried 
over Na2SO4, and filtered. Then, the solution was evaporated to dryness on a rotary evaporator, 
and the residue was purified by preparative RP-HPLC (see Table 2) to afford poststerone 2,3-
acetonide (20E)-oxime (19, 30.7 mg, 69.7%). 
III.1.3.5 Synthesis of (20E/Z)-oxime ether isomeric mixture 20 from substrate 4 [II] 
A 300 mg (0.745 mmol) aliquot of compound 4 was dissolved in 6 ml of freshly distilled 
pyridine. Methoxyamine hydrochloride (186.7 mg, 2.235 mmol, 3 equiv.) was added to the 
solution, which was then stirred at 70 °C for 5.5 hr. Following this, the reaction mixture was 
cooled to 0 °C, and it was neutralized by KOH (125.4 mg; 2.235 mmol) dissolved in 5 ml of 
anhydrous ethanol. Then, the solvent was evaporated under reduced pressure, water (40 ml) 
was added to the residue, and extraction was performed with ethyl acetate (4 × 40 ml). The 
organic fractions were combined, dried over Na2SO4, and filtered. The solution was evaporated 
under reduced pressure, and the residue was purified by flash chromatography (see Table 2) to 
afford a mixture of (E/Z)‐isomers of 20-O-methyl oxime ether (20) in a combined yield of 12% 
(38.6 mg) at a 95:5 ratio (E and Z, respectively). 
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III.1.4 Investigation of self-assembled ecdysteroid nanoparticles of compound 19 [II, III] 
III.1.4.1 Preparation of 1,1’,2-tris-norsqualene alcohol 22 from squalene 
Functionalization of squalene (21) to obtain 1,1ʹ,2-tris-norsqualene alcohol (22) was 
carried out in 4 synthetic steps, as follows. 
(1) An aliquot of 10 g of squalene (24.3 mmol) was dissolved in 70 ml of tetrahydrofuran 
(THF). Water (20 ml) was added dropwise under magnetic stirring to the solution, followed by 
a further 30 ml of THF. Subsequently, N-bromosuccinimide (NBS; 5.20 g, 29.2 mmol) was 
added to the solution in small portions, and the reaction mixture was stirred for 3 hours at RT. 
Following this, THF was evaporated on a rotary evaporator, and the aqueous residue was diluted 
with brine (35 ml) and extracted with ethyl acetate (5 x 50 ml). The combined solution of the 
organic fractions was dried over Na2SO4, filtered, and the solvent was evaporated under reduced 
pressure. The oily residue was purified by flash chromatography (see Table 2) to afford 2-
hydroxy-3-bromosqualene (21a) in a yield of 27% (3.34 g). 
(2) To a solution of compound 21a (3.34 g, 6.58 mmol) in methanol (120 ml), K2CO3 (1.82 
g, 13.16 mmol; 2 equiv.) was added, and the reaction mixture was stirred for two hours at RT. 
Subsequently, the solvent was evaporated under reduced pressure, water (50 ml) was added to 
the oily residue, and the products were extracted with ethyl acetate (4 x 50 ml). The combined 
organic fractions were dried over Na2SO4, filtered, and the solvent was evaporated on a rotary 
evaporator to afford 2,3-oxidosqualene (21b) in a yield of 97% (2.72 g) without further 
purification. 
(3) To a solution of compound 21b (2.72 g, 6.38 mmol) in dioxane (30 ml) an aqueous 
solution (20 ml) of H5IO6 (11.48 mmol; 1,8 equiv.) was added under stirring. The reaction 
mixture was stirred for two hours at RT. Subsequently, the solution was evaporated on a rotary 
evaporator, water (50 ml) was added to the oily residue, and the products were extracted with 
ethyl acetate (4 x 50 ml). The collected organic fractions were combined and dried over Na2SO4. 
Later, the solution was filtered, and the solvent was evaporated on a rotary evaporator that 
afforded 1,1′,2-tris-norsqualene aldehyde (21c) in a yield of 79% (1.94 g) without any further 
purification. 
(4) To a solution of 21c (1.94 g, 5 mmol) in methanol (100 ml), NaBH4 (0.094 g, 2.5 mmol; 
0.5 equiv.) was added in portions, and the reaction mixture was stirred for one hour at RT. 
Subsequently, HCl (1 M) was added to quench the unreacted NaBH4. Following this, the solvent 
was evaporated under reduced pressure, water (200 ml) was added to the oily residue, and 
extraction was performed with ethyl acetate (3 x 50 ml). Then, the organic fractions were 
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combined and dried over Na2SO4. Subsequently, the sample was adsorbed on silica for dry 
loading flash chromatographic purification (see Table 2), which allowed the isolation of 1,1′,2-
tris-norsqualene alcohol (22; 1.38 g, yield: 71 %) as a colorless oil.  
III.1.4.2 Preparation of compounds 23 and 24 from substrate 22 
A 500 mg aliquot of 1,1ʹ,2-tris-norsqualene alcohol 22 (1.29 mmol) was dissolved in 10 
ml of anhydrous dichloromethane. To this solution, 4-dimethylaminopyridine (DMAP; 110.32 
mg, 0.90 mmol; 0.7 equiv.), EDC·HCl (296.75 mmol, 1.55 mmol.; 1.2 equiv.) and, depending 
on which linker was used, either sebacic or 4,4′-dithiodibutyric acid (2.58 mmol; 2 equiv.) were 
added. The reaction mixture was stirred for 6 hours under an argon atmosphere at RT. 
Subsequently, the solution was neutralized with 10% aq. NaHCO3, brine (20 ml) was added to 
it, and the products were extracted with dichloromethane (4 x 30 ml). Following this, the 
organic fractions were combined, dried over Na2SO4, and filtered. Subsequently, the sample 
was adsorbed on silica gel (1-2 g) for dry loading flash chromatographic purification (see Table 
2), which allowed the isolation of compound 23 (458.1 mg, 62%) or the disulfide-bridge 
containing compound 24 (510.6 mg, 65%). 
III.1.4.3 Preparation of ecdysteroid-squalene conjugates 25 and 26 [II, III] 
An aliquot of 34.2 mg (0.08 mmol) of poststerone 2,3-acetonide 20-oxime (19) was 
dissolved in 6 ml of anhydrous dichloromethane in a two-neck round-bottom flask. Depending 
on the linker, 1.5 equivalents of either compound 23 (70.2 mg, 0.12 mmol) or 24 (72.8 mg, 0.12 
mmol) was added dropwise to the solution. Subsequently, DMAP (13.1 mg, 0.16 mmol, 2 
equiv.) and EDC·HCl (39.3 mg, 0.20 mmol, 2.5 equivalents) were added to the mixture, which 
was then stirred for 2 hours under an argon atmosphere at RT. Following this, the solution was 
neutralized by 10% aq. NaHCO3, brine (30 ml) was added to it, and extraction was carried out 
with dichloromethane (4 × 30 ml). The organic fractions were combined, dried over Na2SO4, 
filtered, and evaporated to dryness on a rotary evaporator. The oily residue was subjected to 
flash chromatographic purification (see Table 2) to afford ecdysteroid conjugate 25 (61.0 mg, 
73%) or the disulfide-bridge containing conjugate 26 (66.1 mg, 76%), as colorless oils. 
III.1.4.4 Preparation of self-assembled nanoparticles 25NP and 26NP, heteronanoparticles 
25NP-DOX and 26NP-DOX and their characterization [III] 
Nanoparticles (NPs) and heteronanoparticles (H-NPs) were prepared and characterized 
by the research group of Prof. Daniele Passarella (Department of Chemistry, University of 
Milan, Milan, Italy). Briefly, the following procedure was used. 
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 In the cases of NPs, a 250 μg aliquot of ecdysteroid conjugate 25 or 26 was dissolved in 
125 μl of THF (2 mg/ml), and under mild stirring (400 rpm), this solution was added dropwise 
within a one-minute period of time to a double volume of Milli-Q® (Merck KGaA, Germany) 
ultrapure water at RT. Finally, the organic solvent was evaporated at 30 °C under reduced 
pressure to obtain the corresponding aqueous nanosuspensions 25NP and 26NP in a final 
concentration of 1 mg/ml.  
H-NPs were prepared by mixing a solution of ecdysteroid conjugate 25 or 26 (125 μL, 
250 μg, 2 mg/ml) with squalene-functionalized doxorubicin solution (2 mg/ml) in THF in a 
1:50 molar ratio of ecdysteroid conjugate/doxorubicin conjugate –to obtain a mixture in a final 
concentration of 2 mg/ml. Squalene-functionalized doxorubicin was previously prepared by the 
collaborating research group. The self-assembly process was performed as described above, to 
afford the aq. nanosuspensions of 25NP-DOX or 26NP-DOX at a final concentration of 1 mg/ml.   
The average diameter and polydispersity index (PdI) of each nano assembly was 
determined by dynamic light scattering (DLS) technique on a Malvern ZS zetasizer (Malvern 
Panalytical Ltd., UK) instrument with disposable folded capillary. During the investigations, 
100-150 µg/ml concentration aq. samples were diluted from the dispersions, which were then 
placed in the electrophoretic cell of the Malvern ZS zetasizer, to determine their zeta potential. 
Transmission electron microscopy (TEM) images were obtained at 25 °C, upon filtering the 1 
mg/ml nanosuspensions through a 0.45 μm filter. 
III.1.5 Procedures for the structure elucidation of obtained products [I, II] 
1H (950 or 500 MHz) and 13C (239 or 125 MHz) NMR spectra of ecdysteroid and squalene 
derivatives were recorded at room temperature on a Bruker Avance-II or Avance-III 
spectrometer (Bruker Co., Billerica, MA, USA) equipped with cryo probeheads. The 
investigations were performed in research collaboration with Prof. Dr. Gábor Tóth (Department 
of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, 
Budapest, Hungary), Dr. Dóra Bogdán (Department of Organic Chemistry, Semmelweis 
University, Budapest, Hungary) and Dr. Rainer Haessner (Institute of Organic Chemistry and 
Biochemistry, Technical University of Munich, Garching, Germany) [I, II]. 
High‐resolution mass spectrometry (HR-MS) analysis of the obtained products was 
carried out utilizing a Waters Acquity I-Class UHPLC system (Waters Co., USA) coupled with 
a Thermo Scientific Q Exactive Plus orbitrap mass spectrometer (Thermo Fisher Scientific Inc., 
USA) equipped with heated electrospray ionization (HESI) source. Each spectrum was recorded 
in positive ionization mode. 
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III.1.6 Biological evaluation of ecdysteroid derivatives 
III.1.6.1 In vitro antiproliferative assays of compounds 7-18 [I] 
The antiproliferative effects of compounds 7-18 were tested by MTT assay on human 
gynecological cancer cell lines in collaboration with Prof. István Zupkó (Institute of 
Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary). Cell viability 
data were obtained on four human adherent cancer cell lines; MDA-MB-231, MCF-7 (breast 
cancers), HeLa (cervical adenocarcinoma) and SiHa (cervical carcinoma). Cisplatin was used 
as a positive control [I]. 
III.1.6.2 Rhodamine 123 accumulation assay of compounds 5-19 [I] 
ABCB1 inhibitory activities of ecdysteroids 5-19 were studied in vitro in research 
cooperation with Dr. Ana Martins (Department of Medical Microbiology and Immunobiology, 
Faculty of Medicine, University of Szeged, Szeged, Hungary). Functional inhibition of efflux 
by the compounds was measured by the intracellular accumulation of rhodamine 123, a 
fluorescent dye that is an ABCB1 substrate. As a positive control, tariquidar was used [I]. 
III.1.6.3 Cytotoxicity assays of compounds 5-19 on murine lymphoma cell lines [I] 
In vitro cytotoxic activity of ecdysteroid analogs 5-19 alone, or in combination with 
doxorubicin, were tested in research collaboration with Dr. Ana Martins (Department of 
Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary). Two 
mouse lymphoma cell lines were used, a drug-susceptible mouse T-cell lymphoma (L5178) and 
its multi-drug-resistant counterpart (L5178MDR) that had been transfected with pHa MDR1/A 
retrovirus to express the human ABCB1 transporter 125. The checkerboard microplate method 
was used, and results were evaluated by the Chou-Talalay method 126, according to our 
previously published procedure 87. When the ecdysteroids were studied in the presence of 
doxorubicin, the interactions were evaluated at each constant ratio of compound vs. 
chemotherapeutics (M/M), and combination index (CI) values were obtained for 50%, 75%, 
and 90% of growth inhibition [I]. 
III.1.6.4 Cytotoxicity assay of self-assembled ecdysteroid nanoparticles [III] 
The in vitro antiproliferative activity of NPs 25NP and 26NP, and doxorubicin-containing 
H-NPs 25NP-DOX and 26NP-DOX on A2780ADR cancer cells (doxorubicin-resistant human ovarian 
carcinoma) was investigated by the Trypan blue assay in research collaboration with the 
research group of Prof. Daniele Passarella. Results were expressed as GI50 (GI: grow 
inhibition) values, i.e., the concentration of the test agent inducing 50% reduction in cell number 
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compared with control cultures [III]. 
III.2. PROTOFLAVONOIDS 
III.2.1 Preparation of protoapigenone analogs 28-34 as substrates of further semi-
synthetic transformations 
Apigenin (27) was purchased from Changsa Inner Natural Inc. (Hunan, China) in an RP-
HPLC purity of 98% and was used as a starting material for semi-synthetic transformations. In 
a typical reaction, a 1 g aliquot of apigenin (3.70 mmol) was dissolved in a concentration of 1 
mg/ml in a 9:1 (v/v) mixture of acetonitrile and either water or the alcohol to be coupled at C-
1ʹ. Two equivalents of PIFA (3.18 g, 7.40 mmol) were added to the solution, and the mixture 
was stirred at 80 °C for an hour. Following this, the solution was cooled down to RT, and the 
solvent was evaporated under reduced pressure on a rotary evaporator. The obtained residue 
was re-dissolved in acetone and subjected to flash chromatographic purification by our 
previously published methods 114 that afforded protoapigenone analogs 28-34 with the 
following yields: 28 (308.2 mg, 29.1%), 29 (381.1 mg, 34.3%), 30 (380.3 mg, 32.7%), 31 (370.5 
mg, 30.5%), 32 (292.8 mg, 24.1%), 33 (445.9 mg, 35.2%), 34 (372.0 mg, 31.0%). 
III.2.2 Preparation and functionalization of protoflavonoid analogs [IV, V] 
III.2.2.1 Preparation of tetrahydroprotoapigenone analogs 35-40 through the flow 
chemical hydrogenation of the B ring [IV, V] 
Selective saturation of the protoflavone B-ring was achieved relying on the utilization of 
ThalesNano’s H-Cube (ThalesNano Inc., Budapest, Hungary) continuous flow hydrogenation 
system. Part of our device was a stainless-steel cartridge (internal dimensions: 50 mm × 4.6 
mm), filled with 100 or 200 mg of 5% Pd/C catalyst, varied according to the amount of substrate 
desired to be converted. The column was inserted to an external thermostat (Jetstream 2 plus, 
Jasco, Japan) set to 25 °C. Solvent pumping was provided by a standard HPLC pump, that 
ensured a continuous flow rate of 1 ml/min in the presence of 40 bar backpressure. 
In each reaction’s case, a 1 mg/ml solution of the corresponding protoflavone substrate 
was prepared using HPLC grade ethyl acetate or methanol as solvents. For small-scale test 
reactions, 15 ml solutions were prepared. For the transformations, 20 ml substrate solutions 
were prepared, except for compounds 35 and 40, which were synthesized from 360 ml 
solutions. To ensure synthetic reproducibility, the catalyst bed was washed with the solvent for 
15 minutes between the reactions. Following synthesis, the collected solutions were evaporated 
on a rotary evaporator and samples were applied to preparative RP-HPLC (see Table 3) that 
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allowed the isolation of compounds 35-40 with the following yields: 35 (253.0 mg, 69.3%), 36 
(5.1 mg, 25.2%), 37 (15.5 mg, 70.5%), 38 (6.1 mg, 30.1%), 39 (8.9 mg, 44%), 40 (209.4 mg, 
57.5%). 
III.2.2.2 Preparation of tetradeuteroprotoapigenone analogs 41-46 through the flow 
chemical deuteration of the B ring [V] 
Deuteration of the protoapigenone B-ring was carried out utilizing the flow chemical 
conditions described for hydrogenation (for further details, see III.2.2.1 above), but for this 
purpose, as a catalyst, 400 mg of 5% Pd/BaSO4 was applied, and the reservoir of the reactor 
was filled with high purity heavy water (D2O). Following the transformations, each obtained 
sample was evaporated to dryness on a rotary evaporator and was subsequently purified with 
preparative RP-HPLC (see Table 3) that yielded deuterated protoapigenone analogs 41-46 as 
follows: 41 (12.6 mg, 63.1%), 42 (8.2 mg, 40.5%), 43 (12.1 mg, 60.6%), 44 (10.4 mg, 51.4%), 
45 (11.3 mg, 55.8%), 46 (14.7 mg, 73.5%). 
III.2.2.3 Preparation of protoapigenone 4’-oxime derivatives 47-52 [V] 
A 150 mg aliquot of compound 32, 33 or 34 was dissolved in a concentration of 2.5 mg/ml 
in HPLC grade methanol (60 ml). Three equivalents of hydroxylamine hydrochloride were 
added to the solution under stirring, and the mixture was stirred under reflux for 24 h at 70 °C. 
Following this, silica gel (3-5 g) was added to the reaction mixture, and compounds were 
adsorbed on its surface through solvent evaporation under reduced pressure. The acquired 
sample was subjected to flash chromatography to remove soluble and insoluble contaminants, 
and later, the products of the simplified sample were separated by means of preparative RP-
HPLC (see Table 3) that allowed us the isolation of oxime racemates 47-52 with the following 
yields: 47 (41.7 mg, 24.3%), 48 (47.4 mg, 27.8%), 49 (43.1 mg, 25.1%), 50 (50.7 mg, 29.6%), 
51 (56.6 mg, 33.2%), 52 (54.6 mg, 31.8%). 
III.2.2.4 Preparation of tetrahydroprotoapigenone 4’-oxime derivatives 53-54 [V] 
A 60 mg aliquot of tetrahydroprotoflavone substrate 35 or 40 was dissolved in a 
concentration of 2 mg/ml in HPLC grade methanol (30 ml). 4 equivalents of hydroxylamine 
hydrochloride were added to the solution under stirring, and the reaction was stirred under 
reflux for 3 h at 70 °C. Following this, methanol was evaporated under reduced pressure, brine 
(40 ml) was added to the solid residue, and extraction was carried out using ethyl acetate (3 x 
40 ml). The collected organic fractions were dried over Na2SO4. Later, the drying agent was 
removed through filtration, and the solution was evaporated to dryness on a rotary evaporator. 
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The obtained sample was applied to preparative RP-HPLC (see Table 3) that afforded oxime 
racemate 53 (30.5 mg, 48.3%), or 54 (26.4 mg, 42.1%). 
Table 3. List of chromatographic methods that were utilized for the purification of synthetically 
obtained protoflavonoid analogs discussed in relation to this dissertation. “X g silica” columns 
refer to commercially available “RediSep” (plain) silica (Teledyne ISCO, USA) flash 
chromatographic columns; “XB-C18” column: Kinetex 5 µm XB-C18 100A 250 x 21.2 mm 
HPLC Column (Phenomenex Inc, USA); “XDB-C8” column: Agilent Eclipse Zorbax 5 µm 
XDB-C8 250 x 9.4 mm HPLC Column (Agilent Technologies, USA); “Gemini C18” column: 
Phenomenex 5µm Gemini-XN C18 HPLC column 250 x 10 mm (Phenomenex Inc, USA). In 
each case, the yield refers to the isolated yield% of the pure (HPLC peak area% ≥ 95 at the λmax, 
or at the PDA chromatogram recorded between 210-410 nm) compound. Numbers depicted as 
“(x)” indicate the corresponding step of the chromatographic purification. 
cpd. x (yield) column flow rate purification detection 
35 (69.3%) XB-C18 15 ml/min 18% aq. CH3CN 254 nm 
36 (25.2%) Gemini C18 3 ml/min 45% aq. CH3CN 254 nm 
37 (70.5%) Gemini C18 3 ml/min 50% aq. CH3CN 254 nm 
38 (30.1%) Gemini C18 3 ml/min 50% aq. CH3CN 254 nm 
39 (44.0%) Gemini C18 3 ml/min 55% aq. CH3CN 254 nm 
40 (57.5%) XB-C18 15 ml/min 55% aq. CH3CN 254 nm 
41 (63.1%) Gemini C18 3 ml/min 18% aq. CH3CN 254 nm 
42 (40.5%) Gemini C18 3 ml/min 45% aq. CH3CN 254 nm 
43 (60.6%) Gemini C18 3 ml/min 55% aq. CH3CN 254 nm 
44 (51.4%) Gemini C18 3 ml/min 50% aq. CH3CN 254 nm 
45 (55.8%) Gemini C18 3 ml/min 55% aq. CH3CN 254 nm 
46 (73.5%) Gemini C18 3 ml/min 61% aq. CH3CN 254 nm 
48 (27.8%) 
51 (33.2%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) n-hexane : EtOAc (A:B) 
065% B (35 min) 
(2) 38% aq. CH3CN 
254 nm 
300 nm 
49 (25.1%) 
52 (31.8%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) n-hexane : EtOAc (A:B) 065% 
B (35 min) 
(2) 30% aq. CH3CN 
254 nm 
300 nm 
47 (24.3%) 
50 (29.6%) 
(1) 4 g silica 
(2) XDB-C8 
(1) 18 ml/min 
(2) 3 ml/min 
(1) n-hexane : EtOAc (A:B) 
065% B (35 min) 
(2) 35% aq. CH3CN 
254 nm 
300 nm 
53 (48.3%) XB-C18 15 ml/min 18% aq. CH3OH 254 nm 
54 (42.1%) XB-C18 15 ml/min 40% aq. CH3OH 254 nm 
     
III.2.3 Procedures for the structure elucidation of obtained protoflavonoids [IV, V] 
Mass spectra of the protoflavones were recorded on an Agilent 1100 LC-MS system 
(Agilent Technologies, Santa Clara, CA, USA) coupled with Thermo Q-Exactive Plus orbitrap 
analyzer (Thermo Fisher Scientific, Waltham, MA, USA) used in positive mode, or on an API 
2000 triple quadrupole tandem mass spectrometer (AB SCIEX, Foster City, CA, USA) 
equipped with ESI source utilized in negative ionization mode. 
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 1H, 13C, 13C HSQC, and 13C HMBC NMR spectra of the derivatives were recorded on a 
Bruker Avance DRX 400 MHz instrument or on a Bruker Avance NEO 500 MHz spectrometer 
(Bruker Co., Billerica, MA, USA) equipped with a Prodigy BBO 5 mm CryoProbe using TMS 
as an internal standard. In general, 5-10 mg of the corresponding protoflavone was dissolved in 
DMSO-d6 and transferred to NMR tubes for spectra record. Data report and spectra analysis 
were carried out with MestReNova v6.0.2-5475 software (Mestrelab Research S.L., Santiago 
de Compostela, Spain). The NMR investigations were performed in research collaboration with 
Dr. Norbert Kúsz (University of Szeged, Institute of Pharmacognosy, Szeged, Hungary). 
III.2.4 Biological evaluation of protoflavonoid derivatives [IV, V] 
III.2.4.1 Antitumor assays of compounds 35 and 40 [IV] 
Compounds 35 and 40 were tested for their in vitro cytotoxicity on MCF-7 (breast), HeLa 
(cervix), and SiHa (cervix) human adherent cancer cell lines. In this regard, different dilutions 
were prepared from the compounds, which were then analyzed using the checkerboard 
microplate method. The surviving cells were detected by the MTT method.  
Furthermore, the analogs were tested for their potential to interfere with the ATR/ATM 
signaling pathways, whose inhibition would confer them chemo-sensitizing activity towards 
DNA-damaging chemotherapeutics. The investigation was carried out by pre-treating MCF-7 
cells with or without 5, 10 or 20 µM of compounds for 30 min, and DNA damage was induced 
by exposing the cells to 1 µm of doxorubicin for 6 h. The detection of DNA damage response 
was achieved by Western blot assay, as previously described 113. The studies were performed 
in research cooperation with Dr. Ching-Ying Kuo and Dr. Hui-Chun Wang (Graduate Institute 
of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, 
R.O.C.) [IV]. 
III.2.4.2 Antiviral testing of protoflavonoids [V] 
Antiretroviral assay against HIV. Derivatives 28, 32-40 and 47-54 were tested against 
HIV-1 using a pseudotype virus assay (U373-CD4-CCR5 cells infected by pseudotyped virus) 
allowing only one cycle of viral replication and being more sensitive for compounds targeting 
the early steps of HIV replication, such as reverse transcription and integration. Drug 
cytotoxicity was evaluated by using the MTT assay. The measurements were performed in a 
scientific research collaboration with Dr. Carole Seguin-Devaux (Department of Infection and 
Immunity, Luxembourg Institute of Health, Luxemburg) [V]. 
Antiviral activity against EBV. Derivatives 28 and 32-54 were tested for their effects 
on the immunoblot assays of EBV Rta Protein. The concentration selected for wide-scale 
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screening was 0.25 µM, where protoapigenone (28) was previously found to exert a strong 
activity 122. Additionally, we examined the cytotoxicity of the active analogs on P3HR1 cells. 
For the analysis, 96-well plates were used, and the compounds’ cytotoxicity was determined by 
Cell Proliferation Kit I. The tests were performed in research collaboration with Dr. Li-Kwan 
Chang (Department of Biochemical Science and Technology, College of Life Science, National 
Taiwan University, Taipei City, Taiwan [V]. 
IV. RESULTS 
IV.1 ECDYSTEROIDS 
IV.1.1 Preparation of compounds 3 and 4 as substrates for further transformations 
IV.1.1.1 Synthesis of poststerone (2) through the oxidative side-chain cleavage of 20E 
Oxidative cleavage of the sterol side-chain of 20E (1) was achieved using hypervalent 
iodine reagent PIDA as previously reported by our research group 127. 
Briefly, one equivalent of the reagent was added portion-wise to 20E dissolved in 
methanol, and this resulted in a total conversion of the substrate and highly selective cleavage 
of its sterol side-chain within 45 min of intensive stirring. Flash chromatographic purification 
resulted in the successful isolation of poststerone (2) in high yield (72.9%) (see Table 2 of 
section III.1.1 for the chromatographic method, and Scheme 1 for the transformation.). 
IV.1.1.2. Acetonide formation of the vicinal diols of 20E (1) and poststerone (2) 
We achieved the preparation of the 2,3-acetonide and 2,3;20,22-diacetonide analogs of 
poststerone (2) and 20E (1), respectively, following our previously described synthetic strategy 
90. Using phosphomolybdic acid as a catalyst in acetone resulted in the protection of the vicinal 
diols of the substrates (Scheme 1). The products were purified by flash chromatography that 
afforded 20E 2,3;20,22-diacetonide (3) in fair (5.95 g, 51%), and poststerone 2,3-acetonide (4) 
in good yield (7.88 g, 71%; for details of the chromatographic purification, see Table 2). 
 
Scheme 1. Semi-synthesis of compounds 2-4 through the transformation of 20E (1). 
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IV.1.2 Synthesis and derivatization of oxime analogs from substrates 3 and 4  
IV.1.2.1 Preparation of 6-oximes 5 and 6 from 20E 2,3;20,22-diacetonide (3) [I] 
To obtain the 6-oxime analogs of 20E 2,3;20,22-diacetonide (3), we followed a previously 
published procedure 92. Briefly, we reacted substrate 3 with hydroxylamine hydrochloride in 
pyridine that eventually afforded a pair of E/Z-isomeric oxime products, wherein the 14α-OH 
moiety was eliminated on both derivatives. As compared to the publication that provided the 
methodical basis of the synthesis 92, we succeeded in the separation of the corresponding oxime 
isomers by applying preparative RP-HPLC that yielded ecdysteroid (6E)-oxime 5 (0.31 g, 31%) 
and ecdysteroid (6Z)-oxime 6 (0.38 g, 38%) in pure form and in high purity (see Table 2 of 
section III.1.1). Scheme 2 depicts the transformation. 
IV.1.2.2 Preparation of 6-oxime ethers 7-17 from 20E 2,3;20,22-diacetonide (3) [I] 
We succeeded in the synthesis of the 6-oxime ether derivatives of ecdysteroid substrate 
3, by employing the appropriate alkoxyamine reagent in pyridine, depending on the oxime ether 
moiety desired at C-6. Following the transformations, we neutralized the reaction mixtures with 
methanolic solutions of KOH that allowed the preparation of both 14,15-anhydro- and intact 
ecdysteroid oxime ethers. This way, we obtained compounds 7-17, a total of 11 ecdysteroid 
derivatives. Subsequently, we carried out the chromatographic purification of the products in 
two steps: at first, we used flash chromatography for fractionation, and this was followed by 
semi-preparative RP-HPLC (see Table 2) that allowed the isolation of each geometric isomer 
in pure form. Scheme 2 shows the synthetic scheme. 
IV.1.2.3 Beckmann-rearrangement of compound 5 to ecdysteroid lactam 18 [I] 
Beckmann-rearrangement of ecdysteroid (6E)-oxime 5 was performed considering a 
previously published procedure 128. In contrast to the 24 h reaction time reported in the 
publication, with the transformation’s periodic TLC monitoring, we found that the use of TsCl 
in acetone, in the presence of Na2CO3, can effectively furnish the seven-membered lactam ring 
of the product, and succeeds with the total conversion of the substrate within only 6 hours. 
In our publication related to the thesis [I], we employed liquid-liquid extraction for 
reaction work-up and purified the crude sample mixture by preparative RP-HPLC that afforded 
compound 18 (11 mg, 8%) in very low yield (see section III.1.3.3.). Here we report an update 
to our former work-up strategy: following the transformation process, the reaction solution 
needs to be evaporated to dryness, and after re-dissolving the solid residue in dichloromethane, 
it should be subjected to normal-phase solid-phase extraction (SPE) on silica previously pre-
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conditioned with the solvent. Column washing with dichloromethane allows the selective 
elution of the apolar TsCl, while the dilution of the eluent with methanol in 10% (v/v), can elute 
the retained ecdysteroid product. By subjecting the pre-purified sample to preparative RP-
HPLC (see Table 2), we can obtain compound 18 in a notably higher yield (23.2%) than before 
[I]. The reaction scheme is shown in Scheme 3. 
 
Scheme 2. Semi-synthesis of compounds 5-17 through the transformation of substrate 3.  
 
Scheme 3. Preparation of ecdysteroid lactam 18 through the transformation of (6E)-oxime 5.  
 
IV.1.2.4 Preparation of 20-oxime analogs of poststerone 2,3-acetonide (4) [II] 
By employing hydroxylamine- or methoxyamine hydrochloride reagents to transform 
poststerone 2,3-acetonide (4) in pyridine, we achieved the preparation of its 20-oxime (19) and 
20-O-methyl oxime ether (20) analogs, respectively. During this work, we found that our 
procedure was highly regioselective to afford 20-oxime analog 19 at ambient temperature. In 
contrast, we succeeded in effecting the transformation of the substrate to its 20-oxime ether 
analog 20 by applying heating and larger reactant amounts. Following transformations, we 
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performed neutralization on each reaction mixture with an ethanolic solution of KOH that 
allowed the convenient, decomposition-free work-up of the products. We purified compound 
19 using semi-preparative RP-HPLC (see Table 2) that afforded the derivative in high yield 
(30.7 mg, 69.7%). Products of the oxime ether synthesis were separated by flash 
chromatography, which allowed us the isolation of a mixture of (E/Z)-isomeric 20-O-methyl 
oxime ethers (20) in a low combined yield (12 %, 38.6 mg). Scheme 4 shows the reactions. 
 
Scheme 4. Preparation of compounds 19-20 from poststerone 2,3-acetonide (4). 
IV.1.3 Preparation of self-assembled nanoparticles from ecdysteroid oxime 19 [II, III] 
IV.1.3.1 Preparation of compound 22 through the transformation of squalene (21) 
Squalene (21) lacks a proper anchor point for the chemical linking, therefore it requires 
preliminary functionalization at its terminal double bond to serve the task. In this regard, we 
prepared our self-assembly inducing molecule, 1,1ʹ,2-tris-norsqualene alcohol (22), considering 
previously published procedures 99,103. 
Briefly, at first, we oxidized squalene (21) to 2-hydroxy-3-bromosqualene (21a) 
employing NBS in an aqueous-organic medium, and subsequently converted the molecule’s 
terminal bromohydrin moiety to epoxide using K2CO3 as a base in the substrate’s methanolic 
solution to afford 2,3-oxidosqualene (21b). Then, oxidative opening of the epoxide ring of 2,3-
epoxysqualene was performed by aq. periodic acid in dioxane medium to afford 1,1′,2-tris-
norsqualene aldehyde (21c). Eventually, we achieved the reduction of the aldehyde moiety of 
intermediate 21c to alcohol using NaBH4 in ethanol that resulted in the formation of 1,1′,2-tris-
norsqualene alcohol (22).  The product was purified by flash chromatography (see Table 2) and 
the pure compound was obtained in a yield of 71% (1.38 g). Scheme 5 presents the synthetic 
process. 
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Scheme 5. Preparation of 1,1’,2-tris-norsqualene alcohol (22) from squalene (21). 
Compounds 21a-21c represent synthetic precursors. 
IV.1.3.2 Condensation of compound 22 with chosen dicarboxylic acid linkers 
We successfully reacted our self-assembly inducer compound 22 with two different 
dicarboxylic acids, sebacic acid or 4,4′-dithiodibutyric acid, intending to obtain monoester 
carboxylic acids that we can later link to a hydroxylated biomolecule through esterification.  
We achieved the activation of the terminal carboxyl function of the acids with EDC 
hydrochloride in dry dichloromethane that, in the presence of DMAP catalyst, allowed the 
formation of the desired esters through condensation reactions with substrate 22. Flash 
chromatographic purification on silica columns (see Table 2) afforded compound 23, or the 
disulfide-bridge containing compound 24 as pure oils, in relatively good yields (compound 23: 
458.1 mg, 62%; compound 24: 510.6 mg, 65%). Scheme 6 shows the reactions. 
 
Scheme 6. Preparation of compounds 23 and 24 from substrate 22.  
IV.1.3.3 Synthesis of squalene-linked bioconjugates from compound 19 [II, III] 
Poststerone 2,3-acetonide 20-oxime (19) was selected as a substrate for functionalization 
with the prepared self-assembly inducer squalene derivatives 23 and 24. Condensation of the 
ecdysteroid with these was straightforward using similar reaction conditions for the 
esterification to those presented in section IV.3.2., and this resulted in the formation of 
squalene-coupled bioconjugates. In this regard, we found the conjugation process regioselective 
towards the hydroxyl group of the C-20 oxime moiety of compound 19. By employing flash 
chromatographic purification (see Table 2), both derivatives were obtained in high yields 
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(conjugate 25: 61.0 mg, 73%; conjugate 26: 66.1 mg, 76%). Reactions are shown in Scheme 7. 
 
Scheme 7. Synthesis of conjugates 25 and 26 from their substrates. 
Compounds 25 and 26 were further studied in collaboration with the group of Dr. Daniele 
Passarella, together with several further related compounds prepared by our collaborators. In 
the following sub-chapters, a brief description of these results is provided in context of the 
compounds prepared by our group. 
IV.1.3.4 Preparation of self-assembled nanoparticles through nanoprecipitation [III] 
Self-assembly of NPs was achieved by the nanoprecipitation approach, which relies on 
the prolonged, dropwise addition of the conjugates into ultrapure water under continuous 
stirring. Four different ecdysteroid-containing nanosuspensions were prepared from our 
compounds, two that contained only an ecdysteroid conjugate in their matrix (25NP and 26NP,), 
and two that contained heteronanoparticles (H-NPs) prepared from the 1:50 molar ratio mixture 
of an ecdysteroid conjugate and squalene-functionalized doxorubicin, respectively (25NP-DOX 
and 26NP-DOX).  
IV.1.3.5 Colloid chemical characterization of nano assemblies [III] 
Physical characterization of nanosuspensions was achieved by DLS and TEM techniques. 
Results of the DLS analysis are shown below, in Table 4. 
Table 4. Characterization of nano assemblies 25NP-26NP, and 25NP-DOX-26NP-DOX by dynamic 
light scattering. h.d., hydrodynamic diameter; PdI, polydispersity index; ζ-pot., ζ-potential. 
NPs / H-NPs (#) h.d. ± SD (nm) PdI ζ-pot. ± SD (mV) 
25NP 366.3 ± 20.17 0.161 ± 0.032 −21.5 ± 4.55 
26NP 221.8 ± 4.879 0.081 ± 0.088 −21.7 ± 1.50 
25NP-DOX 187.7 ± 14.48 0.223 ± 0.069 −13.5 ± 9.65 
26NP-DOX 298.7 ± 11.43 0.264 ± 0.014 −11.1 ± 3.48 
DLS results confirmed the formation of nano assemblies in an aqueous medium. Nano 
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assemblies 25NP and 26NP were found monodisperse, exerting a polydispersity index (PdI) 
lower than the theoretical threshold of 0.2. In contrast, slightly higher values, though still close 
to the theoretical optimum, were recorded for H-NPS that also contained squalene-
functionalized doxorubicin in their matrix. Besides, highly negative ζ-potential values (<−20.0 
mV) were found for 25NP and 26NP, suggesting that the electrostatic repulsion between the NPs 
contributed to their stability in an aqueous medium. At the same time, nearly two-fold higher 
values were recorded for the corresponding H-NPs, indicating the slight possibility of particle 
aggregation on their long-term storage. 
The nano assemblies were further characterized by TEM to investigate their morphology. 
Figure 6 shows images recorded on 26NP and 26NP-DOX. 
 
 
Figure 6. TEM analysis of 26NP (a, scale: 1 μm) and 26NP-DOX (b, scale: 500 nm). 
The images suggested the formation of fluid, droplet-like structures. While for the sample 
of 26NP (Figure 6, a) the mean diameter of the particles was somewhat smaller, in the case of 
26NP-DOX (Figure 6, b) it was in good agreement with the results of the DLS studies. 
IV.1.4 Structure elucidation of the prepared compounds [I, II, III] 
Compounds 1-4 and 21-24 were previously fully characterized, and 2-3 mg aliquots from 
them were readily available in our laboratory. These samples were utilized as pure reference 
materials during the large-scale synthetic preparation of novel batches 89,95,103. Aliquots of 
derivatives 21-24 were provided for our use by the research group of Dr. Daniele Passarella. 
Structure elucidation of derivatives 5-20 and 25-26 was performed by HR-MS, and 1D 
and 2D NMR techniques (see section III.1.5). The HR-MS analysis allowed the accurate 
determination of the molecular mass of products concerning the [M+H]+ parental ion, which 
was systematically observed as the base peak of the mass spectra, predominantly accompanied 
by the presence of [M+Na]+ or [M+K]+ adducts. At the same time, HR-MS measurements 
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afforded experimental verification for the molecular formula of the compounds. 
Chemical structures of the derivatives were determined by employing comprehensive 1D 
and 2D NMR methods. In general, modifications on the ecdysteroid skeleton were recognized 
by comparing the 1H and 13C chemical shifts of the products with those of the previously 
characterized starting materials. In the case of ecdysteroid oximes, the transformation of the 
carbonyl moiety to oxime resulted in a ca. 50 ppm diamagnetic shift of the corresponding 
carbon atom on the 13C NMR spectra. For ecdysteroid 6-oximes, characteristical differences 
between the chemical shifts of the α-CH carbon atom in the syn and anti-position with respect 
to the oxime hydroxyl group could be used to determine the (E/Z)-configuration of the oxime 
moiety. This way, compounds 7-8, 10, 12 and 17 were unambiguously assigned as E-isomers, 
while compounds 9, 11, and 13-16 as Z-isomers. We determined the configuration of 
ecdysteroid 20-oxime 19 through the analysis of its 20-O-methylated oxime ether analogs that 
were available as a mixture of both isomers (20). Selective ROESY experiments revealed that 
compound 19 belongs to the E-series. We verified the success of the Beckmann-rearrangement 
of ecdysteroid (6E)-oxime 5 to compound 18 by considering a 13.1 ppm paramagnetic shift on 
δC-5 providing a proof that on the product, the nitrogen atom was coupled to C-5, and the 
appearance of the signal of C-6 at 170.6 ppm supported the formation of the lactam ring. 
Structures of conjugates 25 and 26 were determined by correlating their chemical shift 
signals with those of compound 19, while the appearance of five ═CH signals of substrates 23 
or 24 in the 1H (δH: 5.20–5.00 ppm) and 13C (δC: 125.2–124.2 ppm) NMR spectra justified the 
connection of the lipophilic side‐chain to the steroid. Thanks to our collaboration partners 
providing opportunity for 950 MHz NMR measurements, the complete 1H and 13C NMR signal 
assignment of both conjugates was achieved. 
Among the synthesized products, derivatives 5, 7-18, 20 and 25-26, a total of 15 
compounds and a compound mixture (20) were new. 
IV.1.5 Results of the bioactivity tests 
IV.1.5.1. Antiproliferative activities against human gynecological cancer cell lines [I] 
Compounds 5-18 were tested in collaboration for their antiproliferative effects on HeLa, 
SiHa, MDA-MB-231 and MCF7 human gynecological cancer cell lines. Briefly, the analogs 
exhibited weak to moderate activities against the tested cell lines with IC50 values in the range 
of ca. 8-30 µM or above, while the activity of the positive control cisplatin was exceeded by 
only one compound (12) on the HeLa and MDA-MB-231 models (IC50=8.4 and 12.4 µM, 
respectively) [I].  
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IV.1.5.2. Cytotoxic activity, ABCB1-inhibition, and interaction with doxorubicin [I] 
Compounds 5-19 were investigated for their cytotoxic activity and ability to interfere with 
the efflux function of the ABCB1 transporter on a murine lymphoma cell line pair, i.e., a drug-
susceptible cell line (L5178) and its multi-drug-resistant counterpart (L5178MDR) transfected to 
express the human ABCB1 transporter. Table 5 shows the results of these bioassays. 
Table 5. Cytotoxicity of compounds 3-19 on L5178 and L5178MDR cells, and functional 
inhibition of the ABCB1 transporter. Dox = doxorubicin; for the ABCB1 inhibition, (+) control: 
100 nM of tariquidar (112.4% inhibition), (-) control: 2% DMSO (-0.07% inhibition). 
Compound 
Change in the 14-OH or IC50 (µM) [95% confidence intervals] b ABCB1 inhibition (%) 
B-ring of 3 a Δ14,15 L5178 L5178MDR 2 µM 20 µM 
3 - 14-OH 110.3 [77.50-157.1] 97.69 [71.07-134.3] 2.54 20.91 
4 89 - 14-OH >75 >75 0.08 0.64 
5 (E)-oxime Δ14,15 20.91 [17.68-24.74] 24.63 [19.82-30.63] 10.57 82.95 
6 (Z)-oxime Δ14,15 34.22 [28.21-41.51] 28.35 [21.97-36.58] 7.15 81.09 
7 (E); R=Me 14-OH 40.92 [35.66-46.97] 55.05 [41.53-72.98] 2.25 25.05 
8 (E); R=Et 14-OH 35.02 [25.35-48.38] 47.00 [31.14-70.93] 17.54 78.79 
9 (Z); R=Et 14-OH 37.26 [25.65-54.11] 42.16 [41.24-43.10] 18.96 75.03 
10 (E); R=Allyl 14-OH 31.48 [23.71-41.80] 51.91 [42.69-63.13] 20.98 89.39 
11 (Z); R=Allyl 14-OH 36.66 [28.32-47.44] 49.29 [43.07-56.40] 24.17 81.80 
12 (E); R=t-But 14-OH 28.06 [21.30-36.98] 29.12 [25.12-33.76] 38.75 112.4 
13 (Z); R=Me Δ14,15 45.95 [36.97-57.11] 53.14 [43.54-64.86] 33.36 106.2 
14 (Z); R=Et Δ14,15 53.20 [38.64-73.26] 58.94 [45.86-75.74] 56.41 107.7 
15 (Z); R=Allyl Δ14,15 55.28 [46.21-66.13] 52.72 [39.97-65.53] 61.13 102.7 
16 (Z); R=t-But Δ14,15 63.23 [58.57-68.26] 51.22 [39.13-67.04] 58.99 78.76 
17 (E); R=t-But Δ14,15 63.84 [45.70-89.19] 65.44 [55.66-76.94] 67.46 93.95 
18 δ-lactam Δ14,15 63.42 [47.51-84.65] 72.35 [64.39-81.29] 1.16 4.27 
19 - 14-OH 162.3 [82.41-319.7] 142.1 [77.47-260.5] 0.68 1.53 
Dox - - 0.080 [0.053-0.12] 4.49 [3.43-5.89] - - 
a
 R groups refer to the alkyl substituents of ecdysteroid 6-oxime ethers 7-17 
b IC50 values were calculated by the CompuSyn software as the median cytotoxic activities (Dm) from the control 
lanes on the checkerboard plates of the combination 
Although the tested compounds demonstrated weak to moderate cytotoxic effects on the 
mouse lymphoma cell line pair, all derivatives obtained through the transformation of 20E 
2,3;20,22-diacetonide (4), ecdysteroids 5-18, respectively, were stronger than the parental 
compound. In contrast, we observed feeble cytotoxic effect for poststerone 2,3-acetonide 20-
oxime (19); in this analog’s case, the formation of the oxime moiety at C-20 could almost two-
fold-decrease the cytotoxicity compared to its parental compound 4.  
Cytotoxic properties of the compounds were also tested in combination with doxorubicin, 
to which the MDR cells show efflux-mediated resistance, to study possible drug-drug 
interactions. Results of the combination assays are summarized in Table 6. 
As it is displayed in the table, all tested compounds acted in synergism with doxorubicin, 
in other words, they exerted a chemo-sensitizing activity towards the cytotoxic effect of 
doxorubicin. The most promising compound we identified was the ecdysteroid lactam 18, 
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which was slightly stronger than our previous lead (compound 3) on both the MDR and the 
non-MDR cell lines. It is of further interest that this derivative, along with poststerone 2,3-
acetonide 20-oxime (19), was found practically inactive as a functional inhibitor of the efflux 
transporter unlike compound 3 that was a weak inhibitor. 
Table 6. Chemo-sensitizing activity of compounds 3 and 5-19 on the L5178 and L5178MDR cell 
lines towards doxorubicin at 50, 75 and 90% of growth inhibition (ED50, ED75 and ED90, 
respectively). CI: combination index; CIavg: weighted average CI value; CIavg = (CI50 + 2CI75 + 
3CI90)/6. CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and antagonism, 
respectively. Dm, m, and r represent antilog of the x-intercept, slope, and linear correlation 
coefficient of the median-effect plot, respectively. 
        CI at           
Compound Cell line 
Drug 
ratio 
ED50 ED75 ED90 Dm m r CIavg 
3 91 L5178MDR 20.4 : 1 0.27 0.14 0.07 11.678 3.246 0.964 0.13 
  L5178 163 : 1 0.67 0.55 0.46 11.236 2.103 0.942 0.53 
5 L5178MDR 15 : 1 0.26 0.16 0.12 4.454 6.638 1.000 0.16 
  L5178 150 : 1 0.80 0.79 0.78 10.748 2.572 0.997 0.78 
6 L5178MDR 30 : 1 0.32 0.25 0.20 7.595 3.981 0.994 0.24 
  L5178 150 : 1 0.98 0.76 0.61 16.049 3.239 0.986 0.72 
7 L5178MDR 15 : 1 0.17 0.16 0.16 6.605 3.721 0.978 0.16 
  L5178 150 : 1 1.06 0.79 0.62 14.306 2.947 0.971 0.75 
8 L5178MDR 7.5 : 1 0.18 0.14 0.12 5.001 5.858 1.000 0.14 
  L5178 37.5 : 1 0.55 0.58 0.60 8.598 2.495 0.972 0.59 
9 L5178MDR 3.75 : 1 0.27 0.16 0.13 3.030 3.329 0.993 0.16 
  L5178 37.5 : 1 0.63 0.52 0.45 8.078 3.858 0.952 0.50 
10 L5178MDR 15 : 1 0.17 0.13 0.13 4.939 3.193 0.955 0.14 
  L5178 150 :1 1.03 0.81 0.69 8.970 2.178 0.991 0.79 
11 L5178MDR 15 : 1 0.17 0.16 0.17 7.338 3.771 0.947 0.17 
  L5178 75 : 1 0.70 0.83 1.03 8.202 1.722 0.956 0.91 
12 L5178MDR 7.5 : 1 0.30 0.20 0.17 3.928 4.610 1.000 0.20 
  L5178 37.5 : 1 0.58 0.63 0.70 7.606 2.502 0.966 0.66 
13 L5178MDR 7.5 : 1 0.17 0.16 0.15 5.224 3.722 0.971 0.16 
  L5178 37.5 : 1 0.77 0.47 0.31 8.165 3.044 0.982 0.44 
14 L5178MDR 7.5 : 1 0.21 0.14 0.11 6.133 4.890 0.992 0.14 
  L5178 75 : 1 0.49 0.50 0.52 7.864 2.094 0.961 0.51 
15 L5178MDR 3.75 : 1 0.25 0.15 0.11 5.614 5.805 1.000 0.15 
  L5178 37.5 : 1 0.46 0.47 0.47 8.295 2.882 0.981 0.47 
16 L5178MDR 7.5 : 1 0.34 0.26 0.23 8.365 3.378 0.939 0.26 
  L5178 37.5 : 1 0.53 0.59 0.66 9.652 2.400 0.961 0.62 
17 L5178MDR 7.5 : 1 0.27 0.24 0.23 8.739 3.813 0.960 0.24 
  L5178 37.5 : 1 1.16 0.85 0.64 7.199 3.273 0.977 0.80 
18 L5178MDR 15 : 1 0.20 0.12 0.09 6.419 4.953 0.970 0.12 
  L5178 150 : 1 0.40 0.42 0.46 10.477 2.033 0.966 0.44 
19 L5178MDR 30 : 1 0.34 0.20 0.13 30.423 2.306 0.968 0.22 
  L5178 300 : 1 0.56 0.45 0.40 84.393 1.665 0.995 0.47 
 
IV.1.5.3 Antiproliferative effect of self-assembled ecdysteroid NPs on A2780ADR cells [III] 
Ecdysteroid NPs and H-NPs 25NP, 26NP, 25NP-DOX and 26NP-DOX were tested for their 
potential to inhibit the cell growth of A2780ADR cells, a human ovarian carcinoma doxorubicin-
resistant cell line. The results are shown in Table 7. 
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Table 7. Inhibitory activity of NPs and H-NPs of compounds 25 and 26 on the growth of 
A2780ADR cells. Dox-Sq: squalene-functionalized doxorubicin, GI: grow inhibition, GI50: 
concentration of the test agent inducing 50% reduction in cell number compared with control 
cultures. Values are the mean ± SD of at least four independent experiments. 
 A2780ADR cells (GI50, µM) 
Compound (X) XNP XNP-DOX 
25 19 ± 3 0.34 ± 0.08 
26 39 ± 4 0.26 ± 0.03 
Dox-Sq 1.17 ± 0.06 ---- 
The results indicated remarkable differences between the cytotoxicity of the NPs and H-
NPs of conjugates 25 and 26. Accordingly, ecdysteroid NPs 25NP and 26NP exerted a 
measurable, yet low antiproliferative effect, while 25NP-DOX and 26NP-DOX displayed 
cytotoxicity in the sub-micromolar range, and presence of the ecdysteroid in these H-NPs 
resulted in a nearly four-time increase of activity as compared to that of squalene-coupled 
doxorubicin NPs. 
IV.2 PROTOFLAVONOIDS 
IV.2.1 Preparation of compounds 28-34 as substrates for further transformations 
We achieved the oxidative dearomatization of the B-ring of apigenin (26) utilizing PIDA 
in acetonitrile medium in the presence of water or an appropriate alcohol according to the 
desired alkyl substituent to be coupled at C-1ʹ. Under reflux, the reaction resulted in 
protoapigenone (28) or its 1ʹ-O-alkyl ether analogs (29-34) in an hour. Purification of the 
derivatives was straightforward by flash chromatography, which afforded the pure products in 
typically fair yields. During the separation process, we used the chromatographic conditions 
similar to those described in our previous publication 114. Compounds 28-34 served as 
intermediates for further transformations, therefore their synthesis is presented jointly with 
those in Scheme 8. 
IV.2.2 Results of synthetic modifications on the protoapigenone B-ring 
IV.2.2.1 Continuous-flow saturation of the B-ring of protoflavones 28-33 [IV, V] 
We carried out the selective hydrogenation of the protoflavone B-ring of starting 
materials 28-33 employing a modified version of H-cube® continuous flow hydrogenation 
reactor. For this task, we developed a general synthetic procedure by performing a series of 
small-scale test reactions with compounds 28 and 33 to identify optimal synthetic conditions. 
Figure 7 summarizes the results of this study. 
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Entry 
Starting 
materiala 
Catalyst Solvent 
p 
(bar) 
T (°C) 
Flow 
(ml/min) 
Conv.b 
(%) 
Selectivityb (%) 
28a or 33a 35 or 40 27 
1 33 Lindlar catalyst EtOAc 20 25 1 19 not detected 
2 33 Lindlar catalyst EtOAc 40 25 1 43 0 88 12 
3 33 Lindlar catalyst EtOAc 80 25 1 99 0 92 8 
4 33 Lindlar catalyst EtOAc 80 25 1.5 38 0 not detected 
5 33 Lindlar catalyst EtOAc 40 50 1 78 0 66 34 
6 33 Lindlar catalyst MeOH 80 25 1 97 0 81 19 
7 33 5% Pd/C EtOAc 20 25 1 71 0 82 18 
8 33 5% Pd/C EtOAc 40 25 1 100 0 84 16 
9 28 5% Pd/C EtOAc 40 25 1 99 traces 77 23 
10 28 5% Pd/C MeOH 40 25 1 99 traces 80 20 
Figure 7. Results of the optimization of conditions for the continuous-flow hydrogenation of 
compounds 28 and 33. a: cstarting material=1 mg/ml; 
b: Determined by 1H NMR spectroscopic 
analysis of the crude product mixture. 
We achieved our best results for the selective saturation of the B ring by employing 5% 
Pd/C catalyst, 1 ml/min sample solution flow rate, and 40 bar pressure at ambient temperature 
(Figure 7, entry 9 and 10). These conditions were then applied to prepare further B-ring reduced 
derivatives. The substrates were dissolved in ethyl acetate (compounds 29-33) or methanol 
(compound 28), considering their relative polarity. Following the transformations, we purified 
the products by preparative RP-HPLC to afford tetrahydroprotoapigenone derivatives 35-40 in 
fair yields (See Table 3 for the details of chromatographic purification). In addition, we aimed 
to further increase the available number of interesting, potentially bioactive protoflavone 
derivatives by performing selective deuteration of the B-rings of substrates 28-33. To this, we 
slightly modified the procedure employed during the hydrogenations, and by using 5% 
Pd/BaSO4 catalyst, and ethyl acetate as a sample solvent, we successfully obtained the desired 
tetradeuteroprotoapigenone analogs 41-46 (Scheme 8). The compounds were purified by 
preparative RP-HPLC (see Table 3) to afford them in fair yields. 
IV.2.2.2 Synthesis of protoflavone 4ʹ-oxime derivatives [V] 
We successfully transformed the 4ʹ-keto group of protoapigenone analogs 32-34, and 
tetrahydroprotoapigenone derivatives 35 and 40 to an oxime, by using hydroxylamine 
hydrochloride reagent in methanol. Each reaction was regioselective towards the 4ʹ-keto group; 
however, in the cases of substrates 32-34, the transformation was accompanied by the acid-
catalyzed Michael-addition of the solvent at C-2ʹ that resulted in the saturation of one double 
bond on the p-quinol dienone. Product mixtures were successfully purified by flash 
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chromatography and preparative RP-HPLC (see Table 3) to afford the corresponding 2ʹ-
methoxy-2ʹ3ʹ-dihydroprotoapigenone 4ʹ-oxime analogs 47-52, or tetrahydroprotoapigenone 4ʹ-
oximes 53-54 as racemates, in low to moderate yields. Reactions are presented in Scheme 8. 
 
Scheme 8. Synthesis of tetrahydro-, tetradeutero- or 4ʹ-oxime analogs of protoapigenone and 
its 1ʹ-O-alkyl or propargyl ether derivatives. Oximes 47-54 were obtained as racemates; for 
simplicity only one enantiomer is shown. 
IV.2.3 Structure elucidation of the prepared protoflavonoids [IV, V] 
Protoflavonoid derivatives 28-34 were previously synthesized and fully characterized by 
our research group, therefore, their identification was straightforward in comparison with our 
readily available reference compounds. 
Structure elucidation of products 35-54 was performed by means of HR-MS, MS, and 
1D- and 2D-NMR spectroscopy (see section III.2.3). Molecular formula of derivatives 35 and 
40 was confirmed by HR-MS [IV], and MS analysis of products 36-39 and 41-54 allowed the 
determination of their molecular mass with respect to the [M-H]-  parental ion that was 
systematically observed as the base peak of the spectra [V].  
Modifications in the protoflavonoid B ring were analyzed by comparing the 1H and 13C 
chemical shifts of the products 35-54 with those of the corresponding parent compounds (see 
Scheme 8). The synthesized cis-trans oxime isomers were assigned considering the 
characteristic coupling constant patterns observed between H-2ʹ and H-3ʹa or H-3ʹb. Structures 
were optimized by the MMFF94x force field in CCG-MOE, the H2ʹ-C2ʹ-C3ʹ-H3ʹa, and H2ʹ-
C2ʹ-C3ʹ-H3ʹb dihedral angles were measured, and theoretical 1H-1H 3J coupling constants were 
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calculated utilizing the Bothner-By equation 129. The experimental coupling constants were in 
good agreement with the calculated ones allowing the assignation of compounds 47-49 as the 
1ʹ,2ʹ-trans, and 50-52 as the 1ʹ,2ʹ-cis isomers. The orientation of the oxime moieties was 
determined by using compounds 53-54 as internal references; their C-3ʹ (syn) and C-5ʹ (anti) 
13C NMR chemical shifts appeared at ca. 18.8 and 26.2 ppm, respectively. The 13C NMR signals 
of the 3ʹ-CH2 moieties of compounds 47-52 appeared within the range of 22.7–23.7 ppm, which 
suggested that the oxime is present in E-configuration in each of these compounds while we 
also considered the effect of the electron-rich neighbouring OCH3 group. 
Among the obtained protoflavonoid analogs, derivatives 36-54, a total of 11 compounds 
and 8 racemates were new. 
IV.2.4 Results of the bioactivity tests 
IV.2.4.1. Cytotoxicity on cancer cell lines and inhibition of DNA-damage response [IV] 
In vitro cytotoxic activity of compounds 35 and 40 were tested on MCF-7, HeLa, and 
SiHa human adherent cancer cell lines. As expected, selective saturation of the protoflavone B-
ring resulted in a dramatic decrease in the compounds’ cytotoxicity. Consequently, we could 
only determine an IC50 value for compound 40 on HeLa cells (55.12 ± 1.11 µM); in all other 
cases, the 50% inhibitory concentrations were systematically above 100 µM. 
Besides, compounds 35 and 40 were also tested for their potential to inhibit the activation 
of DNA damage response through the ATR/ATM signaling pathways. While we found 
derivative 35 completely inactive inhibiting the phosphorylation of Chk1 and Chk2, its 1ʹ-O-
butyl ether 40 could exert measurable effect on Chk1, yet only at its highest tested dose (20 
µM). To study the possible relevance of this finding, the compounds’ chemo-sensitizing activity 
toward doxorubicin was tested by a series of combination studies, and neither protoflavonoid 
derivative was found to interact with this chemotherapeutic agent (data not presented). 
IV.2.4.2 Antiviral activities of obtained protoflavonoid products [V] 
Protoflavonoid products 28, 32-40 and 47-54 were tested against HIV-1 by a pseudotype 
virus assay (see section III.2.4.2). Among these compounds, tetrahydroprotoapigenone (35) was 
able to inhibit viral infection by ca. 50% at a concentration of 100 µM, while no cytotoxicity 
was observed up to a concentration of 500 µM (data not presented).  
Further, compounds 28 and 32-54 were tested for their activity against the EBV lytic 
cycle. To this, the expression of the EBV lytic protein Rta was studied in P3HR1 host cells. 
First screening was performed at a concentration of 0.25 µM, and three compounds (32-34) 
were found active. Then, dose-dependency of this activity was determined, as well as the 
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compounds’ cytotoxicity on P3HR1 cells. Results are summarized in Figure 8. 
 
Figure 8. A) Inhibition of the expression of Epstein–Barr Virus (EBV) lytic protein Rta by 
protoapigenone (28) and its analogs 32-34. P3HR1 cells were treated with the compounds at 
the time of lytic induction with SB and TPA. Cell lysates were harvested at 24 h after lytic 
induction. B) Cytotoxicity of the compounds on P3HR1 cells. Cells were cultured for 24 h in a 
medium containing protoapigenone (28) or compounds 32-34. Cell viability was evaluated by 
the MTT assay. Cells treated with 1% Triton X-100 (TX) were used as a positive control. 
Results of the anti-EBV activity testing (Figure 16-A) indicated the ability of all three 
compounds 32-34 to cause a reduction in the Rta levels at concentrations of 0.50, 0.25 and 0.50 
µM, respectively. The calculated IC50 values for the positive control protoapigenone (28) and 
the tested protoflavonoids 32-34 were 0.127, 0.467, 0.208 and 0.285 µM, respectively. 
 Regarding the results of the cytotoxicity assays (Figure 16-B), compounds 33 and 34 
were similarly active as protoapigenone (28), while the isopropyl ether derivative 32 was much 
weaker in this regard. Based on our results, selectivity of the anti-EBV vs cytotoxic effect of 
compounds 28 and 32-34, expressed as a ratio of the corresponding IC50 values, were calculated 
as 30.1, 73.0, 9.80 and 17.3, respectively. Accordingly, we found a 73-times selectivity of 
antiviral over cytotoxic activity in the case of protoapigenone 1ʹ-O-isopropyl ether (32), in 
contrast with the slightly stronger antiviral, yet much more cytotoxic protoapigenone (28).  
V. DISCUSSION 
V.1 ECDYSTEROIDS 
V.1.1 Preparation and further derivatization of ecdysteroid oximes 
Selection of ecdysteroid acetonide substrates. Since the discovery of certain 
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ecdysteroids’ chemo-sensitizing activity, our research group performed several studies aiming 
to explore relevant SARs. We know that presence of acetonide groups on the ecdysteroid vicinal 
diols, particularly that of the 2,3-moiety is a prerequisite of a strong effect 87. It is important to 
stress that, while acetonide is a widely used, popular protective group in organic chemistry, it 
is also a fully biocompatible building block for drug design. This is well demonstrated by the 
example of an approved drug, the corticosteroid triamcinolone acetonide that is not a pro-drug 
but acts in its intact form 130. 
When we started to explore the chemical space of ecdysteroid oximes, 20E 2,3;20,22-
diacetonide (3) was as a natural choice for transformation due to its potent chemo-sensitizing 
activity 87, and due to the abundance of its synthetic precursor 20E (1). We had kilogram-scale 
quantities of 20E as a high-purity (ca. 90% by HPLC) commercial product prepared from 
Cyanotis arachnoidea and marketed as a food supplement 131. A second substrate we found 
particularly attractive for oximation was poststerone 2,3-acetonide (4): the key biosynthetic 
precursor of this compound is poststerone (2), which was identified as an in vivo metabolite of 
20E (1) in mice after oral administration 132. Poststerone (2) can also conveniently be prepared 
through semi-synthesis from 20E (1) by oxidative cleavage of the sterol chain in a yield of up 
to ca. 80% 64. Poststerone (2) can simply be transformed to its 2,3-acetonide (4) that has similar 
chemo-sensitizing activity as 20E 2,3;20,22-diacetonide (3) but without interfering with the 
efflux function of P-gp 89. Additionally, the C-20 carbonyl moiety of compound 4 was a 
promising target for oximation in our synthetic strategy to increase the number of interesting, 
potentially bioactive compounds for pharmacological testing.  
Semi-synthesis of ecdysteroid 6-oxime and oxime ether analogs [I]. There is 
considerable scientific interest towards antitumor steroid oximes 133,134. However, to the best of 
our knowledge, ecdysteroid oximes have not been studied previously for their bioactivities. 
Galyautdinov et al. reported the preparation of several ecdysteroid 6-oximes from 20E 
2,3;20,22-diacetonide (3) through a variety of synthetic procedures that afforded derivatives 
retaining the 14-hydroxyl group, as well as 14,15-anhydro 6-oxime isomers 92. Our synthetic 
approach confirmed their previous observations on the formation of these compounds, and 
highlighted regularity in the product patterns of ecdysteroid 6-oximation depending on the 
neutralization procedure applied. First, if the reaction’s work-up process does not include a 
neutralization step, a mixture of 14,15-anhydro (E/Z)-isomeric oxime pairs are formed. Second, 
if neutralization is performed with alkali dissolved in anhydrous methanol, a 2-4 components 
mixture of both intact 14-hydroxy- and 14-OH-eliminated derivatives is formed. Third, if the 
neutralizing alkali is dissolved in anhydrous ethanol, a mixture of intact 14-hydroxy-(E/Z)-
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oxime isomer pair can be obtained. It is worth noting that in our case, the relatively low isolated 
yield of the oxime and oxime ether products was not really a drawback, since the high structural 
diversity of the obtained compounds was coherent with our objectives to enhance chemical 
diversity towards potentially bioactive compounds instead of maximizing yields. 
Beckmann-rearrangement of ecdysteroid (6E)-oxime 5. Previously, Shafikov et al. 
reported an in-depth study on the Beckmann-rearrangement of ecdysteroid 6-oximes 128. 
Briefly, they found that this rearrangement of ecdysteroid oximes does not work through acid 
catalysis; instead, TsCl catalyst should be used in acetone in the presence of Na2CO3. It is 
essential to emphasize the importance of alkali; as mentioned above (see Figure 3 of chapter 
II.3), the presence of the 2,3-acetonide is required for the strong antitumor activity, and, 
unfortunately, this moiety is highly acid-sensitive. Since under the applied reaction conditions 
the rearrangement process gives rise to hydrochloric acid, the use of alkali is particularly 
important in our case, to prevent the acid-promoted cleavage of the acetonide pharmacophore. 
Further, the Beckmann-rearrangement is known as a stereospecific reaction that involves the 
migration of the chemical group located in anti-position with respect to the oxime’s hydroxyl. 
In case of (6Z)-oxime 6, the corresponding group is C7H with an sp2-hybridized carbon atom 
whose migration is chemically disabled, and therefore this reaction does not produce the desired 
7-membered lactam ring, but an ecdysteroid (6Z)-O-tosyloxime instead. Accordingly, we could 
perform the Beckmann-rearrangement solely of ecdysteroid (6E)-oxime 5. 
In our publication related to the thesis, we used liquid-liquid extraction for the reaction 
work-up [I]. Following this, we performed the RP-HPLC purification of the obtained 
ecdysteroid lactam derivative 18 that afforded the product in a very low, 8% yield (see section 
IV.1.2.3). In this Ph.D. dissertation, an update to this former work-up strategy is presented with 
the use of SPE instead of LLE. Due to its relatively low polarity, TsCl tends to remain in large 
quantities in the organic phase during LLE. Therefore, the sample’s straightforward SPE 
fractionation on plain silica gel might represent a simple, yet effective work-up alternative that 
ensures the quantitative removal of unreacted reagent remains.  This way, we can prevent the 
occurrence of rapid and undesired product decomposition related to the activity of the retained 
reagent, and subsequently isolate ecdysteroid lactam 18 in remarkably higher yields. 
Semi-synthesis of ecdysteroid 20-oxime analogs. Previously, Savchenko et al. reported 
a procedure on the regioselective C-20 oximation of poststerone 2,3-acetonide (4) 135. However, 
following the method described, we failed to obtain the desired 20-oxime product and instead, 
our attempt afforded a pair of isomeric dioximes. Consequently, we decided to perform the 
synthesis of the C-20 oxime (19) and methyl oxime ether (20) analogs of substrate 4 by 
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modifying the procedures we applied for the preparation of ecdysteroid 6-oxime and oxime 
ethers 5-17. First, we performed small-scale test reactions to identify suitable synthetic 
conditions that could afford the products’ synthesis with reasonable efficiency. As a result, we 
found different synthetic conditions optimal for the preparation of compounds 19 and 20. This 
way, we achieved a complete conversion and the highly selective preparation of compound 19 
in pyridine, upon stirring the reaction mixture for 25 minutes at RT. In contrast, when using the 
same reaction conditions for the synthesis of ecdysteroid oxime ether 20, only traces of the 
target compound were formed. Thus, we decided to perform the transformation under heating 
and using higher reagent amounts. Results of our synthetic work-up method were in complete 
agreement with our previous observations since the 14-OH group was not eliminated in either 
of the products upon neutralizing their post-reaction mixture with an ethanolic solution of KOH.  
V.1.2 Preparation of self-assembled ecdysteroid nanoparticles 
To the best of our knowledge, self-assembling drug conjugates of ecdysteroids have not 
been prepared and studied before. Nano-formulation of these compounds may have several 
benefits. First, the acid sensitivity of the pharmacologically crucial 2,3-acetonide group is a 
weak point concerning the stability of these compounds, and this problem may be solved with 
such a formulation. Further, currently little is known about the in vivo efficacy and safety of 
ecdysteroid acetonides, and these properties may also be improved by this strategy 136. 
Previously, Couvreur et al. described the concept of squalenoylation, which is based on the use 
of squalene (21) as a covalent partner in lipid-drug conjugates for drug delivery and targeting 
purposes 99 (for details, please see section I.4.2). Considering the simplicity, efficiency and 
flexibility of the method, in this Ph.D. study, we planned to initiate exploring the yet unknown 
chemical and pharmacological space of squalenoylated ecdysteroid bioconjugates and their 
corresponding self-assembled NPs.  
Synthesis of squalenoylated ecdysteroid bioconjugates. Since ecdysteroids are 
relatively hydroxylated molecules, we found it reasonable to obtain their bioconjugates through 
esterification. To assure regioselectivity, this required the presence of possibly one single 
sterically accessible, reactive hydroxyl group on the antitumor ecdysteroid. Taking this into 
account, poststerone 2,3-acetonide 20-oxime (19) was a particularly attractive substrate for 
functionalization from multiple-aspects: 1) similarly to its parent compound 4 (and ecdysteroid 
lactam 18), the adjuvant antitumor effect of compound 19 was not accompanied by efflux pump 
inhibitory activity (see Table 5 of section IV.1.5.2); and, 2) the hydroxyl on the 20-oxime group 
of compound 19 appeared as free and easily accessible, in contrast with the 14α-OH and 25-
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OH moieties of e.g., compounds 4 and 18, respectively. 
Considering the above, nano-formulation of compound 19 was performed in three major 
steps. First, squalene (21) was transformed to 1,1ʹ,2-tris-norsqualene alcohol (22) in four 
synthetic steps according to the synthetic route previously described by Borelli et al. 95. As 
mentioned in section I.4.1., the use of a well-chosen linker in bioconjugates may influence the 
in vivo fate of a drug. Previously, Borelli et al. reported the use of a linker bearing a disulfide 
bridge that could enhance the in vitro antitumor properties of squalenoylated paclitaxel NPs 95. 
Considering this, the second major step of this work was to condensate 1,1ʹ,2-tris-norsqualene 
alcohol (22) with two different types of dicarboxylic acid linkers, sebacic acid and its SS-bond-
containing analog 4,4′-dithiodibutyric acid, to obtain monoesters 23 and 24, respectively. 
Finally, in the third major step, poststerone 2,3-acetonide 20-oxime (19) was esterified by the 
monocarboxylic acids 23-24 to afford ecdysteroid conjugates 25 and 26, respectively. 
Preparation and characterization of ecdysteroid nanoparticles. Self-assembly of 
squalenoylated bioconjugates is typically obtained through nanoprecipitation in aqueous 
medium 93. Fumagalli et al. previously demonstrated that NPs can be obtained by not only the 
self-assembly of a single bioconjugate but also from combined mixtures of drug conjugates that 
may consequently form heteronanoparticles (H-NPs). Accordingly, the concept of preparing H-
NPs might be a promising approach to improve the pharmacological performance of either 
squalenoylated constituent in a task-oriented manner by adequately varying the ratio of the 
combined drugs 137. Recognizing this, at this point of our study, batches from the ecdysteroid 
conjugates 25 and 26 were mixed with squalenoylated doxorubicin, which has been reported to 
have a better therapeutic index than free doxorubicin 103. Therefore, self-assembly led to the 
formation of a total of four nano assemblies that were subsequently characterized by TEM and 
DLS techniques. TEM-images were recorded for the purposes to confirm the formation of NPs 
and to study their morphology. By employing DLS, two fundamental characteristics were 
studied: particle size distribution, which is a major determinant of biodistribution and retention 
of NPs in targeted tissues, and surface charge expressed as zeta potential, which influences the 
interaction of NPs with the environment 98. At this point, however, it needs to be stressed that 
colloid chemical estimates of the biological efficacy of squalenoylated NPs might be of little in 
vivo relevance. This is because, once administered, these particles suffer a relatively fast 
disassembly by endogenous lipoproteins that will then transport the dismantled bioconjugates 
in the blood stream until taken up by the lipoprotein receptors of the target tissue 102. 
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V.1.3 In vitro antitumor activity of the ecdysteroid derivatives obtained  
It was our hypothesis that the nitrogen-containing moieties of the newly prepared 
ecdysteroids may substantially influence their antitumor properties. Accordingly, we subjected 
derivatives 5-19 to related bioactivity testing. 
Antiproliferative activities on human gynecological cancer cell lines. When analyzing 
SARs, we found that the orientation of the 6-oxime or oxime ether function had little if any 
impact on the observed antiproliferative activity, although the presence of a larger alkyl ether 
group on the oxime resulted in a noticeably stronger effect. Besides, on the MCF-7 cell line, a 
retained 14-αOH group was found favorable over the Δ14-15 olefin moiety, though the same 
conclusion could not be drawn from the results on other cell lines. 
Cytotoxicity on murine lymphoma cell lines, and ABCB1-inhibition. Multi-drug 
resistance (MDR) is a major limitation to the chemotherapy of cancer 138. Previously, we found 
that less polar ecdysteroid derivatives can strongly sensitize both MDR and drug-susceptible 
cancer cell lines to various chemotherapeutics 87,88. Therefore, we subjected the synthesized 
ecdysteroid diacetonide derivatives 5-19 for related bioactivity testing. First, cytotoxicity of the 
compounds was tested on a susceptible/resistant murine lymphoma cell line pair. Then, the 
compounds were tested for their inhibitory activity on the ABCB1 efflux transporter, whose 
over-expression is the most frequent cause of the acquisition of an MDR phenotype in cancer 
138. Results of these assays (see Table 5) revealed several SARs. We found that, while each 
compound showed only weak to moderate cytotoxicity, the non-substituted 6-oxime derivatives 
5 and 6 were stronger on both cell lines than the 6-oxime ethers (7-17) or the side-chain cleaved 
20-oxime (19), and among the two isomers, the (6E)-oxime (5) was more potent. In this 
tendency, the only exception was compound 12 containing a t-butyl substituent and a retained 
14-OH group; this compound exerted a cytotoxic effect comparable to that of the non-
substituted oximes (5-6). Further, while derivatives with a retained 14-OH group were 
systematically more cytotoxic than those with a 14,15-anhydro moiety, the cytotoxic effect of 
the 20-oxime derivative 19 was ca. 2-3 times weaker than that of any of the B-ring modified 
analogs. Results of the rhodamine accumulation assay (see Table 5) indicated that only two 
compounds, the ecdysteroid lactam (18) and the side-chain cleaved 20-oxime (19) were inactive 
as functional efflux pump inhibitors at as much as 20 µM concentration. We consider this as a 
positive feature, since our main research interest concerns compounds that can sensitize MDR 
cancer cells without directly interfering with drug efflux. For other derivatives, we found that 
oxime, and particularly oxime ether formation significantly increased the ABCB1 inhibitory 
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activity. In this regard, for 6-oxime and oxime ether derivatives possessing the same type of D 
ring and oxime configuration, we found that the increase of C atom number in the C-6 
substituent increased this activity. Further, while the orientation of the oxime moiety had no 
considerable influence on the ABCB1-inhibition, elimination of the 14-OH group could 
markedly increase this activity. 
The compounds were subsequently tested for their chemo-sensitizing properties on the 
same murine lymphoma cell line pair towards the cytotoxicity of doxorubicin. Here, due to a 
large number of highly active compounds, SARs were concluded using our previously 
described “best ratio” approach that compared the compounds’ chemo-sensitizing activities at 
their strongest effect observed on the checkerboard plates, instead of comparing activities at the 
same compound vs. doxorubicin ratio 87. On the MDR cell line, we observed strong to very 
strong activities, according to the rating of Chou 126. The length or nature of the oxime ethers’ 
alkyl substituent had no apparent influence on the compounds’ chemo-sensitizing property. 
Although we could observe a slight tendency for water eliminated derivatives possessing 
stronger activities than those with a retained 14-OH, this phenomenon was not unequivocal. 
Potent sensitizing activities were observed on the non-MDR cell line too; here, the formation 
of oxime moieties together with the elimination of the 14-OH group (5 and 6) decreased the 
strength of synergism with doxorubicin as compared to the parental compound 3. In the case of 
the oxime ethers, derivatives with a 14,15-anhydro moiety were typically stronger chemo-
sensitizers than their analogs with intact 14-OH groups, except compounds 12 and 17 with t-
butyl substituents. Accordingly, we can hypothesize that a larger, bulky substituent might 
contribute to a decreased sensitizing property. 
Nevertheless, taken all aspects together, the most promising compound we identified was 
the ecdysteroid lactam (18) due to its low intrinsic cytotoxicity, and strong ability to sensitize 
MDR and non-MDR cancer cells to doxorubicin without interfering with the efflux function of 
P-gp. Therefore, we suggest this compound as a promising novel lead for further studies. 
Antitumor activity of self-assembled NPs. To the best of our knowledge, before our 
investigations, the adjuvant antitumor effect of ecdysteroids has not been studied in self-
assembling nano-delivery systems. The most important finding of our study was that these 
compounds retain their chemo-sensitizing activities after such a formulation, and this was 
shown to contribute to the ability of their doxorubicin-containing H-NPs to overcome the drug 
resistance of A2780ADR cells. The obtained results may provide a promising basis for further 
investigations on the use of ecdysteroid acetonides in similar or other types of antitumor 
nanostructures, and such conjugates may provide a useful platform to overcome unfavorable 
46 
 
pharmacokinetic properties (such as acid sensitivity and poor water solubility) of these 
compounds. Additionally, the differences observed between the activity of the NPs underline 
the relevance of the linker entities in the intracellular penetration of the drug. 
V.2 PROTOFLAVONOIDS 
V.2.1 Semi-synthesis of protoflavonoid derivatives 
Protoflavonoids are mostly recognized for their antitumor properties; however, evidence 
suggests that they may exert various bioactivities that point beyond their antitumor action 121,122. 
In this Ph.D. work, we aimed to extend their chemical and pharmacological space towards less 
cytotoxic derivatives to initiate exploring their pharmacological potential in new directions.  
We selected protoapigenone (28), and its 1ʹ-O-alkyl analogs (29-34) as substrates of our 
studies; some of these derivatives have been previously reported to exert interesting, non-
tumor-related bioactivities 121,122. Since the key pharmacophore for the cytotoxicity of 
protoflavones is the symmetric dienone on the B-ring 124, we chose this moiety as the target of 
our semi-synthetic transformations to prepare less cytotoxic, yet potentially bioactive 
derivatives. In this context, we employed two different synthetic strategies: 1) the selective 
saturation of the protoflavone B-ring to obtain analogs possessing the rare, naturally occurring 
dihydro- and/or tetrahydroprotoflavone structural elements 139,140; and/or 2) the substitution of 
the protoflavone 4ʹ-oxo moiety with an oxime function. To the best of our knowledge, none of 
these transformations have been performed before our studies. 
The first step of our preparative strategy (see Scheme 8 of section IV.2.2.1) was the 
oxidative dearomatization of apigenin (27), which was carried out according to our previously 
published procedure using hypervalent iodine reagent PIFA in acetonitrile in the presence of 
water or alcohol 114. Following a thorough chromatographic purification, we used the obtained 
products 28-34 as intermediates in subsequent synthetic transformations, while, from this set of 
derivatives, compound 32 was already a compound of interest for our bioactivity studies due to 
its very weak cytotoxicity when compared to the others 114. 
Selective hydrogenation of the protoflavonoid B-ring. The selective hydrogenation of 
the protoflavonoid B-ring appeared as a significant synthetic challenge, since the process may 
be accompanied by numerous undesired side reactions such as the reduction of the carbonyl 
groups 141, the partial hydrogenation of the C- or even the A-ring, and the possible 
rearomatization of the B-ring 142. Moreover, if hydrogenation is performed under traditional 
batch-based conditions, further difficulties should be taken into account, including the 
inconvenience of handling the explosive gas, inadequate control over the reaction conditions, 
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and the lack of sustainability and safety 143. Considering that heterogeneous catalytic 
hydrogenations can provide notable benefits through the advantageous features of continuous 
processing 144, we set out to perform our planned transformations in a modified H-cube® 
continuous flow hydrogenation reactor. During operation, the device generated the hydrogen 
gas in situ by electrolytic decomposition of deionized water. The triphasic reaction took place 
in a stainless-steel cartridge that was previously filled with the hydrogenation catalyst and was 
subsequently placed in a thermostat to assure temperature control.  
We selected two model substrates for method optimization: the protoflavone antitumor 
lead protoapigenone (28) and its less polar, 1ʹ-O-butyl ether analog (33) that is more cytotoxic 
on certain cell lines and has improved chemical stability 114. Considering previous results on 
the selective C-C double bond reduction of aromatic enones 141, our initial choice for the role 
of the catalyst fell on the Lindlar catalyst, and at first, we examined the applied pressure’s 
influence on the transformation. At ambient temperature and a fixed flow rate, the total 
conversion of substrate 3 significantly increased as a function of the pressure (Figure 7, entries 
1-3). Although we observed an almost complete conversion at 80 bar, the reaction’s selectivity 
was decreased due to the rearomatization of the B-ring (Fig. 7, entry 3), leading to the formation 
of around 10% apigenin (27). Considering that rearomatization is known to be related to 
palladium-mediated hydrogenolysis at C-1ʹ 145, we attempted to suppress side-product 
formation by increasing the flow rate, thus reducing the residence time on the catalyst bed (Fig. 
7, entry 4). Unfortunately, this attempt resulted in a significant decrease in conversion. 
Furthermore, the increase of the temperature was also disadvantageous, whereas it resulted in 
a decrease in the selectivity suppressing the formation of apigenin (Fig. 7, entry 5). Taken 
together, at this point, the reaction performed at 25 ℃ and 80 bar provided the complete and 
highly selective saturation (Fig. 7, entry 3) of the B ring of compound 3; however, rapid 
deactivation of the catalyst prevented any synthetic scale-up. Considering this, we switched 
from Lindlar catalyst to 5% Pd/C, and after a couple of test reactions (Fig. 7, entries 7 and 8), 
we achieved total conversion and great chemoselectivity toward the formation of the desired 
tetrahydroprotoflavone product 40. In this case, we observed no catalyst deactivation, and we 
could successfully up-scale the synthesis for preparative purposes. The method was compatible 
with other derivatives as well and afforded the convenient preparation of products 36-39 from 
their substrates. In the case of protoapigenone (28), due to the compound’s poor solubility in 
ethyl acetate, the saturation was performed in methanol instead.  
Selective deuteration of the protoflavonoid B-ring. Deuterium is of potential interest 
for drug discovery since it can considerably influence the bioactivity of a compound due to the 
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so-called isotope effect 146. Considering this, we set out to perform the selective continuous 
flow deuteration of the B-rings of substrates 28-33. We performed the reactions by slightly 
modifying the method used for the hydrogenations on the bases of previously published 
procedures 141,145. Accordingly, we in situ generated the D2 gas necessary for the 
transformations from high-purity D2O with H-Cube
®. Since activated charcoal might contain 
protic contaminations on its surface, we used barium sulfate as the catalyst carrier to ensure that 
no hydrogen-deuterium exchange occurs during the transformations. For the same reason, we 
performed the reactions strictly in an aprotic solvent, ethyl acetate. In every other aspect, we 
adopted the protocol employed during the hydrogenations. 
Semi-synthesis of protoflavonoid 4ʹ-oxime derivatives. It was among our primary aims 
in this Ph.D. work to prepare new protoflavonoid oxime derivatives. Since we intended to 
maximize chemical and pharmacological diversity for our research, we selected substrates with 
different B-ring saturation (32-35 and 40) and/or 1ʹ-O-alkyl substituents for the preparation of 
their 4ʹ-oxime analogs. Our preliminary test reactions showed that the oxime formation of 
protoflavones in the 4ʹ-keto function is regioselective, and under the synthetic conditions used, 
it is not accompanied by the formation of 4-oxime or 4,4ʹ-dioxime side product. However, other 
factors, such as solvent quality, had a crucial influence on the outcome of the transformations. 
Typically used solvents in oxime synthesis are ethanol, pyridine or acetonitrile, but none of 
these worked in our case. Eventually, we found methanol to be the most suitable for reacting 
protoflavones with hydroxylamine. The yields of the transformations greatly varied depending 
on the substrate’s concentration, and, eventually, our best results were obtained at around 2-2.5 
mg/ml concentrations. It is important to mention that while the transformations were 
straightforward for tetrahydroprotoapigenone analogs 35 and 40, in the cases of compounds 32-
34, we observed the regioselective Michael-addition of the solvent at C-2ʹ. 
V.2.2 In vitro biological activity of the protoflavonoid derivatives obtained 
Cytotoxicity on cancer cell lines, and inhibition of DNA-damage response. 
Protoflavonoids are known to be cytotoxic on a broad array of cancer cell lines 110, and certain 
analogs such as protoapigenone (28) exert chemo-sensitizing properties towards DNA-
damaging chemotherapeutics due to their interference with the ATR/ATM signaling pathways 
119. Therefore, we subjected compounds 35 and 40, B-ring saturated analogs of the antitumor 
leads protoapigenone (28) and its 1ʹ-O-butyl ether derivative (33), respectively, to related 
bioactivity assays. The results clearly demonstrated that the selective saturation of the 
protoflavone B-ring could knock out these bioactivities of the derivatives that could potentially 
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confer them toxic side effects. Even though at the highest tested dose (20 µM) the 1ʹ-O-butyl 
ether derivative 40 could significantly inhibit the ATR-dependent phosphorylation of Chk1, 
none of the tested analogs interacted with the in vitro cytotoxicity of doxorubicin.  
Accordingly, our preparative flow chemical strategy allowed us not only to obtain the rare, 
naturally occurring tetrahydroprotoflavone moiety, but it also served as an effective tool to 
eliminate the cytotoxicity of protoflavones. 
Antiviral activities. We hypothesized that protoflavones can exert specific antiviral 
properties based on two considerations. First, protoapigenone (28) was previously found to be 
active against the lytic cycle of EBV 122 at below-cytotoxic concentrations. Besides, 
protoflavones possess a 5-hydroxyflavone moiety, which is a known pharmacophore against 
HIV-integrase that may consequently confer them anti-HIV properties 147. To the best of our 
knowledge, no previous studies on the antiviral activity of protoflavone derivatives have been 
performed, other than the above-mentioned study on EBV that was performed in collaboration 
with our group. Therefore, our less cytotoxic protoflavonoids, obtained from the oxidative de-
aromatization of apigenin (compound 32) and subsequent continuous-flow hydrogenation, 
deuteration, and/or 4ʹ-oxime formation (compounds 35-54), were subjected to related 
bioactivity testing. 
The results of the anti-HIV assay revealed only one compound, tetrahydroprotoapigenone 
(35) exerting a significant anti-HIV activity. Though this activity was rather weak (50% 
inhibition of HIV-1 infection at 100 µM), it might still be of interest for further studies, whereas 
the derivative was not cytotoxic on the host cells at as high as 500 µM concentration. 
Considering the results of the anti-EBV assays, protoapigenone 1ʹ-O-isopropyl ether (32) 
was identified as a promising new lead for a possible design of protoflavone-inspired anti-EBV 
agents due to its 73-times selectivity of antiviral over cytotoxic activity, which exceeds 
protoapigenone’s (28) selectivity by 2.4-times. As a first rational step to such a design, one may 
consider that protoapigenone 1ʹ-O-butyl ether 33 showed an over two-fold stronger anti-EBV 
activity than compound 28; therefore, it may be a relevant future strategy to study further 
analogs possessing a longer, branching substituent at position C-1ʹ (e.g. i-butyl or i-pentyl). 
Concerning our new protoflavone oximes, even though they did not came out as hits in 
these first-line bioassays, they are considered to be tested in various further screening assays 
performed in our collaboration network. On the basis of the anti-EBV activity of compound 28, 
we are also planning to develop a chemoselective strategy for the 4ʹ-oximation of protoflavones 
that would leave the symmetric diene of the B-ring intact, to explore the pharmacological 
potential of derivatives whose cytotoxicity is abolished only by replacing the 4ʹ-oxo group.  
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VI. SUMMARY 
 The aim of the present Ph.D. study was to further extend the chemical diversity of 
ecdysteroids and protoflavonoids towards novel derivatives, and to examine the 
pharmacological potential of introducing oxime function to the structure of these compounds. 
We can summarize our results as follows. 
ECDYSTEROIDS 
1. The preparation and further transformation of ecdysteroid oxime derivatives. A series 
of ecdysteroid oximes and oxime ethers were synthesized from two of our previous ecdysteroid 
antitumor leads, by reacting their available carbonyl functions with appropriate hydroxyl- or 
alkoxyamine derivatives. Further, one of the ecdysteroid 6-oximes was converted to a lactam 
through Beckmann-rearrangement. This way, a total of 16 nitrogen-containing ecdysteroid 
derivatives were prepared, including 14 new compounds. 
2. The preparation of self-assembled NPs from an ecdysteroid oxime. Poststerone 2,3-
acetonide 20-oxime 19 was selected for nano-formulation. The preparation of two different, 
novel squalenoylated bioconjugates (25 and 26) from the derivative was successfully achieved 
through a series of synthetic transformations. Following this, collaborative studies led to the 
successful preparation and characterization of four aqueous nano assemblies: two that contained 
NPs (25NP or 26NP), and two that contained H-NPs of an ecdysteroid conjugate and 
squalenoylated doxorubicin (25NP or 26NP) in their matrix. 
3. Biological evaluation of the ecdysteroids obtained. Results on the in vitro antitumor 
activities of the synthesized ecdysteroid derivatives and ecdysteroid nano assemblies were 
achieved in research co-operations and could briefly be summarized as follows. 
 Antiproliferative effects. Compounds 5-18 were tested on human gynecological cancer cell 
lines and moderate activities were observed, while compound 12 was stronger than the 
positive control cisplatin on HeLa and MDA-MB-231 cell lines. 
 Functional inhibition of the ABCB1-mediated efflux transport. Compounds 5-19 were 
tested; several SARs were revealed, and two derivatives, the ecdysteroid lactam 18 and 
poststerone 2,3-acetonide 20-oxime 19 were inactive in this regard. 
 Chemo-sensitizing activity in combination with doxorubicin. Compounds 5-19 were tested, 
and each of them could considerably sensitize both the MDR and the susceptible cancer cell 
line, with a noticeable selectivity towards the former.  The lactam 18 was identified as our 
most interesting compound for further studies; its chemo-sensitizing activity exceeded that 
of our previous lead (compound 3), while it did not inhibit the efflux function of P-gp. 
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 Inhibition of the growth of A2780ADR cells: ecdysteroid NPs and H-NPs were tested, and 
the chemo-sensitizing effect of squalenoylated ecdysteroid oxime 19 contributed to the 
ability of doxorubicin-containing H-NPs to overcome the drug resistance of the cancer cells 
with cytotoxic activity in the submicromolar range. 
PROTOFLAVONOIDS 
4. Preparation of B-ring modified protoflavone derivatives including oximes. With the aim 
of obtaining less cytotoxic protoflavones for bioactivity testing, synthetic modification of the 
B-ring was targeted. A total of 27 derivatives, including 19 new compounds, were successfully 
semi-synthesized from apigenin through oxidative de-aromatization and subsequent 
regioselective continuous-flow hydrogenation, deuteration, and/or 4ʹ-oximation. The 
continuous-flow method that was developed allowed the first-time synthetic preparation of 
compounds containing the rare, naturally occurring tetrahydroprotoflavone moiety. 
5. Biological evaluation of the protoflavones obtained. The following results on the 
bioactivity of the prepared protoflavone derivatives were achieved in research co-operations. 
 Cytotoxic effects against cancer cell lines and DNA-damage response inhibitory activities. 
Tetrahydroprotoflavone derivatives 35 and 40 were tested; the reduction of the double bonds 
in the p-quinol B-ring of the derivatives resulted in a great decrease in the bioactivity of the 
compounds towards the tested properties. Accordingly, the employed synthetic strategy may 
serve as an effective tool to knock out these bioactivities of protoflavonoids that could 
potentially confer them toxic side effects.   
 Antiretroviral activity. Compounds 28, 32-40 and 47-54 were tested against HIV-1 on a 
pseudotype virus assay; among these compounds, tetrahydroprotoapigenone (35) was found 
to inhibit viral infection by ca. 50% at 100 µM that was more than 5-times below its 
cytotoxic concentration.  
 Antiviral activity against EBV. Compounds 28 and 32-54 were tested; these studies revealed 
a 73-times selectivity of antiviral over cytotoxic activity in the case of protoapigenone 1ʹ-
O-isopropyl ether (32). 
Altogether, a total of 47 semi-synthetic derivatives of natural enones were prepared 
during this work, including 16 new ecdysteroids and 19 new protoflavones. Moreover, 
bioactivity studies revealed a prospective novel lead compound in both major chemical 
directions, i.e., compound 18 (ecdysteroid; potent modulator of multi-drug resistance in cancer 
that does not inhibit P-gp) and compound 32 (protoflavone; potent antiviral agent against EBV 
that is more selective than its parent compound).    
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a b s t r a c t
Multidrug resistance is a widespread problem among various diseases and cancer is no exception. We
had previously described the chemo-sensitizing activity of ecdysteroid derivatives with low polarity on
drug susceptible and multi-drug resistant (MDR) cancer cells. We have also shown that these molecules
have a marked selectivity towards the MDR cells. Recent studies on the oximation of various steroid
derivatives indicated remarkable increase in their antitumor activity, but there is no related bioactivity
data on ecdysteroid oximes. In our present study, 13 novel ecdysteroid derivatives (oximes, oxime ethers
and a lactam) and one known compound were synthesized from 20-hydroxyecdysone 2,3;20,22-
diacetonide and fully characterized by comprehensive NMR techniques revealing their complete 1H
and 13C signal assignments. The compounds exerted moderate to strong in vitro antiproliferative activity
on HeLa, SiHa, MCF-7 and MDA-MB-231 cell lines. Oxime and particularly oxime ether formation strongly
increased their inhibitory activity on the efflux of rhodamine 123 by P-glycoprotein (P-gp), while the new
ecdysteroid lactam did not interfere with the efflux function. All compounds exerted potent chemo-
sensitizing activity towards doxorubicin on a mouse lymphoma cell line and on its MDR counterpart,
and, on the latter, the lactam was found the most active. Because of its MDR-selective chemo-sensitizing
activity with no functional effect on P-gp, this lactam is of high potential interest as a new lead for further
antitumor studies.
© 2017 Elsevier Masson SAS. All rights reserved.
1. Introduction
Synthetic modification of steroidal compounds remains a
promising strategy in the hunt for novel drug candidates since even
minor changes in the substitution pattern of their chemical back-
bone may significantly modify specific bioactivities. Certain ste-
roidal oximes and oxime ethers were shown to have antioxidant
[1], antimicrobial [1], antineoplastic [2] or neuromuscular blocking
[3] activities.
Currently, the antitumor activity of steroid oximes is by far the
most deeply investigated and has recently attracted great scientific
attention. For example, oximes and lactams of cholest-4-en-6-one
were tested on two human cancer cell lines and were shown to
have very high, tumor selective anticancer activity on HeLa cells [4].
Another study on the structure-activity relationships (SAR) of
hydroxyiminosteroids bearing the oxime group on the steroid A
and/or B ring showed that a C-6 oxime function is preferential over
a 6-keto group concerning in vitro cytotoxic activity of these type of
compounds [5]. In a follow-up study on the same compounds, the
importance of 3- and 6-hydroxy functions was highlighted [6].
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Furthermore, a set of in vitro experiments on 63 novel estrone 16-
oximes and oxime ethers revealed two oximes as promising anti-
proliferative agents with selectivity towards HeLa cells; the com-
pounds modulated cell cycle and induced apoptosis through
caspase-3 [7]. In a most recent study, a series of steroidal oximes
and lactams were described to possess significant in vitro anti-
proliferative activity, and a 6,23-dioxime derivative, obtained from
diosgenin acetate, was identified to be the most effective [8].
Several further recent reports can be found in the literature where
well-defined mechanistic changes could also be connected to the
increase in the antiproliferative activity observed after introducing
an oxime moiety into an oxo-compound. For example, a number of
a,b-unsaturated, cyclohexanone-based oximes showed greatly
increased activity as compared to their parental oxo-compounds
against BRAFV600E (the most common mutation in the v-raf mu-
rine sarcoma viral oncogenes homolog B1, involved in carcino-
genesis and cancer agressiveness) and/or epidermal growth factor
receptor TK kinases (involved in cell proliferation, evasion of
apoptosis and invasive capacity) [9], or focal adhesion kinase (FAK;
involved in stimulating metastasis and tumor progression) [10].
These reports suggest that the preparation of oxime derivatives
from ketosteroids, and particularly from those with an a,b-enone
moiety, should be a reasonable strategy to extend the chemical
space towards new, potentially antitumor compounds.
Ecdysteroids are a,b-unsaturated 6-ketosteroids that occur in a
wide range of plant species; as analogs of the insect molting hor-
mone ecdysone, these compounds possess several biological
functions in the flora and the fauna [11,12]. Since the isolation of the
most abundant ecdysteroid 20-hydroxyecdysone (20E), these
compounds were reported to also exert various, beneficial bio-
activities in mammals [13,14,15,16]. Additionally, our group
revealed that relatively apolar ecdysteroids can strongly sensitize
cancer cells to chemotherapeutics (i.e. “chemo-sensitizing” activ-
ity), and suggested 20-hydroxyecdysone 2,3;20,22-diacetonide (1)
as a promising anticancer lead compound [17]. Interestingly, this
sensitization towards various chemotherapeutics could be
observed both on multi-drug resistant (MDR) and drug susceptible
cancer cell lines [18]. After several further studies, exploring this
particular anticancer activity of ecdysteroids, we now know that 1)
apolar substituents on the 2,3-diol moiety are more important than
those at positions 20 and 22 [19], and 2) an oxidative side-chain
cleavage knocks out the inhibitory activity on the efflux function
of the ABCB1 transporter (P-glycoprotein; P-gp) while maintaining
MDR selective sensitizing activity towards doxorubicin [20].
Regarding semi-synthetic modifications accompanied by the in-
clusion of heteroatoms, a difluorinated derivative of 20E 2,3;20,22-
diacetonide was found to be a stronger P-gp inhibitor than its
parental molecule (compound 1), while, surprisingly, MDR selec-
tivity of the difluorinated compound was lower: it sensitized a P-gp
expressing MDR cell line to doxorubicin similarly to its parental
compound 1, and a stronger effect than that of 1was observed on a
non-MDR cell line [21]. The chemical structures of 20E and com-
pound 1 are shown in Fig. 1.
Galyautdinov et al. have previously reported the successful
preparation of several (E/Z)-isomeric ecdysteroid 6-oxime and
some lactam derivatives [22]. Considering the above mentioned
antitumor potential of steroidal oximes and the fact that no studies
are available on the bioactivity of ecdysteroid oximes or lactams,
the aim of the present work was to prepare a series of such com-
pounds, and study their in vitro antitumor potential with a focus on
their chemo-sensitizing activity.
2. Results and discussions
2.1. Chemistry
20-hydroxyecdysone 2,3; 20.22-diacetonide 1 and its 6-oxime
and lactam derivatives were synthesized following previously
published procedures [22,23]. Briefly, compound 1 was reacted
with hydroxylamine or, aiming to prepare new oxime ethers, an
alkoxylamine in pyridine at 70 C. A total of 14 nitrogen-containing
derivatives were prepared this way (Scheme 1).
Following each reaction, neutralization with KOH dissolved in
anhydrous methanol was utilized with the aim of obtaining several
different, structurally diverse and potentially bioactive products,
including mixtures of 14,15-anhydro- and intact oxime derivatives:
the oximes 2 and 3, and oxime ethers with different 6-O-alkyl
substituents 5e15, respectively, were obtained through this
method. Our results confirm previous observations that ecdyste-
roid 6-oximation can result in 3 different types of product mixtures
depending on the neutralization procedure [22]: a mixture of 14,15-
anhydro (E/Z)-isomeric oxime pairs form if the reaction does not
include a neutralization step; a 2e4 components mixture of both
intact and 14OH-eliminated derivatives is obtained if alkali dis-
solved in anhydrous methanol is added; and a mixture of intact (E/
Z)-isomeric oxime pair with retained 14-OH groups is obtained if
the neutralizing alkali is dissolved in anhydrous ethanol.
A second transformation involving the Beckmann-
rearrangement of the (6E)-oxime compound 2 was performed
utilizing p-toluenesulfonyl chloride (TsCl) in acetone in the pres-
ence of sodium carbonate to obtain a new ecdysteroid derivative,
compound 4, with a seven-membered lactam ring (Scheme 2). As
expected, the (6Z)-oxime compound did not form the corre-
sponding lactam but a tosylate was obtained (not presented, for
more details see also reference [23]).
2.2. Structure elucidation
We have recently reported the structure elucidation and com-
plete 1H and 13C signal assignment of a series of dioxolane de-
rivatives of 20-hydroxyecdysone [19,20,21,24]. Here we discuss the
complete 1H and 13C signal assignment of the corresponding 6-
oxime and 6-oxime ether derivatives.
The structure and NMR signals of the products were assigned by
comprehensive one- and two-dimensional NMR methods, such as
1H, 13C, DEPTQ, gradient-selected COSY, edited HSQC, HMBC, ROESY
(Rotating frame Overhauser Enchancement Spectroscopy) spectra
and 1D-selective variants thereof. It is worth mentioning that due
to the molecular mass (500e700 Da) the signal/noise value of the
selective ROE experiments strongly exceeds that of the selective
NOEs.
To facilitate the comparison of NMR signals of structurally
analogous hydrogen and carbon atoms of the starting compound 1
with those of the 6-oxime 2, and of its Beckmann rearranged
product 4 and 6-oxime-ether derivatives 5e15, we applied the
usual steroid numbering, and for the central atoms of the 2,3;20,22-
diacetonide moieties C-28 and C-29, respectively. The 13C chemical
shifts of compounds 1, 2 and 4e15 in methanol-d4 are compiled in
Fig. 1. Chemical structures of 20-hydroxyecdysone (20E) and 20-hydroxyecdysone
2,3;20,22-diacetonide (1).
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Table 1. The characteristic 1H data of compounds with a D14,15 C¼CH
ethylenemoiety 2, 4 and 11e15 are summarized in Table 2, whereas
that of the HO-C(14) derivatives 5e10 are shown in Table 3.
It is well known that oximation of ketones is accompanied with
characteristic changes of several 13C and 1H chemical shifts. Suc-
cessful conversion of a C¼O group to C¼N-OH results of ca. 50 ppm
diamagnetic shift of the corresponding carbon atom, whereas the
chemical shift of a-CH carbon atom in the syn position with respect
to the oxime hydroxyl group exhibits ~14 ppm, in the anti position
~9 ppm diamagnetic shift. The significant (Dd syn-anti) parameters
on C-5 and¼C-7 signals successfully can be utilized for the
assignment of (Z/E) isomers. Galyautdinov et al. reported some
NMR data on 20-hydroxyecdysone oxime [22], including com-
pound 3 (Z isomer), but they failed on isolating the isomeric com-
pound 2with Z configuration. In addition they have taken the NMR
measurements in solvents with rather different anisotropic nature
(e.g. pyridine-d5, methanol-d4) and so in some cases the solvation
effect was comparable with the Dd syn-anti parameters. To avoid
this ambiguity, we have performed our NMR experiments exclu-
sively in methanol-d4.
On the basis of our data, all of the oxime derivatives in Table 1
with dC-5 ~ 38.6 and dC-7 ~ 117.5 ppm values, respectively, are Z
isomers, while dC-5 ~ 43.8 and dC-7 ~ 111.0 ppm values assign the E
isomers. It is worth noting that the less different dC-4 (~30/27 ppm)
and dC-6 (~157/161 ppm) values also reflect on the E or Z isomers,
respectively.
In case of compounds 2 and 4, and the 6-oxime-ether de-
rivatives 11e15 the DEPTQ and HSQC measurements revealed only
seven methylene groups, one less than in the parent compound 1,
and simultaneously distinctive chemical shift changes appeared at
dC-14: 85.4/C¼ ~142 ppm and dН2C-15: 31.8/HC¼ ~124 ppm,
respectively, indicating the emergence of an D14,15 C¼CH ethylene
moiety. All this means that in these compounds (2, 11e15), simul-
taneously with the oximation, dehydration by the elimination of
the 14-OH group also took place. The presence of the 14-OH sub-
stituent in compounds 5e10 appears straightforward, considering
of the chemical shift of C-14 (dC-14e85 ppm) confirmed by the
HMBC cross-peak H3-18/C-14. Success of the Beckmann rear-
rangement of ecdysteroid (6E)-oxime 2 into lactam 4 could be ex-
pected from the E configuration of the parent oxime. Indeed, the
significant (13.1 ppm) paramagnetic shift on dC-5 proves that in 4
the nitrogen atom coupled to C-5, the appearance of the signal at
170.6 ppm supports the formation of the lactam ring.
Thanks to the comprehensive one- and two-dimensional NMR
techniques utilized in the structure elucidation process, a complete
1H signal assignment could be achieved for all compounds. The
Scheme 1. Synthesis of oxime and oxime ether derivatives of 20-hydroxyecdysone 2,3;20,22-diacetonide.
Reagents and conditions: a) pyridine, NH2OH$HCl, 70 C, 3 days; b) pyridine, NH2OR$HCl (R¼Me, Et, Allyl, or tBut), 70 C, 24 h; work-up with KOH in anhydrous MeOH.
Scheme 2. Beckmann rearrangement of ecdysteroid (6E)-oxime 2 into lactam 4.
Reagents and conditions: c) acetone, p-toluenesulfonyl chloride (TsCl, 2 equiv of oxime 2), Na2CO3 (1 equiv of oxime 2), RT, 6 h.
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characteristic 1H NMR data of the 14,15-anhydro derivatives 2, 4
and 11e15 are summarized in Table 2, whereas that of the other
compounds 5e10 in Table 3. The main difference between the two
sets of data is that in Table 2, besides H-7, a second olefinic signal
appears for H-15 (~d5.80 dd) instead of the H2-16 hydrogen signals.
The retained cis junction of the A/B rings in each compound was
obvious by considering the strong H3-19/Hb-5 ROESY response,
whereas the assignment of the a/b position of the diastereotopic
methylene hydrogens of the skeleton were revealed by the one-
dimensional selective ROESY measurements irradiating e.g. the
H3-18, H3-19 and H-5 atoms in combination with the observed
proton-proton coupling pattern.
Considering the data of Tables 2 and 3 it is clear that the values
of dH-5 and dH-7 chemical shifts allow the easy and unequivocal
differentiation between the E and Z isomers. In case of the 14,15-
anhydro derivatives 2 and 11e15, the H-5 signals resonate around
2.25 ppm in the E and at 3.15 ppm in the Z isomers, and the dH-7
chemical shifts appear at 6.76 ppm in the E and at 6.16 ppm in Z
isomers. Similar trend was observed for the compounds in Table 3,
the chemical shift of H-5 in the anti position with respect to the
oxime hydroxyl group exhibits ~2.23 ppm, while in the Z isomer it
is ~3.18 ppm. The corresponding values for H-7 are 6.45 and
5.88 ppm, respectively.
To facilitate the comparison between the NMR data of Z and E
isomeric pairs, the stereo-structures with atomic numbering (in red)
of compounds 7 (upper) and 6 (lower) are shown in Fig. 2. Blue 
numbers refer to 1H chemical shifts; black numbers give the d 13C
values.
2.3. Biology
Antiproliferative activity of compounds 4e15 was tested on a
panel of gynecological cancer cell lines, including cervical (HeLa,
SiHa) and breast cancer cell lines (MDA-MB-231, MCF7); the results
are presented in Table 4.
Although most of the ecdysteroid analogs displayed moderate
activities against the tested cell lines, the t-butyl substituted com-
pound 10 was stronger than the positive control cisplatin on the
HeLa and MDA-MB-231 cell lines. In our previous study, the anti-
proliferative IC50 values of compound 1 were 106.1 and 75.1 mM on
the MDA-MB-231 and MCF7 cell lines, respectively [21], showing
that the inclusion of certain oxime ether functions can increase this
activity by nearly an order of magnitude. While the orientation of
the oxime ether had no obvious effect on the activity, a larger alkyl
group led to a stronger antiproliferative action. It appears to be
clear that the retained 14-OH function is favorable over the D14,15
moiety in this regard on the MCF-7 cell line (compounds 7 vs. 12, 9
vs. 13, and 10 vs. 15), while such a conclusion cannot be drawn on
the other cell lines.
Compounds 2e15were also tested for their cytotoxic activity on
a murine lymphoma cell line pair, including L5178 and its multi-
drug resistant counterpart transfected to express the human
ABCB1 transporter, L5178MDR. Following this, the compounds were
tested for their potential to inhibit the ABCB1 efflux transporter
through measuring the intracellular accumulation of rhodamine
123 by flow cytometry. Degree of inhibition (%) values were
calculated by means of the rhodamine 123 accumulation of the
ABCB1 transfected L5178MDR cells (i.e. 0% inhibition) and that of the
Table 1
13C chemical shifts of compounds 2, 4e15 as compared to that of their parental compound 1 (20-hydroxyecdysone 2,3; 20,22-diacetonide) [21]; in methanol-d4.
No. 1 2 4a 5 6 7 8 9 10 11 12 13 14 15
1 39.0 39.5 43.2 39.7 39.7 39.4 39.7 39.4 39.8 39.1 39.1 39.1 39.3 39.5
2 73.7 73.4 73.2 73.6 73.6 73.6 73.6 73.6 73.7 73.4 73.5 73.5 73.6 73.6
3 73.3 74.0 75.5 74.0 74.0 73.9 74.0 73.8 74.2 73.7 73.8 73.8 74.0 74.1
4 27.9 30.3 30.9 30.0 30.0 27.0 29.9 27.0 30.0 27.3 27.2 27.2 27.3 30.4
5 52.7 43.5 56.6 43.8 43.8 38.6 43.8 38.7 44.0 38.4 38.5 38.6 38.2 43.7
6 205.8 157.0 170.6 157.2 156.9 160.3 157.4 160.7 155.7 160.8 160.6 161.0 159.4 155.8
7 122.0 110.0 119.9 110.7 110.9 117.5 110.8 117.3 111.3 117.0 117.2 117.0 118.3 110.8
8 167.1 151.5 151.6 154.1 153.8 150.7 154.1 151.0 152.3 151.0 151.1 151.1 151.3 151.6
9 35.9 40.2 45.9 35.5 35.5 34.4 35.5 34.4 35.7 39.1 39.2 39.2 39.2 40.2
10 38.9 38.0 40.7 37.8 37.7 37.0 37.7 37.0 37.6 37.1 37.1 37.1 37.0 37.9
11 21.8 21.9 25.4 21.5 21.5 21.5 21.5 21.5 21.5 21.8 21.8 21.9 21.9 21.9
12 32.5 41.3 42.4 32.6 32.6 32.5 32.6 32.5 32.6 41.1 41.1 41.1 41.2 41.3
13 48.7 49.0 50.2 49.0 48.6 48.3 48.6 48.3 48.6 48.6 48.6 48.7 48.6 48.7
14 85.4 144.3 154.4 85.9 85.9 85.7 85.9 85.7 86.0 142.4 142.1 142.4 140.6 143.8
15 31.8 125.3 125.6 32.0 32.0 32.1 32.0 32.1 32.0 124.4 124.3 124.4 123.6 125.0
16 22.6 32.4 32.6 22.6 22.6 22.7 22.6 22.6 22.6 32.3 32.3 32.4 32.3 32.4
17 50.6 59.0 59.3 50.6 50.6 50.7 50.6 50.7 50.6 58.9 58.9 59.0 59.0 59.1
18 17.8 19.7 19.6 18.0 18.0 18.0 18.0 18.0 18.1 19.6 19.6 19.6 19.6 19.7
19 24.2 23.9 18.1 24.3 24.3 24.3 24.3 24.3 24.3 24.1 24.0 24.1 24.1 24.9
20 86.0 84.9 84.7 86.0 86.0 86.1 86.0 86.1 86.0 84.9 84.9 85.0 85.0 84.9
21 22.8 22.0 21.9 22.7 22.7 22.7 22.7 22.7 22.7 22.0 22.0 22.0 22.0 22.0
22 83.5 83.1 83.1 83.4 83.4 83.4 83.4 83.4 83.4 83.2 83.2 83.2 83.2 83.2
23 24.9 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.9 24.9 24.9
24 42.4 42.1 42.1 42.3 42.3 42.4 42.3 42.4 42.3 42.1 42.1 42.1 42.1 42.7
25 71.3 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.1 71.2 71.2 71.2 71.2
26 29.1 29.0 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.0 29.0 29.0 29.0
27 29.0 29.7 29.6 29.6 29.6 29.6 29.6 29.5 29.6 29.7 29.7 29.7 29.7 29.7
28 109.6 109.5 109.4 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.2 109.4
28Mea 26.8 26.6 26.8 26.8 26.8 26.8 26.8 26.9 26.8 26.7 26.7 26.7 26.8
28Meb 29.0 28.9 29.0 29.0 29.0 29.0 29.0 29.0 29.1 29.0 29.0 29.0 29.0
29 108.2 108.0 108.1 108.0 108.1 108.0 108.1 108.0 108.0 108.0 108.1 108.0 108.1
29Mea 29.5 29.3 29.5 29.5 29.5 29.5 29.4 29.5 29.4 29.4 29.4 29.4 29.4
29Meb 27.3 27.3 27.3 27.3 27.3 27.4 27.3 27.3 27.3 27.3 27.2 28.0 27.3
10 61.8 70.1 70.4 75.5 75.7 78.9 62.2 70.5 75.8 79.3
20 15.0 15.2 135.9 136.0 28.0 15.2 135.9 28.0
30 117.6 117.5 117.6
a To facilitate the comparison of NMR data of the Beckman product 4 and the parental oxime ethers we applied the steroid atomic numbering also for compound 4.
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L5178 cells (i.e. 100% inhibition); results are presented in Table 5.
While the compounds also exerted weak to moderate cytotoxic
activities on the mouse lymphoma cell line pair, all of them were
more potent than their parental compound 1. No cross resistance
was observed to any of them on the ABCB1 over-expressing MDR
cells. The oximes 2 and 3 showed the strongest activity on either
cell lines with IC50 values ca. 4e5 times below that of compound 1,
and the E-oxime (2) was more cytotoxic than the Z-oxime (3). The
oxime ethers typically exerted weaker cytotoxic activities than the
non-substituted oximes, with the exception of compound 10where
a bulky t-butyl substituent and a retained 14-OH group were pre-
sent. When comparing corresponding analogs with a retained 14-
OH group or a D14,15 moiety, there appeared to be a clear ten-
dency for the former structural element to be associated with a
stronger cytotoxic activity on the mouse lymphoma cells, similarly
to the case of MCF-7 cells (see above).
Evaluation of the results obtained from the rhodamine accu-
mulation assay reveals that the lactam derivative (4) is the only one
among the compounds that was completely inactive in this regard
at as much as 20 mM concentration. For the other compounds,
several structure-activity relationships could be observed. The
oxime formation markedly increased the ABCB1 inhibitory activity,
and this was particularly true for oxime ethers. The orientation of
the oxime group had little if any influence on the ABCB1 inhibition
(compound 2 vs. 3, 6 vs. 7, 8 vs. 9, and 14 vs. 15), while the 14-OH
elimination, forming a D14,15 double bond in the ecdysteroid D-
ring, clearly increased this activity (compound 7 vs.12, 9 vs.13, and
10 vs.15). When comparing the activity of oximes and oxime ethers
between analogs containing the same type of D-ring and
orientation of oxime but different substituents on the latter, the
following order of bioactivity could be concluded:
H<Me< Et< Allyl t-But.
The compounds were also tested for their ability to sensitize the
susceptible/resistant mouse lymphoma cell line pair towards the
cytotoxic activity of doxorubicin. Since each compound showed a
measurable cytotoxic activity on both cell lines when applied alone,
combination indices could be determined through the checker-
board microplate method similarly to our previous related studies
[17,19]. Table 6 shows the strongest activity observed for each
compound on the L5178 and L5178MDR cell lines; further details and
results at other compound:doxorubicin ratios are available in
supporting information Table S1.
All tested derivatives showed strong synergism (0.1< CIavg< 0.3)
[25] with doxorubicin on the P-gp expressing L5178MDR cells,
similarly to their parental compound (1). As it was previously re-
ported by us, chemo-sensitizing activity of ecdysteroids has little if
any correlation to their (most typically weak) inhibitory effect on
the efflux function of P-gp [20]. This was clearly confirmed in the
present study as well: even though for example compounds 11e15
are much stronger P-gp inhibitors than their parental compound 1,
no difference can be observed in the strength of synergismwith the
P-gp substrate doxorubicin on the MDR cell line. Most interestingly,
among all derivatives obtained, the ecdysteroid lactam 4was found
to express the strongest chemosensitization on the MDR cells,
while being the only one to show no interference with P-gp func-
tion. Accordingly, this compound has a further advantage over the
diacetonide of 20E, namely that it would likely be free from the
potential adverse effects and unwanted drug-drug interactions
Table 2
1H chemical shift, multiplicities and coupling constants of compounds 2, 4, 11e15 in methanol-d4.
No. 2 J (Hz) 4a J (Hz) 11 J (Hz)b 12 13 14 15
1 a 1.98 dd; 14.0, 6.5 2.19 dd; 14.0, 6.8 1.95 dd; 13.9, 6.3 1.94 1.95 1.92 1.98
b 1.25 1.30 1.26 1.28 1.28 1.29 1.25
2 4.19 ddd; 11.0, 6.5, 4.5 4.25 ddd; 12.0, 6.8, 5.0 4.18 ddd; 10.8, 6.3, 4.5 4.19 4.19 4.19 4.19
3 4.26 td; 4.5, 1.7 4.39 dt; 5.0, 3.0 4.24 td; 4.5, 1.2 4.25 4.25 4.24 4.27
4 a 1.77 1.29 1.60 1.60 1.61 1.57 1.77
b 1.97 2.06 2.10 2.11 2.14 2.11 1.95
5 2.25 dd; 12.1, 4.2 3.30 dd; 10.2, 6.5 3.14 dd; 12.8, 4.6 3.15 3.19 3.15 2.26
7 6.81 d; 2.7 5.94 d; 2.6 6.14 d; 2.6 6.16 6.16 6.20 6.70
9 2.27 2.37 ddd; 11.5, 3.6, 2.6 2.31 2.31 2.31 2.29 2.24
11 a 1.65 1.88 1.63 1.63 1.62 1.61 1.64
b 1.72 1.74 1.68 1.68 1.67 1.67 1.71
12 a 1.53 1.60 1.50 1.50 1.50 1.50 1.52
b 2.23 2.21 2.22 dt; 12.7, 3.0 2.22 2.22 2.22 2.22
15 5.86 dd; 3.5, 2.0 5.74 dd; 3.5, 1.9 5.81 dd; 3.3, 2.1 5.81 5.81 5.79 5.82
16 a 2.33 2.33 2.32 2.32 2.31 2.31 2.32
b 2.60 2.58 2.58 2.58 2.58 2.58 2.59
17 2.04 dd; 10.7, 7.7 2.11 dd; 10.7, 7.8 2.02 dd; 10.8, 7.7 2.02 2.02 2.01 2.03
18 1.06 1.06 1.05 1.05 1.05 1.05 1.05
19 0.83 0.96 0.84 0.84 0.85 0.84 0.81
21 1.22 1.21 1.22 1.22 1.22 1.22 1.22
22 3.76 3.75 3.76 3.76 3.76 3.77 3.76
23 a 1.53 1.53 1.53 1.53 1.53 1.53 1.54
b 1.53 1.53 1.53 1.53 1.53 1.53 1.54
24 a 1.48 1.48 1.48 1.48 1.48 1.48 1.48
b 1.72 1.72 1.72 1.72 1.72 1.72 1.72
26 1.20 1.20 1.19 1.19 1.19 1.19 1.19
27 1.21 1.21 1.21 1.20 1.20 1.21 1.21
28Mea 1.30 1.30 1.31 1.31 1.31 1.32 1.32
28Meb 1.47 1.46 1.49 1.49 1.49 1.50 1.49
29Mea 1.40 1.40 1.40 1.40 1.40 1.40 1.40
29Meb 1.30 1.30 1.30 1.30 1.30 1.30 1.31
10 3.86 4.11 4.56 e e
20 1.27 6.00 1.29 1.29
30 Z 5.19
E 5.29
a To facilitate the comparison of NMR data of the Beckman product 4 and the parental oximethers, we applied the steroid atomic numbering also for 4.
b Because the stereostucture of the steroid frame is nearly identical within compounds 11e15, we described the J coupling contents only for 11.
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connected to P-gp inhibitors [26,27].
Considering structure-activity relationships, the several highly
active compounds obtained in this work led us to follow our pre-
viously applied “best ratio” principle [17]. This means that we
aimed to compare the compounds' chemo-sensitizing activities at
their strongest, regardless of the compound vs. doxorubicin ratio
where this activity was observed.
The length or nature of the alkyl function had no apparent effect
on the compounds potency in sensitizing the MDR cells to doxo-
rubicin, all compounds showed similarly high activity in this re-
gard. A slight tendency may be observed for the D14,15 compounds
(2e4, 11e15) acting stronger in this regard than their correspond-
ing analogs where the 14-OH group was retained (5e10), but the
differences are so small that it is hard tomake a sound judgment on
the relevance of this phenomenon.
On the other hand, larger differences were observed between
the compounds' activities on the non-MDR L5178 cells. On this cell
line, the strongest synergism with doxorubicin was observed for
the lactam (4) and compound 11, a methyl substituted D14,15 (Z)-
oxime ether. The oxime formation together with the elimination of
the 14-OH group (2 and 3) decreased the strength of synergism
with doxorubicin as compared to the case of compound 1. In case of
the oxime ethers, the 14,15-anhydro derivatives typically exerted
stronger sensitizing activity to doxorubicin than their analogs with
intact 14-OH groups, except for compounds 10 vs. 15. Since oxime
ethers substituted with bulky t-buthyl groups seem to show a
tendency for decreased activity as compared to the corresponding
analogs with ethyl groups (6 vs 10 and 12 vs. 14), one could hy-
pothesize that the effect of the t-butyl group in the oxime ether
function may overwrite that of the D14,15 moiety in compound 15.
3. Conclusions
The present study reports the preparation and in vitro phar-
macological investigation of 14 ecdysteroid diacetonide oximes,
oxime ethers and a lactam, with 13 novel derivatives obtained in
pure form for the first time. The synthetic procedure was utilized in
a way to obtain product mixtures in order to increase chemical
diversity, and subsequent use of high-performance separation
techniques allowed us to obtain the compounds in high purity. All
compounds are reported with a complete NMR signal assignment.
Evaluation of the antiproliferative and cytotoxic activity of the
compounds on several cancer cell lines revealed several structure-
activity relationships (SAR). A new, t-butyl substituted ecdysteroid
oxime ether (10) was found to exert stronger antiproliferative effect
on HeLa and MDA-MB-231 cells than cisplatin. The D14,15 E-oxime
derivative (2) exerted a substantially increased cytotoxic and P-gp
inhibitory activities in the L5178/L5178MDR cell line pair, as
compared to its parental compound.
Clear SAR was observed for the compounds' activity as func-
tional P-gp inhibitors, and many of them were identified as highly
potent MDR-selective chemo-sensitizers. In particularly, a novel
D14,15 d-lactam ecdysteroid derivative (4) was revealed as a most
promising new lead compound with low intrinsic cytotoxicity, and
strong ability to sensitize MDR and also non-MDR cancer cells to-
wards doxorubicin without interfering with the efflux function of
P-gp. Accordingly, it can be expected that a combined treatment of
cancer with this compound as a chemo-sensitizer and a chemo-
therapeutic agent would 1) be effective on the initial, susceptible
state of the tumor, and 2) have a strong chance to prevent the
acquisition of P-gp mediated resistance through an increased
killing effect on the cell population becoming adapted to the
chemotherapy.
4. Experimental section
4.1. Chemistry
All applied reagents were purchased from Sigma (Sigma-Aldrich
Co., USA). Solvents were obtained from Macron Fine Chemicals
(Avantor Performance Materials, USA).
1H (500.1MHz) and 13C (125.6MHz) NMR spectra were recor-
ded at room temperature on a Bruker Avance-II spectrometer and
on Avance-III spectrometer equipped with a cryo probehead.
Regarding the compounds, amounts of approximately 1e10mg
were dissolved in 0.1ml of methanol-d4 and transferred to 2.5mm
Bruker MATCH NMR sample tube. Chemical shifts are given on the
d-scale and are referenced to the solvent (MeOH-d4: dC¼ 49.1 and
dH¼ 3.31 ppm). Pulse programs of all experiments (1H, 13C, DEPTQ,
DEPT-135, one-dimensional sel-ROE (mixing time: 300ms), edited
gs-HSQC and gs-HMBC) were taken from the Bruker software li-
brary. The NMR signals of the product were assigned by compre-
hensive one- and two-dimensional NMR methods using widely
accepted strategies [28,29,30]. Most 1H assignments were accom-
plished using general knowledge of chemical shift dispersion with
the aid of the proton-proton coupling pattern (1H NMR spectra).
Mass spectra were obtained on a Waters Acquity iClass UPLC
coupled with Thermo Q Exactive Plus with HESI source (Waters Co.,
USA).
Reaction progress was monitored by thin layer chromatography
(TLC) on Kieselgel 60F254 silica plates obtained fromMerck (Merck,
Germany), and examined under UV illumination at 254 nm.
Table 3
1H chemical shifts, multiplicities and coupling constants of compounds 5e10 in
methanol-d4.
No. 5 J (Hz)a 6 7 8 9 10
1 a 1.98 1.98 1.94 1.98 1.95 1.98
b 1.22 1.23 1.24 1.23 1.24 1.23
2 4.21 ddd; 10.5, 6.7, 5.1 4.21 4.21 4.22 4.21 4.22
3 4.28 4.28 4.26 4.28 4.27 4.28
4 a 1.93 1.93 1.73 1.93 1.74 1.92
b 1.93 1.93 2.06 1.93 2.08 1.92
5 2.22 dd; 12.2, 5.5 2.23 3.16 2.24 3.19 2.26
7 6.44 d; 2.7 6.47 5.88 6.49 5.88 6.47
9 2.72 ddd; 11.8, 6.9, 2.7 2.71 2.72 2.72 2.73 2.70
11 a 1.65 1.65 1.65 1.64 1.63 1.64
b 1.59 1.58 1.58 1.59 1.58 1.59
12 a 2.03 td; 12.0, 5.5 2.04 2.04 2.04 2.04 2.03
b 1.80 dm; 12.0 1.81 1.80 1.81 1.80 1.80
15 a 1.61 1.62 1.63 1.62 1.63 1.62
b 1.96 1.97 1.94 1.97 1.94 1.96
16 a 1.85 1.85 1.85 1.86 1.85 1.85
b 2.00 2.00 2.02 2.01 2.02 2.02
17 2.28 dd; 9.1, 7.8 2.28 2.27 2.29 2.27 2.28
18 0.80 0.81 0.81 0.81 0.81 0.81
19 0.83 0.83 0.84 0.83 0.85 0.82
21 1.17 1.17 1.17 1.17 1.17 1.17
22 3.68 3.68 3.68 3.68 3.68 3.68
23 a 1.52 1.52 1.52 1.52 1.52 1.52
b 1.52 1.52 1.52 1.52 1.52 1.52
24 a 1.48 1.48 1.49 1.48 1.49 1.49
b 1.73 1.73 1.73 1.73 1.73 1.74
26 1.19 1.19 1.19 1.19 1.19 1.19
27 1.20 1.20 1.20 1.20 1.20 1.20
28Mea 1.31 1.31 1.32 1.31 1.32 1.32
28Meb 1.47 1.47 1.50 1.47 1.49 1.49
29Mea 1.39 1.39 1.39 1.39 1.39 1.39
29Meb 1.32 1.32 1.32 1.32 1.32 1.32
10 3.82 4.07 4.10 4.53 4.55 e
20 1.25 1.26 5.98 5.99 1.28
30 Z 5.18 5.19
E 5.26 5.28
a Because the stereo-structure of the steroid frame is nearly identical within this
set of compounds, the J coupling constants are given only once.
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Compounds were purified by flash chromatography with
adequately chosen eluents of n-hexane e dichloromethane e
methanol on 12 g RediSep NP-silica flash columns (TELEDYNE Isco,
USA).
For the RP-HPLC separation of isomeric oxime derivatives a
Kinetex XB-C18 250 21.4mm 5 mm preparative (Phenomenex
Inc., USA) or an Agilent Eclipse XDB-C8 250 9.4mm 5 mm semi-
preparative column (Agilent Technologies Inc., USA) was applied
with the use of isocratic grade eluents of acetonitrile and water.
Purity of obtained compounds was determined by RP-HPLC with
the use of a Kinetex XB-C18 250 4.6mm 5 mm analytical column
(Phenomenex Inc., USA). For data collection a Jasco HPLC instru-
ment equipped with an MD-2010 Plus PDA detector (Jasco
Analytical Instruments, Japan) was applied in a detection range of
210e400 nm.
Ecdysteroid substrate 1 was synthesized from 20-
hydroxyecdysone (20E) obtained from Shaanxi KingsSci Biotech-
nology Co., Ltd. (Shanghai, People's Republic of China) at 90% purity
and recrystallized (EtOAc:MeOH e 2:1) to a RP-HPLC purity of
97.8%. During the synthetic procedure, 20E (10 g) was dissolved in
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Fig. 2. Characteristic NMR spectra on differentiation and NMR assignments of the isomeric 6 and 7 ecdysteroid 6-oxime ethers are given in the supporting information.
Table 4
Antiproliferative properties of compounds 4e15 against four human gynecological cancer cell lines. Inhibition concentration at 50% growth (IC50) values of each compound and
the 95% confidence intervals are given for each cell line.
Compound IC50 (mM)
HeLa SiHa MDA-MB-231 MCF7
4 >30 >30 >30 >30
5 >30 >30 >30 >30
6 >30 >30 >30 22.55 [17.24e29.50]
7 29.12 [24.00e32.94] >30 25.12 [17.74e35.57] 13.10 [10.89e15.77]
8 15.55 [13.69e17.66] 25.52 [21.95e29.68] 21.36 [18.86e24.19] 13.63 [11.91e15.60]
9 17.55 [14.77e20.84] >30 26.90 [23.34e31.00] 17.22 [15.21e19.50]
10 8.43 [4.66e9.29] 16.13 [13.02e19.99] 12.36 [11.00e13.89] 11.06 [9.96e12.29]
11 15.43 [12.87e18.50] >30 25.99 [21.67e29.50] 18.03 [15.86e20.50]
12 29.96 [27.03e33.20] >30 26.00 [23.44e28.85] 19.59 [17.09e22.46]
13 >30 >30 29.37 [26.11e33.03] 24.16 [20.36e28.68]
14 20.71 [18.63e23.02] 8.14 [5.62e11.79] 15.70 [13.50e18.25] 17.29 [15.33e19.52]
15 26.06 [22.45e30.25] 14.17 [10.60e18.94] 16.93 [14.71e19.49] 19.34 [16.51e22.66]
Cisplatin 14.02 [12.65e15.56] 7.87 [5.83e10.63] 18.65 [16.67e20.85] 6.01 [5.33e6.79]
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acetone in the concentration of g/100 cm3 and phosphomolybdic
acid was added (10 g) under stirring. After 5min of stirring at RT,
the reaction mixture was neutralized with 10% aqueous NaHCO3.
Acetone was evaporated under reduced pressure and the mixture
was extracted with EtOAc (3 50ml) followed by drying with
Na2SO4. After filtration, the solvent was evaporated under reduced
pressure and the crude mixture was purified by flash chromatog-
raphy with isocratic grade eluents of dichloromethane:methanol e
99:1. (Yield: 51%).
Synthesis of ecdysteroid 6-oximes (2e3). 1 g of compound 1
(1,78mmol) was dissolved in pyridine (10ml) and 1 g of hydrox-
ylamine hydrochloride (14.39mmol) was added to the solution
under stirring. After 3 days of stirring at 70 C the reaction was
complete and the solvent was evaporated under reduced pressure.
Following water addition (50ml), the mixture was extracted with
EtOAc (3 50ml) and the combined organic phase was dried with
Table 5
Cytotoxicity of compounds 1e15 on L5178 and L5178MDR cells, and functional inhibition of the ABCB1 transporter. Dox¼ doxorubicin; for the ABCB1 inhibition, positive control:
100 nM of tariquidar (112.4% inhibition), negative control: 2% DMSO (0.07% inhibition).
Compound Change in the 14-OH or IC50 (mM) [95% confidence intervals]b ABCB1 inhibition (%)
B-ring of 1 a D14,15 L5178 L5178MDR 2 mM 20 mM
1 e 14-OH 110.3 [77.50e157.1] 97.69 [71.07e134.3] 2.54 20.91
2 (E)-oxime D14,15 20.91 [17.68e24.74] 24.63 [19.82e30.63] 10.57 82.95
3 (Z)-oxime D14,15 34.22 [28.21e41.51] 28.35 [21.97e36.58] 7.15 81.09
4 d-lactam D14,15 63.42 [47.51e84.65] 72.35 [64.39e81.29] 1.16 4.27
5 (E); R¼Me 14-OH 40.92 [35.66e46.97] 55.05 [41.53e72.98] 2.25 25.05
6 (E); R¼ Et 14-OH 35.02 [25.35e48.38] 47.00 [31.14e70.93] 17.54 78.79
7 (Z); R¼ Et 14-OH 37.26 [25.65e54.11] 42.16 [41.24e43.10] 18.96 75.03
8 (E); R¼ Allyl 14-OH 31.48 [23.71e41.80] 51.91 [42.69e63.13] 20.98 89.39
9 (Z); R¼Allyl 14-OH 36.66 [28.32e47.44] 49.29 [43.07e56.40] 24.17 81.80
10 (E); R¼ t-But 14-OH 28.06 [21.30e36.98] 29.12 [25.12e33.76] 38.75 112.4
11 (Z); R¼Me D14,15 45.95 [36.97e57.11] 53.14 [43.54e64.86] 33.36 106.2
12 (Z); R¼ Et D14,15 53.20 [38.64e73.26] 58.94 [45.86e75.74] 56.41 107.7
13 (Z); R¼Allyl D14,15 55.28 [46.21e66.13] 52.72 [39.97e65.53] 61.13 102.7
14 (Z); R¼ t-But D14,15 63.23 [58.57e68.26] 51.22 [39.13e67.04] 58.99 78.76
15 (E); R¼ t-But D14,15 63.84 [45.70e89.19] 65.44 [55.66e76.94] 67.46 93.95
Dox e e 0.080 [0.053e0.12] 4.49 [3.43e5.89] e e
a R groups refer to the alkyl substituents of the oxime ethers as in Scheme 1.
b IC50 values were calculated by the CompuSyn software as the median cytotoxic activities (Dm) from the control lanes on the checkerboard plates of the combination
studies, n¼ 2.
Table 6
Chemo-sensitizing activity of compounds 1e15 on the L5178 and L5178MDR cell lines towards doxorubicin at 50, 75 and 90% of growth inhibition (ED50, ED75 and ED90,
respectively). CI: combination index; CIavg: weighted average CI value; CIavg¼ (CI50þ 2CI75þ 3CI90)/6. CI< 1, CI¼ 1, and CI> 1 represent synergism, additivity, and antagonism,
respectively. Dm, m, and r represent antilog of the x-intercept, slope, and linear correlation coefficient of the median-effect plot, respectively.
Compound Cell line Drug ratio CI at Dm m r CIavg
ED50 ED75 ED90
1 [21] L5178MDR 20.4: 1 0.27 0.14 0.07 11.678 3.246 0.964 0.13
L5178 163: 1 0.67 0.55 0.46 11.236 2.103 0.942 0.53
2 L5178MDR 15: 1 0.26 0.16 0.12 4.454 6.638 1.000 0.16
L5178 150: 1 0.80 0.79 0.78 10.748 2.572 0.997 0.78
3 L5178MDR 30: 1 0.32 0.25 0.20 7.595 3.981 0.994 0.24
L5178 150: 1 0.98 0.76 0.61 16.049 3.239 0.986 0.72
4 L5178MDR 15: 1 0.20 0.12 0.09 6.419 4.953 0.970 0.12
L5178 150: 1 0.40 0.42 0.46 10.477 2.033 0.966 0.44
5 L5178MDR 15: 1 0.17 0.16 0.16 6.605 3.721 0.978 0.16
L5178 150: 1 1.06 0.79 0.62 14.306 2.947 0.971 0.75
6 L5178MDR 7.5: 1 0.18 0.14 0.12 5.001 5.858 1.000 0.14
L5178 37.5: 1 0.55 0.58 0.60 8.598 2.495 0.972 0.59
7 L5178MDR 3.75: 1 0.27 0.16 0.13 3.030 3.329 0.993 0.16
L5178 37.5: 1 0.63 0.52 0.45 8.078 3.858 0.952 0.50
8 L5178MDR 15: 1 0.17 0.13 0.13 4.939 3.193 0.955 0.14
L5178 150:1 1.03 0.81 0.69 8.970 2.178 0.991 0.79
9 L5178MDR 15: 1 0.17 0.16 0.17 7.338 3.771 0.947 0.17
L5178 75: 1 0.70 0.83 1.03 8.202 1.722 0.956 0.91
10 L5178MDR 7.5: 1 0.30 0.20 0.17 3.928 4.610 1.000 0.20
L5178 37.5: 1 0.58 0.63 0.70 7.606 2.502 0.966 0.66
11 L5178MDR 7.5: 1 0.17 0.16 0.15 5.224 3.722 0.971 0.16
L5178 37.5: 1 0.77 0.47 0.31 8.165 3.044 0.982 0.44
12 L5178MDR 7.5: 1 0.21 0.14 0.11 6.133 4.890 0.992 0.14
L5178 75: 1 0.49 0.50 0.52 7.864 2.094 0.961 0.51
13 L5178MDR 3.75: 1 0.25 0.15 0.11 5.614 5.805 1.000 0.15
L5178 37.5: 1 0.46 0.47 0.47 8.295 2.882 0.981 0.47
14 L5178MDR 7.5: 1 0.34 0.26 0.23 8.365 3.378 0.939 0.26
L5178 37.5: 1 0.53 0.59 0.66 9.652 2.400 0.961 0.62
15 L5178MDR 7.5: 1 0.27 0.24 0.23 8.739 3.813 0.960 0.24
L5178 37.5: 1 1.16 0.85 0.64 7.199 3.273 0.977 0.80
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Na2SO4. A filtration was made to remove drying agent and the
solvent was evaporated under reduced pressure. Purification of the
crude mixture was carried out by preparative RP-HPLC to obtain (E/
Z)-isomeric oximes 2e3, respectively.
Synthesis of ecdysteroid lactam derivative (4). 0.138 g of
oxime 2 (0,25mmol) was dissolved in anhydrous acetone (10ml),
then 0.027 g of Na2CO3 (0.25mmol) and 0.096 g of p-toluene-
sulfonyl chloride (0,5mmol) was added to the solution under stir-
ring. After 6 h of stirring at RT, the reaction was stopped and the
mixturewas cooled to 0 C. Under stirring, water (10ml) was added
and the mixture was extracted into ethyl acetate (3 50ml). After
evaporation under reduced pressure, the mixturewas purified with
semi-preparative RP-HPLC to obtain lactam derivative 4.
General Procedure for the synthesis of ecdysteroid 6-oxime
ethers (5e15). 200mg of 1 (0,35mmol) was dissolved in pyridine
(8ml), and, depending on the oxime ether to be obtained, 200mg
of the appropriate alkoxyamine-hydrochloride was added to the
solution under stirring. After stirring at 70 C for 24 h, the mixture
was cooled down to 0 C, neutralized with KOH dissolved in
anhydrous methanol, and evaporated under reduced pressure.
Water (50ml) was then added, and the mixture was extracted with
EtOAc (3 50ml). The combined organic layers were dried with
Na2SO4, and, after filtration, the solvent was evaporated under
reduced pressure. Purification of the crudematerial was carried out
by flash chromatography on silica gel to obtain compounds 5e15,
respectively. In cases of oxime pairs 2e3, 6e7, 8e9, 14e15 pre-
parative RP-HPLC was applied to separate the isomeric oxime and
oxime ether derivatives.
Compound 4: White solid; yield: 8% (11.04mg); RP-HPLC pu-
rity: 98.1%; for 1H and 13C NMR data, see Tables 2 and 3, respec-
tively; HR-HESI-MS: C33H52O6N, calcd. 558.3789, found: 558.3737.
Compound 5: White solid; yield: 28.3% (59.53mg); RP-HPLC
purity: 99.8%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C34H56O7N, calcd. 590.4051, found:
590.4045.
Compound 6: White solid; yield: 15.2% (32.75mg); RP-HPLC
purity: 99.6%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found:
604.4198.
Compound 7: White solid; yield: 2.8% (6.06mg); RP-HPLC pu-
rity: 98.7%; for 1H and 13C NMR data, see Tables 1 and 3, respec-
tively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found: 604.4199.
Compound 8: White solid; yield: 15.5% (34.05mg); RP-HPLC
purity: 98.3%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C36H58O7N, calcd. 616.4208, found:
616.4201.
Compound 9:White solid; yield: 1.6% (3.5mg); RP-HPLC purity:
99.6%; for 1H and 13C NMR data, see Tables 1 and 3, respectively;
HR-HESI-MS: C36H58O7N, calcd. 616.4208, found: 616.4200.
Compound 10: White solid; yield: 38.9% (87.67mg); RP-HPLC
purity: 98.5%; for 1H and 13C NMR data, see Tables 1 and 3,
respectively; HR-HESI-MS: C37H62O7N, calcd. 632.4521, found:
632.4515.
Compound 11: White solid; yield: 43.3% (88.32mg); RP-HPLC
purity: 97.7%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C34H54O6N, calcd. 572.3946, found:
572.3937.
Compound 12: White solid; yield: 33.3% (69.59mg); RP-HPLC
purity: 97.5%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C35H56O6N, calcd. 586.4102, found:
586.4099.
Compound 13: White solid; yield: 2% (4.25mg); RP-HPLC pu-
rity: 98.3%; for 1H and 13C NMR data, see Tables 2 and 3, respec-
tively; HR-HESI-MS: C36H56O6N, calcd. 598.4102, found: 598.4094.
Compound 14: White solid; yield: 8.3% (18.17mg); RP-HPLC
purity: 98.7%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found:
614.4411.
Compound 15: White solid; yield: 2.5% (5.48mg); RP-HPLC
purity: 95.8%; for 1H and 13C NMR data, see Tables 2 and 3,
respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found:
614.4407.
4.2. Biology
Cell cultures. The human gynecological cancer cell lines MDA-
MB-231 and MCF7 (breast cancers), and HeLa (cervical adenocar-
cinoma) were purchased from ECACC (European Collection of Cell
Cultures, Salisbury, UK), while SiHa (cervical carcinoma) was pur-
chased from ATCC (American Tissue Culture Collection, Manassas,
Virginia, USA). The cells were grown inMinimumEssential Medium
(MEM) supplemented with 10% fetal calf serum (FCS), 1% non-
essential aminoacids, and 1% penicillin-streptomycin. All media
and supplements for these experiments were obtained from Lonza
Group Ltd. (Basel, Switzerland). The cells were maintained at 37 C
in humidified atmosphere containing 5% CO2. Two mouse lym-
phoma cell lines were also used: a drug susceptible cell line, L5178
mouse T-cell lymphoma (ECACC catalog number 87111908, U.S.
FDA, Silver Spring,MD, U.S.), and its multidrug resistant counterpart
(L5178MDR) obtained by transfection with pHa MDR1/A retrovirus
[31]. Cells were cultured in McCoy's 5A media supplemented with
nystatin, L-glutamine, penicillin, streptomycin, and inactivated
horse serum, at 37+C and 5% CO2. The MDR cell line was selected by
culturing the infected cells with 60 g/L colchicine (Sigma). Media,
fetal bovine serum, horse serum, and antibiotics were purchased
from Sigma.
Antiproliferative assay on human gynecological cancer cell
lines. The growth-inhibitory activities of the prepared ecdysteroid
analogs were determined by the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) method on four human
adherent cancer cell lines of gynecological origin [32]. Briefly, cells
were seeded into 96 well plates (5000 cells/well) and incubated
with increasing concentrations of the tested compounds
(0.1e30.0 mM) under cell-culturing conditions. After incubation for
72 h, 5mg/ml MTT solution was added and the samples were
incubated for another 4 h. The precipitated formazan crystals than
were dissolved in dimethyl sulfoxide and the absorbance was
measured at 545 nmwith a microplate reader. Cisplatin, a clinically
used anticancer agent was used as a positive control. In order to
calculate fifty percent inhibitory concentrations (IC50), sigmoidal
doseeresponse curves were fitted to the measured points by using
the non-linear regression model log (inhibitor) vs. normalized
response and variable slope with a least squares (ordinary) fit of
GraphPad Prism 5.01 software (GraphPad Software Inc., San Diego,
CA, USA).
Cytotoxicity assay on murine lymphoma cell lines. Cytotoxic
activities on the L5178 and L5178MDR cell lines were performed as
described before [18]. Briefly, 5 104 cells/well were incubated
with serial dilutions of each compound (n¼ 3) in McCoy's 5 A
medium (Sigma-Aldrich) for 48 h at 37 C, 5% CO2. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma)was added to eachwell at a final concentration of 0.5mg/mL
per well and after 4 h of incubation, 100 mL of sodium dodecyl
sulfate (SDS) 10% (Sigma-Aldrich) in 0.01M HCl was added to each
well. Plates were further incubated overnight, the optical densities
were read at 540 and 630 nm using an ELISA reader (Multiskan EX,
Thermo Labsystem, Milford, MA, USA), and IC50 values were
calculated as described above.
Rhodamine 123 accumulation assay. ABCB1 inhibitory activ-
ities of the compounds were studied through their effect on the
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accumulation of rhodamine 123, a fluorescent dye that is an ABCB1
substrate. Flow cytometry was used as described before [15].
Briefly, 2 106 cells/mL were treated with 2 or 20 mM of each
compound. After 10min incubation, rhodamine 123 (Sigma-
Aldrich) was added to a final concentration of 5.2 mM and the
samples were incubated at 37 C in a water bath for 20min. Sam-
ples were centrifuged (Heraeus Labofuge 400, Thermo Fisher Sci-
entific, Waltham, MA, USA) (2000 rpm, 2min) and washed twice
with phosphate buffer saline (PBS, Sigma). The final samples were
re-suspended in 0.5mL PBS and its fluorescence measured with a
Partec CyFlow flow cytometer (Partec, Münster, Germany). 100 nM
of tariquidar was used as positive control, which was kindly pro-
vided by Dr. Milica Pesic from the Institute for Biological Research
Sinisa Stankovic, Belgrade, Serbia.
Cytotoxicity assay in combination with doxorubicin. The
checkerboard microplate method was utilized to test the combined
activity of doxorubicin (Teva, Budapest, Hungary) and the ecdys-
teroid derivatives on the L5178 and L5178MDR cell lines, as described
before [17]. Briefly, 5 104 cells/well were incubated with doxo-
rubicin and the compound to be tested in McCoy's 5 A medium
(Sigma-Aldrich) for 48 h at 37 C, 5% CO2. Then, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma) was added to eachwell at a final concentration of 0.5mg/mL
per well, and after 4 h of incubation, 100 mL of sodium dodecyl
sulfate (SDS) 10% (Sigma-Aldrich) in 0.01M HCl was added to each
well. The plates were further incubated overnight, and the optical
densities were read at 540 and 630 nm using an ELISA reader
(Multiskan EX, Thermo Labsystem, Milford, MA, USA). The inter-
action was evaluated using the CompuSyn software (CompuSyn
Inc., Paramus, NJ, USA) at each constant ratio of compound vs.
doxorubicin (M/M), and combination index (CI) values were ob-
tained for 50%, 75%, and 90% of growth inhibition. Single-drug data
obtained from the duplicate control lanes of each plate were uti-
lized to determine cytotoxic activities for each compound.
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Stereochemistry and complete 1H and 13C NMR signal
assignment of C‐20‐oxime derivatives of posterone 2,3‐
acetonide in solution state
1 | INTRODUCTION
Less polar derivatives of ecdysteroids, and particularly
their acetonides and other dioxolane analogs, were
previously shown by our group to exert a strong chemo‐
sensitizing activity on cancer cells to common chemo-
therapeutics, including doxorubicin, vincristine, and
paclitaxel.[1,2] While this sensitizing activity could also
be observed on drug‐susceptible cancer cells, a high
selectivity was found towards multidrug resistant (MDR)
cancer cell lines transfected to overexpress the ABCB1
multidrug transporter.[2,3] Interestingly, the chemo‐
sensitizing activity was independent of a functional efflux
inhibition: even though some of the tested compounds
showed a mild to moderate ABCB1 inhibitory activity;
structure–activity relationships for efflux inhibition
were significantly different to those describing chemo‐
sensitizing activity.[1] In particular, several poststerone
derivatives, containing a substituted dioxolane (e.g.,
acetonide) moiety connected to their A‐ring, were found
to be free from the efflux pump inhibitory activity, while
acting as strong chemo‐sensitizers in combination with
doxorubicin.[3] In addition to this, ecdysteroid 6‐oximes
and oxime ethers demonstrated markedly increased
ABCB1 inhibitory activity, while acting as similarly potent
chemo‐sensitizers as their corresponding 6‐oxo analogs.[4]
Self‐assembling nanoparticles provide a promising
novel approach against cancer.[5] These can be prepared
by functionalizing a potential antitumor agent with a
long lipophilic side‐chain through functional group(s)
hydrolysable in a biological environment (e.g., ester),
which will make them working as prodrugs once
released. The role of the side‐chain in such a conjugate
is to induce the self‐assembly to nanoparticles in aqueous
Received: 26 February 2018 Revised: 23 April 2018 Accepted: 5 May 2018
DOI: 10.1002/mrc.4750
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environment due to secondary interactions.[6–8] In our pre-
vious work, we applied two different types of linkers: one
only with CH2 units and another with S―S disulfide
bridge in the middle of this unit. This last one was found
rather advantageous to release the drug molecules from a
prodrug form mainly in the inner environment of cancer
cells.[9] As part of a research program aiming to prepare
and study such compounds from certain ecdysteroids, we
turned our attention towards the 20‐oxime of poststerone
2,3‐acetonide, a potentially strong antitumor ecdysteroid
derivative, and its conjugates with long lipophilic side‐
chains. Due to the abundancy of overlapping signals in
the aliphatic region, a complete NMR signal assignment
of such compounds bears a significant challenge. Accord-
ingly, to the best of our knowledge, no previous studies
are available on the full NMR characterization of such
self‐assembling drug conjugates.
Most recently, Savchenko and coworkers reported the
regioselective preparation of this ecdysteroid oxime, along
with its X‐ray single crystal investigation and NMR data lim-
ited to the nonoverlapping 1H signals.[10] In the present
study, our aim was to perform an in‐depth, high‐resolution
NMR investigation on this compound, two of its oxime ether
derivatives, and two of its conjugates with long lipophilic
side‐chains, potentially able to self‐assemble. Publication of
the antitumor activity and nanoparticle forming properties
of the latter two compounds is just accepted elsewhere.[11]
2 | EXPERIMENTAL
2.1 | Substances
Chemical structures and synthesis of compounds 2–7 are
shown in Figure 1.
2.1.1 | Synthesis and purification of com-
pound 2
Poststerone 2,3‐acetonide (1) was prepared according to
previously published procedures.[3] Oximation of deriva-
tive 1 was performed at RT, by dissolving 42.2 mg
(0.104 mmol) of the substrate in a round‐bottom flask in
freshly distilled pyridine. A 10.9 mg (0.157 mmol;
1.5 equivalents) of hydroxylamine hydrochloride was
added, and the solution was left stirring for 25 min. Fol-
lowing this, the reaction mixture was cooled to 0 °C,
and potassium hydroxide (8.8 mg; 0,157 mmol), dissolved
in 1 ml of anhydrous ethanol, was added under stirring.
The obtained mixture was evaporated under reduced
pressure using a rotary evaporator, and water (30 ml)
was added to the crude solid followed by extraction with
ethyl acetate (4 × 30 ml). The combined organic fractions
were dried over Na2SO4 and filtered, and the solution was
evaporated under reduced pressure to obtain 40.17 mg of
crude mixture. RP‐HPLC purification was performed
using an Agilent Eclipse XDB‐C8 250 × 9.4 mm 5 μm
semipreparative column (Agilent Technologies Inc.,
USA) by using isocratic elution with 35% acetonitrile
and 65% water at a flow rate of 3 ml/min to obtain
poststerone 2,3‐acetonide 20‐oxime (2) in a yield of
69.7% (30.69 mg) and a RP‐HPLC purity of 99.1%.
2.1.2 | Synthesis and purification of com-
pound mixture 3
Three hundred milligrams (0.745 mmol) of ecdysteroid
substrate 1 was dissolved in 6 ml of freshly distilled pyri-
dine in a round‐bottom flask. A 186.7 mg (2.235 mmol,
three equivalents) of methoxyamine hydrochloride was
FIGURE 1 Chemical structures and preparation of ecdysteroid derivatives 2–3 and 6–7. Reagents and conditions: (a; 1) NH2OH·HCl
(1.5 eq.), Py, RT, 25 min (2) KOH in anhydrous EtOH; (b; 1) NH2OMe·HCl (3 eq.), Py, 70 °C, 5.5 hr (2) KOH/EtOH; (c) 4 or 5 (1.5 eq.), DCM,
DMAP (2 eq.), EDC·HCl (2.5 eq.), Ar
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added, and the mixture was left stirring at 70 °C for
5.5 hr. Following this, the reaction mixture was cooled
to 0 °C, and neutralization was performed with potassium
hydroxide (125.4 mg; 2.235 mmol) dissolved in 5 ml of
anhydrous ethanol. The obtained mixture was evaporated
using a rotary evaporator, and 40 ml of water was added,
followed by extraction with ethyl acetate (4 × 40 ml). The
combined organic fractions were dried over Na2SO4 and
filtered, and the solution was evaporated under reduced
pressure to obtain a crude mixture of isomeric O‐
methylated 20‐oximes and 6,20‐dioximes. Flash chro-
matographic purification was performed using a 30 g
RP‐C18 column with gradient elution of acetonitrile
increasing from 40% to 55% in 45 min (flow rate:
35 ml/min; UV detection: 254 nm). The fractions collected
between 17 and 30 min were combined and evaporated
under reduced pressure to obtain a mixture of (E/Z)‐
isomeric 20‐O‐methyl oxime ethers (3) in a combined yield
of 12% (38.58 mg, combined RP‐HPLC purity: 98.3%).
2.1.3 | Synthesis and purification of
ecdysteroid conjugates 6 and 7
Functionalization of self‐assembly inducer squalene and
the preparation of its coupled derivatives 4 and 5 attached
to a linker moiety were prepared following previously pub-
lished procedures.[12] A 34.2 mg (0.0819 mmol) of
ecdysteroid substrate 2 was dissolved in 6 ml of anhydrous
dichloromethane in a two‐neck round‐bottom flask. The
1.5 equivalents of the disulfide bridge containing com-
pound 4 (74.6 mg, 0.1229 mmol) or Substrate 5 (70.2 mg,
0.1229 mmol) were added dropwise under stirring. Follow-
ing this, 13.1 mg (0.1638 mmol, two equivalents) of
dimethylaminopyridine and 39.3 mg (0.205 mmol,
2.5 equivalents) of (3‐dimethylaminopropyl)‐N′‐
ethylcarbodiimide hydrochloride were added, and the mix-
ture was left stirring at room temperature under argon
atmosphere for 2 hr. After completion, the mixture was
neutralized with 10% aqueous NaHCO3, brine (30 ml)
was added, and extraction was performed with dichloro-
methane (4 × 30 ml). Following this, the combined
organic fractions were dried over NasSO4 and filtered,
and the solution was evaporated under reduced pressure.
Flash chromatographic purification was carried out on 4‐
g silica columns using isocratic grade eluents of 65% n‐
hexane and 35% ethyl acetate in case of product 6 and
75% n‐hexane and 25% ethyl acetate in case of product 7
to obtain the compounds as colorless oils.
2.2 | Further experimental details
Solvents and reagents were purchased from Sigma
(Sigma‐Aldrich Co., USA). All HPLC analysis, including
purification, were carried out on a Jasco HPLC instru-
ment (Jasco Analytical Instruments, Japan) coupled with
an MD‐2010 Plus PDA detector, applied in a detection
range of 210–400 nm. Flash chromatographic purification
was performed on a Combiflash Rf+ instrument
(TELEDYNE Isco, USA) equipped with diode array detec-
tion ‐ evaporative light scattering detection (DAD‐ELSD)
using commercially available prefilled RediSep columns
(TELEDYNE Isco, USA). High‐resolution mass spectros-
copy (HR‐MS) spectra were obtained on a Waters Acquity
iClass UPLC coupled with Thermo Q Exactive Plus with
HESI source (Waters Co., USA), used in positive mode.
2.2.1 | 20‐Hydroxyecdysone 2,3‐acetonide
20‐O‐methyl‐oxime ether isomers 3
White solid; HR‐HESI‐MS: C25H38O5N, [M + H]
+ Calcd.
432.2750, found: 432.2749.
2.2.2 | Squalenoylated ecdysteroid conju-
gate 6
Colorless oil; HR‐HESI‐MS: C59H91O8NS2Na, [M + Na]
+
Calcd. 1028.60838, found: 1028.60949.
2.2.3 | Squalenoylated ecdysteroid conju-
gate 7
Colorless oil; HR‐HESI‐MS: C61H96O8N, [M + H]
+ Calcd.
970.70912, found: 970.71546.
2.3 | NMR spectroscopy
1H (950 or 500 MHz) and 13C (239 or 125 MHz) NMR
spectra were recorded at room temperature on Bruker
Avance III spectrometers equipped with cryo probeheads.
All of the NMR experiments on compound 6 were taken
at 950/239 MHz, the other compounds 2, 3, and 7 were
measured at 500/125 MHz. Amounts of approximately
1–5 mg of compounds 2, 3, 6, and 7 were dissolved in
0.6 ml of chloroform‐d and transferred to 5 mm NMR
sample tubes. Chemical shifts are given on the δ‐scale
and are referenced to the solvent chloroform‐d: δC = 77.00
and δH = 7.27 ppm. Pulse programs of all experiments
(1H, 13C, DEPTQ, 1D sel‐ROESY [τmix: 300 ms], 1D sel‐
TOCSY, gs‐HSQC, and gs‐HMBC [optimized for 8 and
10 Hz, respectively]), and band‐selective‐HMBC were
taken from the Bruker software library. For 1D measure-
ment, 64 K data points were used to yield the FID. Spec-
tral widths for the 500 MHz 1H spectra were set to
6,500 Hz, whereas in case of 950 MHz to 7,600 Hz. For
2D measurements, on the 500 MHz spectrometer in case
of the HSQC spectrum, the sweep width in F2 was
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7,000 Hz; data points (t2 × t1) were acquired with
2 K × 128, in case of the HMBC spectrum, the sweep
width in F2 was 4,000 Hz; data points (t2 × t1) were
acquired with 2 K × 256, respectively. In the band‐selec-
tive HMBC experiment applied for compound 7, the used
digital resolution was 1.95/1.71 Hz per point. For 2D
measurements, on the 950 MHz spectrometer in case of
the HSQC spectrum, the sweep width in F2 was
7,600 Hz; data points (t2 × t1) were acquired with
2 K × 4 K, in case of the HMBC spectrum, the sweep
width in F2 was 7,600 Hz; data points (t2 × t1) were
acquired with 16 K × 8 K, respectively. For F1, linear
prediction was applied to enhance the resolution. To
achieve an appropriate separation of signals, we uti-
lized 1.86/3.61 and 0.93/2.91 Hz per point digital reso-
lution for the HSQC and HMBC experiments,
respectively. Most 1H assignments were accomplished
using general knowledge of chemical shift dispersion
TABLE 1 1H and 13C chemical shifts, multiplicities, and characteristic coupling constants of the steroid part of compounds 2, 3, 6, and 7 in
chloroform‐d
Atom
no.
2 3 (3Z) 6 7
H C H C H J (Hz)a C H C
1β 1.26 37.58 1.25 37.59 1.27 m 37.61 1.26 37.58
α 1.98 1.97 1.98 m 1.97
2 4.25 72.10 4.25 72.10 4.25ddd 10.0;6.0;4.7 72.10 4.25 72.08
3 4.29 71.55 4.29 71.56 4.29ddd 4.7;4.7;2.3 71.55 4.29 71.54
4β 2.11 26.64 2.11 26.65 2.13 m 26.66 2.11 26.63
α 1.83 1.83 1.83ddd 15.3;12.5;4.7 1.83
5 2.37 50.81 2.37 50.83 2.38dd 12.5;4.7 50.82 2.37 50.81
6 ‐ 202.65 ‐ 202.72 ‐ 202.42 ‐ 202.55
7 5.85 121.49 5.84 121.37 5.86d 2.6 121.69 5.84 121.63
8 ‐ 162.15 ‐ 162.45 ‐ 161.73 ‐ 161.91
9 2.86 34.60 2.85 34.61 2.86ddd 11.7;7.0;2.6 34.60 2.86 34.54
10 ‐ 37.83 ‐ 37.84 ‐ 37.84 ‐ 37.83
11β 1.61 20.59 1.61 20.61 1.61 m 20.60 1.61 20.57
α 1.80 1.78 1.80 m 1.79
12β 1.66 29.85 1.66 29.89 1.70 m 29.90 1.69 29.87
α 2.17 2.14 2.19ddd 13.0;13.0;4.9 2.19
13 ‐ 48.05 ‐ 47.71 ‐ 48.08 ‐ 48.06
14 ‐ 84.38 ‐ 84.47 ‐ 84.39 ‐ 84.33
15β 2.10 32.04 2.08 32.00 2.13 m 32.08 2.08 32.01
α 1.60 1.57 1.61 m 1.57
16β 2.30 21.24 2.35 21.17 2.44 m 21.35 2.44 21.30
α 1.94 1.89 2.00 m 1.99
17 3.11 51.33 3.04 51.35 3.21dd 9.0;9.0 51.95 3.21 51.94
18 0.63 17.20 0.63 (0.69) 17.18 (18.26) 0.70 s 17.36 0.69 17.33
19 0.99 23.60 0.99 (0.86) 23.60 (23.60) 1.00 s 23.60 0.99 23.58
20 ‐ 158.53 ‐ 156.40 ‐ 166.08 ‐ 165.94
21 1.92 15.53 1.83 (1.92) 16.02 (20.26) 1.98 s 17.48 1.83 17.44
22 ‐ 108.32 ‐ 108.29 ‐ 108.33 ‐ 108.33
Meβ‐22 1.50 28.53 1.50 28.52 1.51 s 28.53 1.50 28.52
Meα‐22 1.34 26.44 1.34 26.44 1.35 s 26.44 1.34 26.43
MeO ‐ ‐ 3.85 (3.87) 61.32 (61.53) ‐ ‐ ‐ ‐
aBecause the stereostructure of the steroid frame is identical within compounds of this table, we described the J coupling constants only for 6 detected at
950 MHz. s = singlet, d = doublet, m = unresolved multiplet.
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with the aid of the proton–proton coupling pattern (1H
NMR spectra). The NMR signals of the products were
assigned by comprehensive one‐ and two‐dimensional
NMR methods using widely accepted strategies.[13,14]
The 1H and 13C NMR data for the steroid moiety of
compounds 2–3 and 6–7 are compiled in Table 1,
whereas the signals of the R‐groups in compounds 6
and 7 are summarized in Table 2. The characteristic
NMR and HRMS spectra of compounds 2–3 and 6–7
are presented as Supporting Information.
3 | RESULTS AND DISCUSSION
Savchenko and coworkers most recently reported the 1H
and 13C NMR data of 20‐oxime derivative of posterone
2,3‐acetonide (2), and on the basis of its X‐ray single crys-
tal investigation, they proved the (E)‐configuration of the
oxime moiety.[10] As in the 1H and 13C NMR spectra of
this compound only one set of signals appeared, the mea-
sured diamagnetic change of δC‐20 (Δδ 51 ppm) sup-
ported the C═O → C═NOH conversion, but in the
absence of exact data of Δδ syn‐anti parameters for the
C‐21 signal, the unambiguous identification of the E/Z
isomerism was not possible. We have also taken the
NMR spectra of compound 2 (see Figures S1–S5), and
the NMR data are included in Table 1.
Our HMBC measurement (see Figure S5, cross‐peaks
H‐9/C‐11 and H‐17/C‐16) revealed that the assignment of
the CH2 signals in positions 11 and 16 is in fact the oppo-
site as compared to that published.[10] Furthermore, based
on the edited‐HSQC spectrum (Figure S4), we achieved
full assignment of the diastereotopic methylene hydrogen
atoms as well. It should be mentioned that no remarkable
NOE sterical interaction could be observed between the
broad OH and the H3‐21 (1.92 s) hydrogen atoms, not even
when dmso‐d6 was used as solvent. To overcome this prob-
lem, we synthetized and investigated also the correspond-
ing ―OCH3 20‐oxime‐methylether derivate (3). Two sets
of signals were observed in the NMR spectra in ratio of
95/5, and for the major component, complete 1H and 13C
assignment was achieved. In order to differentiate the β
or α position of the hydrogen atoms, we utilized a series
of selective ROESY experiments (Figure S8). Irradiation
of the OCH3 signal resulted in steric response on the H3‐
21 signal (1.83 ppm), and thereby, we now have an
unequivocal proof of the E configuration of the oxime
group. Even though the signal at 1.83 ppm consists of
the overlapping H3‐21 and Hα‐4 signals, this experiment
marked out not only the OCH3 but also H‐2, H‐3, Hβ‐4,
H‐9, Hβ‐16, H‐17, and H3‐18. In addition to this, the exper-
iments on H3‐18 and H3‐19 resulted in the stereostructure
and complete 1H assignments (see Figure 2).
TABLE 2 1H and 13C chemical shifts of the R group in com-
pounds 6 and 7 in chloroform‐d
Atom
no.
6 7
H C H C
1′ ‐ 170.73 ‐ 171.43
2′ 2.59 31.19 2.43 33.0
3′ 2.11 23.96 1.68 24.81
4′ 2.78 37.62 1.41–1.27 29.08
5′ ‐ ‐ 29.08
6′ ‐ ‐ 29.08
7′ 2.73 37.78 29.08
8′ 2.03 24.22 1.61 24.94
9′ 2.44 32.62 2.29 34.32
10′ ‐ 172.95 ‐ 173.91
11′ ‐ ‐ ‐ ‐
12′ 4.05 64.27 4.04 63.99
13′ 1.73 26.86 1.72 26.86
14′ 2.03 35.78 2.03 35.77
15′ ‐ 133.61 ‐ 133.67
16′ 5.14 125.13 5.13 125.03
17′ 2.08 26.66 2.08 26.63
18′ 1.99 39.67 1.98 39.65
19′ ‐ 135.13 ‐ 135.11
20′ 5.15 124.38 5.14 124.35
21′ 2.02 28.26a 2.01 28.24
22′ 2.02 28.27a 2.01 28.24
23′ 5.155 124.27 5.14 124.25
24′ ‐ 134.97 ‐ 134.96
25′ 1.99 39.75 1.98 39.73
26′ 2.08 26.66 2.08 26.63
27′ 5.13 124.25 5.12 124.23
28′ ‐ 134.91 ‐ 134.89
29′ 1.98 39.72 1.98 39.71
30′ 2.07 26.76 2.06 26.74
31′ 5.11 124.40 5.10 124.37
32′ ‐ 131.26 ‐ 131.25
33′ 1.69 25.70 1.68 25.69
34′ 1.61 17.68 1.60 17.67
35′ 1.61 16.00 1.60 15.99
36′ 1.61 16.05 1.60 16.03
37′ 1.61 16.04 1.60 16.02
38′ 1.61 15.87 1.60 15.86
aTentative assignment.
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In the edited HSQC spectrum of compound 3 (Figure
S12), we have clearly identified the CH3‐18 (0.69/
18.26 ppm) and CH3‐21 (1.92/20.26 ppm) signals also for
the minor isomer.
It should be mentioned that in case of the oxime
derivative compound 2, the C‐21 signal appeared at
15.53 ppm nearly at the same chemical shift as in the
main component of compound 3 (16.02 ppm). This value
unequivocally proofs the E configuration of the oxime
group. That means that compound 2 appears in solution
in the same configuration as in solid phase.[10]
The detected Δδ = 4.2 ppm syn‐anti parameter on the
C‐21 signal in compound 3 is in good agreement with
our results on C‐6 oxime derivatives of ecdysteroids[4]
and unambiguously confirmed the NMR differentiation
of the E/Z isomers. Considering the detected δC‐21
(17 ppm) in compounds 6 and 7, we can conclude that
these compounds are also 20(E)‐oxime derivatives. The
appearance of five ═CH signals of the R‐groups in the 1H
(δ5.20–5.00 ppm) and 13C (δ 125.2–124.2 ppm) NMR spec-
tra of compounds 6 and 7 justifies the connection of the
long lipophilic side‐chain (OR). The atomic numbering
for the OR group is shown in Figure 3, and corresponding
NMR data are summarized in Table 2.
In the 1H spectrum of compound 6 (Figure S13), the
identification of the two O═C―CH2CH2CH2―S moieties
was achieved by sel‐TOCSY experiments (see Figure S14),
and irradiation on the H2‐12′ signal (δ4.05 ppm) led to
the assignment of the O═C―O―CH2CH2CH2―C═ moi-
ety (see Figure S14). Considering the H2‐12′/C‐10′ cross‐
peaks (4.05/172.95‐ppm) in the HMBC spectrum (Figure
S21), the differentiation between the C‐10′ and C′‐1 ester
carbon atoms is straightforward. The H2‐13′ and H2‐14′
hydrogens clearly give HMBC correlation to C‐15′
(δ133.61 ppm; Figure S23), and this way the complete
NMR assignment of C‐1′–C‐15′ fragment is revealed. In
addition to this, the third cross‐peak to C‐15′ in this spec-
trum marked out δH2‐17′ at 2.08 ppm. The H2‐14′/C‐16′
(2.03/125.13 ppm) HMBC response (see Figure S22)
assigned δC‐16′, while the cross‐peak at 1.99/125.13
revealed the δH2‐18′ chemical shift. At the same time,
the H2‐17′ and H2‐18′ hydrogens show HMBC correla-
tions to C‐19′, and this way the signal at δ135.13 can be
assigned to this carbon atom. While C‐19′ displays a fur-
ther HMBC cross‐peak to a methylene group, this signal
at δ2.02 ppm should be H2‐21. In the
1H spectrum, the
intensity of this signal is 4H, and in the edHSQC, we
detected two methylene signals at 28.26 and 28.27 ppm
(controlled also with volume integration); we concluded
that the latter should belong to the CH2 group in position
C‐22′. This way the H2‐22′/C‐24′ HMBC correlation
established the δC‐24′ = 134.97 ppm assignment. This
FIGURE 2 Stereostructure of compound 3 and one‐dimensional selective rotating frame Overhauser enhancement spectroscopy (ROESY)
responses. The red arrows indicate characteristic steric proximities detected by irradiation at MeO, H3‐21+ Hα‐4, H3‐18, and H3‐19 signals,
blue numbers refer to 1H chemical shifts, and black cursive numbers denote atomic numbering
FIGURE 3 Atomic numbering of the long lipophilic side‐chain. X = S (compound 6) or CH2 (compound 7)
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carbon atom shows long‐range correlation also with the
H2‐25′ (δ1.99 ppm) hydrogens.
To continue the signal assignment of the side chain R,
we examined the CH3 signals. Five methyl groups resonate
in the 1H NMR at 1.61 ppm, but the sixth CH3 appears sep-
arately as a quartet (J ~ 1 Hz) at 1.69 ppm, and in the
edited HSQC spectrum (Figures S17–S18), the correspond-
ing cross‐peak is at 1.69/25.70 ppm. In the HMBC experi-
ment (Figure S20), the 1.69/17.68 correlation identified a
geminal dimethyl group, that is, two that are situated on
the end of the side‐chain. Considering the well‐known γ‐
steric effect that necessarily takes place with the methy-
lene in position 31′, their assignment is δC‐34′ = 17.68
and δC‐33′ = 25.70 ppm. Utilizing a sel‐TOCSY experi-
ment irradiating at 1.69 ppm (Figure S15), we managed
to identify the H3‐34′, H‐31′, H2‐30′ and H2‐29′ signals
(because this irradiation affected also the Hβ‐12 atom of
the steroid frame, the Hα‐12, Hα‐11, H‐9 and H‐7 signals
also appeared). The remaining, so far not assigned quater-
nary sp2 = C signal at 134.91 ppm, can only be C‐28′,
which is strongly supported by the H2‐30′, H2‐29′ and H2‐
26′ (δ2.08) HMBC correlations (Figure S23).
In case of compound 7, we used the same methodol-
ogy as in case of 6, but the applied NMR frequency was
only 500/125 MHz. To achieve the appropriate resolution
also in the HSQC and HMBC measurements, we pre-
ferred here their band selective versions. The obtained
1H and 13C chemical shifts of 7 correlated perfectly with
the data of 6, with exception of the methylene groups of
the side chain between positions 2′ and 9′. The method
of choice for studying this structure fragment was again
the one‐dimensional sel‐TOCSY experiment (Figure S25).
Irradiation of the H2‐9′ signal at 2.29 ppm identified not
only the hydrogens till H2‐6′, but, through raising the
mixing time to 200 ms, we could reach till H2‐2′. Due to
the extremely similar 1H chemical shifts of the methy-
lenes in 4′–7′ positions, it was possible to enter for them
region 1.47–1.27 ppm. The experiment on H2‐12′ supplied
H2‐13′ and H2‐14′ data. Joint irradiation of the five ═CH
hydrogens in the 5.17–5.17 ppm area revealed all signals
of their spin systems.
In conclusion, we obtained for the first time the com-
plete 1H and 13C NMR signal assignment of ecdysteroid
C‐20‐oxime derivatives, including two new, promising
potential antitumor agent with a long lipophilic side‐
chain. The preparation of self‐assembling nanoparticles
from these latter two compounds, as well as their bioac-
tivity testing, will be reported in the near future.
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ABSTRACT: Heteronanoparticles (H-NPs) consisting of conjugates characterized by a squalene tail linked to doxorubicin and
ecdysteroid derivatives are presented. Biological evaluation on A2780ADR cell line confirms not only the maintenance of the
activity of the parental drug but also the ability to overcome cancer resistance. The in vitro cell uptake was demonstrated, and the
involvement of an endosomal-mediated pathway was suggested.
KEYWORDS: Self-assembled-nanoparticles, ecdysteroids, doxorubicin, drug toxicity, cancer
The formation of self-assembled nanoparticles (NPs) usinganticancer drug conjugates could be a useful and smart
approach to face cancer.1−3 In the past few years, we developed
a step-by-step project that moved from the preparation of a
novel class of squalene conjugates with paclitaxel, podophyllo-
toxin, camptothecin, and epothilone A4 and reached, as highest
evidence of efficacy, the preparation of heteronanoparticles with
doxorubicin and cyclopamine conjugates that were able to
reduce in vivo the tumor growth and toxicity due to the use of
the single drugs.5−8 The conjugates were characterized by a
squalene tail that makes them able to self-assemble in water and
by a drug unit connected via a disulfide-containing linker to
secure the release inside the cell.
Our interest in facing the resistance of different kinds of
tumor cells9 drove us to consider the formation of self-
assembled heteronanoparticles as a promising approach.
Martins et al. recently reported the chemo-sensitizing effect
of apolar ecdysteroids on MDR cancer cells.10 The anti-
proliferative activity of these compounds was very low, and they
exerted a mild activity in modulating the ABCB1-mediated
efflux of rhodamine 123. Further studies revealed that the
chemo-sensitizing activity can be independent of efflux
inhibition, in particular, ketals of poststerone, a known in vivo
metabolite of 20-hydroxyecdysone that sensitized ABCB1-
transfected cancer cells to doxorubicin in a highly MDR
selective manner without significantly interfering with the efflux
function.
In this scenario, we planned the preparation of some
ecdysone conjugates containing the squalene tail to be
combined with the known squalenoylated doxorubicin11
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(Chart 1) and investigate their ability to form heteronano-
particles (H-NPs) toward the treatment of doxorubicin
resistant cell lines. In the light of the synergistic effect of
ecdysteroid acetonides with doxorubicin,10 we focused our
attention on diketals of 20-hydroxyecdysone and related
derivatives of poststerone.
Five different conjugates were prepared according to
Schemes 1 and 2 (see Table 1 and also the Supporting
Information). 20-Hydroxyecdysone derivatives 3a−c were
synthesized following a three-step procedure (Scheme 1): (a)
condensation reaction between the protected 20-hydroxyecdy-
sone 1 and the proper acid 2, (b) deprotection of the carboxylic
group, and (c) final condensation with 1′,2-tris-norsqualene
alcohol. Compounds 6a and 6b were prepared by a
condensation reaction between compounds 54 and 4.12
Next, the ability of the conjugates to self-assemble in
nanoparticles was investigated. Briefly, compound solution in
THF was added dropwise into ultrapure water. The
spontaneous self-assembly into NPs is a consequence of local
interactions between the hydrophobic molecules, mainly guided
by squalene chains interactions. Subsequently, the organic
solvent was removed under reduced pressure (see Supporting
Information). The nanosuspensions were characterized by
dynamic light scattering (DLS) and transmission electron
microscopy (TEM). DLS analysis confirmed the formation of
nanoassemblies in aqueous medium. The assemblies were
monodisperse (PdI < 0.2) with sizes around 200 nm, except for
the 6a NPs that exhibited a 2-fold larger hydrodynamic
diameter (366.3 ± 20.17 nm) (Table 2). The highly negative ζ-
potential values (<−20.0 mV) suggested that the electrostatic
repulsion between NPs contributed to the stability of the
nanoassemblies in aqueous medium.
Compounds 3a−c and 6a,b were further mixed with
squalene-conjugated doxorubicine (DOXO-Sq) that is well-
known to have a better therapeutic index than doxorubicin11
and to form heteronanoparticles (H-NPs) according to our
recent paper.7 H-NPs were prepared by mixing the compound
solutions (125 μL, 250 μg, 2 mg mL−1) with DOXO-Sq
solution (2 mg mL−1) in THF with a molar ratio compound/
DOXO-Sq of 50 and by dropping the organic solution into 250
μL of ultrapure water as previously described.11 The mixture
became opalescent suggesting the possible formation of
particles. H-NPs filtered with a 0.45 μm filter were
characterized by DLS and TEM. DLS analysis (Table 3)
confirmed the formation of H-NPs in aqueous medium. The
assemblies were monodisperse (PdI < 0.2) but larger compared
to the homogeneous NPs, except for the 6a,b NPs where
DOXO-Sq resulted in a decrease of (or did not alter) the
particle dimension, respectively. Also, the ζ-potential values
decreased.
Chart 1. Schematic Representation of the Building Blocks
and Obtained Conjugates
Scheme 1. Synthesis of the Conjugates 3a−c
Scheme 2. Synthesis of the Conjugates 6a,b
Table 1. Ecdysteroid Conjugates and Corresponding
Starting Material
starting material X PG deprotection product
1a + 2a CH2 Bn H2, Pd(OH)2 3a
1b + 2a CH2 Bn H2, Pd(OH)2 3b
1a + 2b S (CH2)2SiMe3 TBAF 3c
4 + 5a CH2 6a
4 + 5b S 6b
Table 2. NPs Characterization by Dynamic Light Scattering
(ZetaSizer, Malvern)a
NPs h.d. ± SD (nm) P.I. ζ-pot. ± SD (mV)
3a 198.1 ± 0.9 0.106 ± 0.041 −49.8 ± 0.9
3b 205.1 ± 0.6 0.050 ± 0.026 −43.0 ± 0.9
3c 214 ± 3.4 0.086 ± 0.046 −30.0 ± 4.6
6a 366.3 ± 20.17 0.161 ± 0.032 −21.5 ± 4.55
6b 221.8 ± 4.879 0.081 ± 0.088 −21.7 ± 1.50
ah.d., hydrodynamic diameter; P.I., polydispersity index; ζ-pot., ζ-
potential.
Table 3. H-NPs Characterization by Dynamic Light
Scattering (ZetaSizer, Malvern)a
X:DOXO-Sq 50:1
X h.d. ± SD (nm) P.I. ζ-pot. ± SD (mV)
3a 533.1 ± 26.60 0.160 ± 0.104 −9.73 ± 0.95
3b 538.2 ± 33.41 n.d. −9.39 ± 2.91
3c 579.2 ± 104.4 0.226 ± 0.276 −20.3 ± 2.52
6a 187.7 ± 14.48 0.223 ± 0.069 −13.5 ± 9.65
6b 298.7 ± 11.43 0.264 ± 0.014 −11.1 ± 3.48
ah.d., hydrodinamic diameter; P.I., polydispersity index; ζ-pot., ζ-
potential.
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Figure 1 reports TEM analysis for NPs obtained by self-
assembly of compound 6b and the H-NPs 6b/DOXO-Sq
(50:1). The images show compact nanoparticles whose
diameter is smaller if compared with the data obtained by
DLS but similar in the case of H-NPs.
The ability of both NPs and H-NPs to inhibit cell growth was
assayed on A2780ADR cells, a human ovarian carcinoma
doxorubicin-resistant cell line. The obtained results are shown
in Table 4 and are expressed as GI50 values, i.e., the
concentration of the test agent inducing 50% reduction in
cell number compared with control cultures.
Considering the NPs, it can be noted that DOXO-Sq exerts
an interesting inhibitory effect on A2780ADR proliferation,
showing a GI50 value of about 1 μM. This capacity,
notwithstanding about ten times lower with respect to that of
doxorubicin (GI50= 0.16 ± 0.01 μM), confirms, in accordance
with previous studies,11 the ability of the drug to induce an
antiproliferative effect even following squalenoylation. Other-
wise, the NPs obtained by squalene-conjugated ecdysteroids
provoke in the same experimental conditions a negligible effect
on cells, and indeed, only for the nanoassemblies 6a and 6b a
detectable and quite low cytotoxicity on A2780ADR cells was
demonstrated. Notably, the H-NPs obtained by mixing 3a−c
and 6a,b with DOXO-Sq induce a significant antiproliferative
effect, with GI50 values from 1.5 to more than 4 times lower
with respect to that obtained for DOXO-Sq. These data suggest
the ability of the H-NPs to overcome, at least partially, the
resistance phenomenon. In this connection, it was of interest to
investigate the effect of tamoxifen, a well-known inhibitor of the
P-glycoprotein13 on the intracellular uptake of the H-NPs 3a/
DOXO-Sq, taken as an example, and of doxorubicin, used as
reference. The cell internalization in A2780ADR was monitored
by flow cytometry. As expected, the presence of tamoxifen
significantly increased the drug accumulation in these cells. In
detail, the intracellular mean fluorescence intensity of
doxorubicin rose by 27% after exposure to the P-glycoprotein
inhibitor. Otherwise, no difference in fluorescence was observed
between the cells treated and those not treated with tamoxifen.
This result further supports the hypothesis that these new H-
NPs can play a crucial role in drug resistance mechanism,
suggesting the inability or at least the reduction of P-
glycoprotein to mediate their efflux from resistant cells. The
in vitro cell internalization was then further investigated by
fluorescence microscopy to verify any change in the uptake
pathway. For this purpose, A2780ADR cells were incubated for
2 h in the presence of doxorubicin and the H-NPs 3a/DOXO-
Sq. The results are shown in Figure 2a,b, respectively.
The cell penetration of both agents is rapid; nevertheless, the
intracellular localization differs: for the drug, a major local-
ization in the nuclei is observed (a), while for the H-NPs, a
staining almost exclusive in the cytoplasm appears (b).
A more in depth microscopy analysis (Figure 3) highlights in
the cytoplasm of A2780ADR cells treated with the H-NPs 3a/
DOXO-Sq the occurrence of vesicles characterized by a mean
diameter of about 0.9 μm, a value significantly higher with
respect to the hydrodynamic diameter of the corresponding H-
NP (533.1 ± 26.60, Table 3). The more complex membrane
trafficking pathway of NPs14 with respect to free doxorubicin15
could be responsible for the delay in nucleus accumulation of
the H-NPs 3a/DOXO-Sq.
The obtained results highlight the effectiveness of self-
assembled H-NPs to face cancer resistance and show a general
Figure 1. TEM analysis for NPs-6b (a, scale reported 1 μm) and H-
NPs 6b/DOXO-Sq (b, scale reported 500 nm).
Table 4. Inhibition of A2780ADR Cell Growth
A2780-ADR cells (GI50, μM)
a
NPs X:DOXO-Sq 50:1
3a >50 0.50 ± 0.02
3b >50 0.78 ± 0.02
3c >50 0.69 ± 0.15
6a 19 ± 3 0.34 ± 0.08
6b 39 ± 4 0.26 ± 0.03
DOXO-Sq 1.17 ± 0.06 ----
aValues are the mean ± SD of at least four independent experiments.
Figure 2. Fluorescence microscopy of A2780ADR cells incubated for 2
h in the presence of doxorubicin (a) or H-NPs 3a/DOXO-Sq (b) at 5
μM. The nucleus and cytoplasm were stained with DAPI and antibody
antitubulin conjugated with AlexaFluor488, respectively.
Figure 3. Fluorescence microscopy of A2780ADR cell treated for 2 h
with H-NPs 3a/DOXO-Sq.
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strategy that could be applied in various pathologies where
combined therapy could be beneficial.
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Synthesis of Nontoxic Protoflavone Derivatives through
Selective Continuous-Flow Hydrogenation of the
Flavonoid B-Ring
S#ndor B. :tvçs,*[a, b] M#t8 V#gvçlgyi,[c] G#bor Girst,[a, c] Ching-Ying Kuo,[d] Hui-Chun Wang,[d]
Ferenc Felçp,*[a, b] and Attila Hunyadi*[c, e]
Introduction
Protoflavones represent a relatively rare, special class of natural
flavonoids most typically occurring in fern species.[1] These
compounds express a non-aromatic B-ring, that is, a p-quinol-
derived moiety that can be either a dienone or its partially or
fully saturated analogue. Figure 1 shows the structures of a
few selected examples of protoflavonoids isolated from plants :
protoapigenone from Thelypteris torresiana, 5’,6’-dihydroproto-
genkwanone from Phegopteris decursive-pinnata, and tetrahy-
droprotogenkwanone from Pseudophegopteris subaurita.[1]
Protoapigenone was identified as a potent anticancer agent
in various in vitro and in vivo bioassays. Moreover, most proto-
flavones can efficiently bypass multidrug resistance conferred
by the efflux transporters ABCB1 and ABCG2, and several of
these compounds can selectively kill certain resistant cancer
cells that have evolved through adaptation to chemotherapeu-
tics.[2] It may be of particular interest that protoapigenone, to-
gether with its synthetic analogue WYC0209, can interfere with
crucial DNA damage response mechanisms through the ATR/
ATM signaling, which confers these compounds a chemo-sensi-
tizing activity towards DNA damaging chemotherapeutics such
as, for example, cisplatin and doxorubicin.[3] Protoapigenone
can also inhibit GST-p,[4] a detoxifying enzyme that plays an im-
portant role in the chemoresistance of cancer.[5] As for the
structure–activity relationships, it appears that the presence of
a symmetric dienone p-quinol moiety in the B-ring is crucial
for the strong cytotoxic activity of protoflavones, and that B-
Protoflavones are unique natural flavonoids with a non-aro-
matic B-ring, known for their potent antitumor properties.
However, their cytotoxicity represents a strong limitation in the
further exploration of their pharmacological potential. In the
current study, we sought to selectively saturate the p-quinol B-
ring of protoapigenone and that of its 1’-O-butyl ether, in
order to obtain non-toxic protoflavone analogues expressing
the dihydro- or tetrahydroprotoflavone structure also occurring
in nature. The benefits of a strictly controlled continuous-flow
environment in combination with on-demand electrolytic H2
gas generation were exploited to suppress undesired side reac-
tions and to safely and selectively yield the desired substances.
The obtained tetrahydroprotoflavones were free of the cyto-
toxicity of their parent compounds, and, even though tetrahy-
droprotoapigenone 1-O-butyl ether showed a weak inhibition
of DNA damage response through Chk1, neither compounds
influenced the cytotoxicity of doxorubicin either.
Figure 1. Selected examples of natural protoflavones containing B-rings with
different saturation levels.
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ring substituents typically decrease this activity.[6] On the other
hand, a nonbranching aliphatic side chain three or four carbon
atoms in length can be favorable at C-1’: introducing a 1’-O-
butyl ether moiety to the structure of protoapigenone, for ex-
ample, can significantly increase the cytotoxic activity while it
also greatly improves chemical stability.[7]
On the other hand, protoflavones can also exert bioactivities
other than those related to their antitumor effects. Protoapige-
none can inhibit the lytic cycle of Epstein Barr virus by inhibit-
ing the expression of lytic proteins, hence preventing the pro-
liferation of the virus.[8] In a recent study, protoapigenone 1’-O-
propargyl ether was identified as the first nonplanar flavonoid
with a strong xanthine oxidase inhibitory activity; this com-
pound is about twice as effective as allopurinol.[9] These exam-
ples indicate that protoflavones might likely have a versatile
and complex pharmacology, and that a valuable chemical–
pharmacological space is potentially hidden behind the cyto-
toxicity of these compounds.
In this context, the aim of the current study was 1) to inves-
tigate whether it is possible to selectively saturate the protofla-
vone B-ring in order to obtain structural element(s) that are
naturally occurring in the dihydro- and/or tetrahydroprotofla-
vones, and 2) to initiate studies on related pharmacological
changes, first focusing on the cytotoxicity and the effect on
DNA damage response.
Results and Discussion
Synthesis of tetrahydroprotoflavones
Our synthetic strategy toward the anticipated tetrahydroproto-
flavone derivatives involved the oxidative dearomatization of
apigenin (a commercially available 4’,5,7-trihydroxyflavone),
and the catalytic hydrogenation of the B-ring of the resulting
protoflavones. The dearomatization was performed according
to our previously published procedure using a common hyper-
valent iodine reagent, [bis(trifluoroacetoxy)iodo]benzene (PIFA)
in acetonitrile in the presence of water or n-butanol
(Scheme 1).[7] The mixtures were stirred for 1 h at 80 8C to yield
protoapigenone (2) or protoapigenone 1’-O-butyl ether (3)
after a simple chromatographic purification (see the Experi-
mental Section).
The selective hydrogenation of the B-ring of protoflavones 2
and 3 constitutes a significant synthetic challenge in view of
the large number of possible side reactions, including the un-
wanted reduction of the carbonyl group(s),[10] the (partial)hy-
drogenation of the C- or even the A-ring, and also the compet-
itive rearomatization of the dienone core (ring B).[11] Moreover,
in traditional batch-based methodologies, such triphasic cata-
lytic reactions pose a challenge because of the hazardous and
highly explosive nature of the gaseous reactant. Since hetero-
geneous catalytic hydrogenations can offer significant benefits
through the advantageous features of continuous processing,
we set out to exploit the benefits of a strictly controlled con-
tinuous-flow reactor environment.[12]
The heterogeneous catalytic hydrogenations were per-
formed in a high-pressure/high-temperature flow hydrogena-
tion mesoreactor (H-Cube).[13] The H2 gas necessary for the re-
actions was generated in situ by electrolytic decomposition of
deionized water. The hydrogenation catalyst was placed in a
stainless steel cartridge, where the triphasic reaction took
place. These features ensured improved operational safety and
simplicity over traditional hydrogenation techniques.[14] Impor-
tantly, the flow system furnished an excellent level of control
over the most important reaction parameters that determine
the product selectivity.[15] A representation of the flow reactor
is shown in Figure 2.
Based on our previous results on selective C@C double-bond
reductions of various aromatic enones,[10a] we initially chose
the Lindlar catalyst (5% palladium on CaCO3, poisoned with
lead) for a rapid optimization study. In the ambient-tempera-
ture (25 8C) hydrogenation of protoapigenone 1’-O-butyl ether
(3) in ethyl acetate (EtOAc) as solvent (at a flow rate of
1 mLmin@1), the total conversion steeply rose as a function of
the reaction pressure. At 20 and 40 bar, conversions of merely
19 and 43% occurred, respectively (Table 1, entries 1 and 2),
but at 80 bar, almost all the starting material was consumed,
giving a conversion of 99% (Table 1, entry 3). In these cases,
however, the selectivity of the hydrogenation of the dienone
core was decreased by the rearomatization of the B-ring, lead-
ing to the formation of about 10% apigenin (1). As the unde-
sired rearomatization occurs via palladium-mediated hydroge-
nolysis at C-1’,[11] we attempted to reduce the residence time on
the catalyst bed (by improving the flow rate) in order to sup-
Scheme 1. Synthesis of protoflavones 2 and 3 from apigenin.
Figure 2. Schematic representation of the continuous-flow hydrogenation
reactor.
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press apigenin (1) formation. Unfortunately, when we increased
the flow rate, the total conversion fell significantly below opti-
mal (Table 1, entry 4). Furthermore, the extent of unwanted rear-
omatization was found to be strongly dependent on the tem-
perature applied: heating the reactor zone from 25 to 508C at
40 bar resulted in a significant increase in apigenin (1) formation
at the expense of the amount of the desired tetrahydro deriva-
tive 3b (Table 1, entry 2 vs. entry 5). It should be emphasized
that (partial) reduction of the 4H-chromen-4-one core was not
detected under any of the reaction conditions applied.
Although, by using Lindlar catalyst, we managed to find suit-
able reaction conditions for the highly selective formation of
tetrahydroprotoflavone 3b (Table 1, entry 3), unfortunately,
rapid deactivation of the catalyst prevented successful prepara-
tive-scale continuous-flow synthesis (6 h run under the opti-
mized reaction conditions without changing the catalyst
column, see the Experimental Section). We therefore repeated
the reaction at 25 8C and 80 bar with MeOH as the solvent
(Table 1, entry 6). In a small-scale model reaction, the conver-
sion and product ratio were similar to those recorded when
EtOAc was used as the solvent, but scale-up proved again im-
practical because of fast catalyst deactivation. We speculated
that the irreversible nature of the substrate adsorption on the
catalyst support may account for the rapid catalyst deactiva-
tion. We then turned our attention to 5% palladium on char-
coal (Pd/C) as a heterogeneous hydrogenation catalyst. After a
couple of small-scale test reactions (entries 7 and 8), we ach-
ieved complete conversion and an excellent chemoselectivity
toward the formation of the desired tetrahydroprotoflavone
3b (3b/1 ratio was 84:16, entry 8). In this case, no catalyst de-
activation occurred, and successful preparative-scale synthesis
could be achieved.
The previously optimized reaction conditions with 5% Pd/C
as catalyst could simply be transferred to the hydrogenation of
protoapigenone (2) ; however, the solvent was switched to
MeOH due to solubility issues (Table 1, entries 9 and 10). Inter-
estingly, traces of the corresponding dihydroprotoflavone by-
product 2a with a partially hydrogenated B-ring could be de-
tected in this case, but the desired tetrahydro derivative 2b
could be obtained with high chemoselectivity as the main
product (Table 1, entry 10). Upon scaling up, no catalyst deacti-
vation occurred.
Bioactivity testing
In accordance with our overall aim to explore the pharmacolo-
gy of B-ring-saturated protoflavones, compounds 2b and 3b
were tested for their in vitro cytotoxicity on MCF-7 (breast),
HeLa (cervix), and SiHa (cervix) cancer cell lines. As expected,
the compounds did not show relevant cytotoxicity ; an IC50
value could be calculated only for compound 3b on HeLa cells
(55.12:1.11 mm) ; all other results corresponded to less than
50% inhibition at protoflavone concentrations as high as
100 mm. This confirmed our previous assumption that a great
decrease in cytotoxicity should be observed upon saturation of
the B-rings of compounds 2 and 3, which were previously
found to kill, for example, MCF-7 cells at IC50 values of 1.70
and 1.38 mm, respectively.[7]
The compounds were also tested for their potential to inter-
fere with the ATR/ATM signaling pathways, whose inhibition
would confer them chemosensitizing activity towards DNA-
damaging chemotherapeutics. After MCF-7 cells were pretreat-
ed with or without 5, 10, or 20 mm of compound 2b or 3b for
30 min, DNA damage was induced by exposing the cells to
1 mm of doxorubicin for 6 h; the results are shown in Figure 3.
In contrast with the parental protoapigenone (2), com-
pound 2b was found to be inactive on checkpoint kinase 1
and 2 (Chk1 and Chk2, respectively). Compound 3b was able
to exert significant inhibitory activity on the phosphorylation
(i.e. , activation) of Chk1, but only at the highest tested dose,
Table 1. Selective continuous-flow hydrogenation of protoflavones 2 and 3.
Entry Substrate[a] Catalyst Solvent p [bar] T [8C] Flow [mLmin@1] Conversion [%][b] Selectivity [%][b]
3a or 2a 3b or 2b 1
1 3 Lindlar EtOAc 20 25 1 19 n.d. n.d. n.d.
2 3 Lindlar EtOAc 40 25 1 43 0 88 12
3 3 Lindlar EtOAc 80 25 1 99 0 92 8
4 3 Lindlar EtOAc 80 25 1.5 38 n.d. n.d. n.d.
5 3 Lindlar EtOAc 40 50 1 78 0 66 34
6 3 Lindlar MeOH 80 25 1 97 0 81 19
7 3 5% Pd/C EtOAc 20 25 1 71 0 82 18
8 3 5% Pd/C EtOAc 40 25 1 100 0 84 16
9 2 5% Pd/C EtOAc 40 25 1 99 traces 77 23
10 2 5% Pd/C MeOH 40 25 1 99 traces 80 20
[a] csubstrate=1 mgmL
@1. [b] Determined by 1H NMR spectroscopic analysis of the crude material.
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20 mm. This would imply that this compound, at least at a
higher dose, might have potential as a chemosensitizing agent
for use as an adjuvant in chemotherapy. In order to test this
hypothesis, a series of combination studies were performed
with compound 2b or 3b together with doxorubicin. The
checkerboard microplate method was utilized, and three bio-
logical replicates (each in triplicate) were performed in order
to assure the highest possible accuracy and reveal any mild in-
teraction. In this experiment, neither compound was found to
interfere with the cytotoxicity of doxorubicin.
Conclusion
By developing a highly selective and efficient continuous-flow
method, we successfully saturated the B-ring of two cytotoxic
protoflavones, protoapigenone and its 1’-O-butyl ether. This al-
lowed us to obtain, for the first time, compounds containing
the rare, natural tetrahydroprotoflavone moiety. Our study on
the compounds’ cytotoxicity and their effect on the DNA
damage response through the ATR/ATM signaling pathway re-
vealed that related bioactivities, including the inhibition of
Chk1 and Chk2 phosphorylation, require the presence of a
symmetric dienone moiety in the flavonoid B-ring as in protoa-
pigenone. Even though a higher dose of the 1’-O-butyl ether
derivative 3b was able to inhibit Chk1 phosphorylation, none
of the compounds demonstrated any interaction with the in
vitro cytotoxicity of doxorubicin. Accordingly, our synthetic
method can conveniently knock out all those bioactivities of
protoflavonoids that could potentially confer them toxic side
effects. This opens up new possibilities to explore the pharma-
cology of this unique group of natural products.
Experimental Section
Product analysis
The identity of protoflavone substrates 2 and 3 was confirmed by
HPLC-PDA in comparison with authentic reference compounds
whose full characterization has been reported previously.[7] Proto-
flavones 2b and 3b were characterized by means of NMR, MS, and
HPLC methods. 1H, 13C, 13C HSQC, and 13C HMBC NMR spectra were
recorded in [D6]DMSO on a Bruker Avance DRX 400 instrument
with TMS as the internal standard, at 400.1 and 100.6 MHz, respec-
tively. Copies of the NMR spectra can be found in the Supporting
Information. High-resolution mass spectrometry (HRMS) was per-
formed on a Q-Exactive Plus Orbitrap spectrometer (Thermo Fisher
Scientific, USA) in positive-ion mode by using flow injection analy-
sis. Samples were dissolved in methanol at 100 mgmL@1 concentra-
tion, and 10 mL portions were injected at a flow rate of
200 mLmin@1 eluting with a water/acetonitrile mixture (50:50) con-
taining 0.1% formic acid. HRMS spectra are available in the Sup-
porting Information. Each derivative was analyzed by RP-HPLC on
a Jasco HPLC instrument equipped with a MD-2010 Plus PDA de-
tector (Jasco Analytical Instruments, Japan) in a detection range of
210–400 nm. Chromatographic identification of substrate 2 and its
derivatives 1, 2a, and 2b was carried out by using a Kinetex XB-
C18 100A 5m 250V4.6 mm RP-HPLC column (Phenomenex Inc. ,
USA) with isocratic grade elution with MeOH/water (60:40) applied
for a run time of 20 minutes with a flow rate of 0.9 mLmin@1. In
the case of protoflavone substrate 3 and products 1, 3a, and 3b, a
Kinetex Biphenyl 100A 5m 250V4.6 mm RP-HPLC column was
chosen (Phenomenex Inc. , USA) for qualitative chromatographic
analysis, and a gradient elution (acetonitrile/water 35:65 v/v con-
tinuously increasing to 70:30 in 25 minutes) was applied at a con-
stant flow rate of 1 mLmin@1. Following chromatographic purifica-
tion, all obtained derivatives were tested for their purity by RP-
HPLC utilizing the abovementioned methods.
Synthesis of protoflavones 2 and 3
Apigenin was dissolved at a concentration of 1 mgmL@1 in a 9:1 v/
v mixture of acetonitrile (ACN) and water or n-butanol. PIFA
(2 equiv) was added to the mixture. After the mixture had been
stirred at 80 8C for 1 hour, it was was cooled down, evaporated
under reduced pressure, and purified by flash chromatography
using mixtures of CH2Cl2/MeOH (97:3) or n-hexane/EtOAc/acetone
(80:15:5) as eluent to obtain compound 2 or 3, respectively. Char-
acteristic properties of these compounds has been reported previ-
ously; yields of all synthetic attempts were in perfect agreement
with the available data.[7]
General procedure for the continuous-flow hydrogenations
The hydrogenation reactions were carried out in an H-Cube system
(ThalesNano Inc.) The catalyst cartridge (internal dimensions:
30 mmV4 mm) contained approximately 100 mg of the appropri-
ate hydrogenation catalyst. The continuous stream of the reaction
solution was provided by a conventional HPLC pump (KnauerWell-
Chrom K-120). For each reaction, a 1-mgmL@1 solution of the corre-
sponding protoflavone was prepared in EtOAc or MeOH (HPLC
grade). The mixture was homogenized by sonication and then
pumped through the reactor under the selected conditions. For
small-scale test reactions (screening purposes), 15 mL solutions
were prepared. For preparative-scale syntheses, the concentration
of the starting material was not varied, but 360 mL solutions were
prepared and pumped through the instrument without changing
the catalyst cartridge. Between two reactions, the catalyst bed was
washed for 15 min with EtOAc or MeOH at 1 mLmin@1.
The conversion and the product ratio were determined by 1H NMR
analysis of the crude materials, from the relative intensities of the
signals of the dienone B-ring of the starting material, the aromatic
B-ring signals of apigenin, and the A- or C-ring signals of the hy-
drogenated product.
Product purification
Chromatographic purification of products 2b and 3b was carried
out using a CombiFlash Rf+ Lumen flash chromatographic instru-
Figure 3. Inhibition of doxorubicin-induced DNA damage response by com-
pounds 2b and 3b. Chk1 and Chk2: Checkpoint kinase 1 and 2, respectively.
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ment (TELEDYNE Isco, USA) with integrated UV/Vis, PDA, and ELS
detection applied with commercially available prefilled columns
(TELEDYNE Isco, USA) for normal-phase separations in a detection
range of 210–366 nm. Protoflavone derivative 2b was purified
using a poliamide column for gradient-grade separation applying
mixtures of CH2Cl2/MeOH where the ratio of MeOH was set to con-
stantly increase from 2% to 5% in 50 minutes. Product 3b was pu-
rified utilizing a silica column and gradient-grade elution with n-
hexane (solvent A) and ethyl acetate/acetone 3:1 (solvent B). In
this case, the ratio of solvent B was set to continuously increase
from 5% to 20% in 70 minutes.
Analytical data
Tetrahydroprotoapigenone (2b): Yield: 69.3%; RP-HPLC purity:
97.0%; pale-brown solid; 1H NMR (400.1 MHz, [D6]DMSO) dH : 1.99–
2.10 (m, 2H, CH2), 2.16–2.25 (m, 2H, CH2), 2.26–2.37 (m, 2H, CH2),
2.64–2.78 (m, 2H, CH2),6.19 (s, 1H, Ar-H), 6.38 (s, 1H, Ar-H), 6.41 (s,
1H, Ar-H); 13C NMR (100.6 MHz, [D6]DMSO) dC : 35.1, 37.0, 71.2, 94.9,
99.9, 104.4, 105.6, 158.5, 162.3, 165.5, 175.0, 182.9, 210.2. HRMS
C15H15O6, calculated: 291.08631, found: 291.08604.
Tetrahydroprotoapigenone 1’-O-butyl ether (3b): Yield: 57.5%;
RP-HPLC purity: 99.8%; pale-yellow solid; 1H NMR (400.1 MHz,
[D6]DMSO) dH : 0.85 (t, 3H, CH3, J=7.00 Hz), 1.29–1.42 (m, 2H, CH2),
1.47–1.58 (m, 2H, CH2), 2.13–2.27 (m, 4H, 2CH2), 2.32–2.42 (m, 2H,
CH2), 2.52–2.62 (m, 2H, CH2), 3.35 (t, 2H, CH2, J=6.61 Hz), 6.20 (s,
1H, Ar-H), 6.32 (s, 1H, Ar-H), 6.38 (s, 1H, Ar-H); 13C NMR
(100.6 MHz, [D6]DMSO) dC : 14.6, 19.7, 32.0, 32.5, 36.7, 63.5, 76.1,
94.9, 100.0, 104.7, 108.2, 158.6, 162.3, 165.7, 170.2, 182.5, 209.8.
HRMS C19H23O6, calculated: 347.14891, found: 347.14833.
Bioactivity testing
Detection of DNA damage response was achieved by Western blot
assay as previously described.[4] Primary phospho-specific antibod-
ies, which recognize the phosphorylated Chk1 serine345 or Chk2
threonine68 residues, respectively, were used to detect DNA
damage induced by doxorubicin treatment. The antibodies recog-
nize full-length Chk1, Chk2, actin, and gapdh, showing that treat-
ment with the compounds did not affect gene expression of these
proteins, which served as protein loading controls. The binding of
primary antibodies was detected with horseradish peroxidase cou-
pled secondary antibodies followed by an enhanced chemilumi-
nescent reaction. The chemiluminescent signals on the blots were
captured using a luminescent image analyzer. For testing the inter-
action between the new compounds and doxorubicin, the cultured
MCF-7 breast cancer cells were treated by using the checkerboard
microplate method, and a serial dilution (0–80 mm concentration
range) of 2b or 3b was combined with a serial dilution of doxoru-
bicin (0–2 mm concentration range) for 48 hours. The surviving cells
were detected by the MTT assay. In the case of compound 2b
which did not exert measurable cytotoxicity at the applied concen-
tration range when employed alone, IC50 values of doxorubicin
were calculated by the GraphPad Prism 5.03 software (GraphPad
Software Inc. , San Diego, CA, USA), and datasets obtained for the
single treatment were compared with those of the combinations.
In the case of compound 3b, the corresponding wells of the repli-
cate plates were averaged into one dataset, which was then uti-
lized to calculate combination index values for the constant ratios
of compound vs. doxorubicin by using the CompuSyn software
(CompuSyn Inc. , Paramus, NJ, USA).
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Abstract: Protoflavones, a rare group of natural flavonoids with a non-aromatic B-ring, are best
known for their antitumor properties. The protoflavone B-ring is a versatile moiety that might be
explored for various pharmacological purposes, but the common cytotoxicity of these compounds
is a limitation to such efforts. Protoapigenone was previously found to be active against the lytic
cycle of Epstein–Barr virus (EBV). Further, the 5-hydroxyflavone moiety is a known pharmacophore
against HIV-integrase. The aim of this work was to prepare a series of less cytotoxic protoflavone
analogs and study their antiviral activity against HIV and EBV. Twenty-seven compounds, including
18 new derivatives, were prepared from apigenin through oxidative de-aromatization and subsequent
continuous-flow hydrogenation, deuteration, and/or 4′-oxime formation. One compound was active
against HIV at the micromolar range, and three compounds showed significant activity against the
EBV lytic cycle at the medium-low nanomolar range. Among these derivatives, protoapigenone
1′-O-isopropyl ether (6) was identified as a promising lead that had a 73-times selectivity of antiviral
over cytotoxic activity, which exceeds the selectivity of protoapigenone by 2.4-times. Our results open
new opportunities for designing novel potent and safe anti-EBV agents that are based on the natural
protoflavone moiety.
Keywords: natural product; drug discovery; protoflavonoid; continuous-flow chemistry; oxime;
antitumor; antiviral; Epstein–Barr virus; lytic cycle
Int. J. Mol. Sci. 2019, 20, 6269; doi:10.3390/ijms20246269 www.mdpi.com/journal/ijms
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1. Introduction
Protoflavonoids represent a relatively rare, naturally occurring group of flavonoids, which possess
a non-aromatic B-ring and a hydroxyl function at C-1′. This unique structural moiety can appear in
various forms, it is most typically a symmetric dienone p-quinol that may be partially or fully saturated,
as shown by the examples of some natural protoflavones illustrated in Figure 1 [1].
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dienone structure, as in protoapigenone, is prerequisite of a strong cytotoxic activity.
Many protoflavones are known for their potent anticancer activity and, until now, this is the
bioactivit that is by far the most deeply investigated for this compound family. Protoflavone ar
known to be cytotoxic on a wide range of cancer cell lines in vitro, a so e can selectively kill
multi-drug resistant cancer cell lines that are adapted to chemotherapeutics [2,3]. Some protoflavones,
e.g., protoapigenone, were al o tested in vivo and found active against a variety of tumor xenograft
m dels [1]. A particularly inter sti g pharmacody amic property of protoapigenone is that it is a
potent inhibitor of the ATR-mediated activation of checkpoint kinase 1 (Chk1) [4], a DNA damage
response mechanism that is an emerging antitumor target in the focus of several currently ongoing
clinical trials [5].
From the available structure-activity relationships that were obtained from synthetic [6] and
semi-synthetic [7] n logs, it is known that (a) presence of a symmetric die one with a non-substitute
p-quinol B-ring is essential for a strong cytotoxic effe t [8], (b) the presence of a longer non-branching
(e.g., butyl) alkyl substituent at the 1′-OH can further enhance cytotoxicity gainst some cell lines,
and (c) a branching 1′-O-alkyl substituent (e.g., isopropyl) strongly decreases cytotoxicity. It is also
worth noting t at a 1′-O-alkyl substitution results in a chemicall much more stable B-ring when
compared to the non-substituted p-quinol [7].
However, the possible use of protoflavonoids might exceed their antitumor potential.
The non-aromatic B-ring containing an sp3 carbon at C-1
′
makes the three-dimensional (3D) structure
of these compounds very unique among flavonoids. This mig t l a to a versatile pharmacology that is
hardly explored. Previo sly, we identified protoapigenone 1′-O-pr pargyl ether as the first non-pl nar
fl vonoid that can exert a potent inhibitory effect on xanthine oxidase, pro-oxidant enzyme that is
involved in many chronic diseases [9]. I addition to this, we fou d that protoapigenone exerts an
antiviral effect against the Epstein–Barr Virus (EBV) in vitro through inhibiting the ex ressi of EBV
lytic proteins [10]. These results suggest that the chemical space of pr toflavones has still much to offer
in bioactivities other than antitumor effect, while cytotoxicity itself certainly represe ts a limitation for
exploring these.
We recently reported a method for the highly selective saturation of the protoflavone B-ring by
means of continuous flow hydrogenation under mild reaction conditions to overcome this limitation.
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This allowed for us to obtain the rare, naturally occurring tetrahydroprotoflavone moiety, while also
providing an effective tool to eliminate the cytotoxicity of the derivatives [11].
The aim of our current work was to further explore the antiviral potential of protoflavonoids by
preparing a series of less cytotoxic derivatives, and then test them against EBV and, while considering
the antiretroviral activity of various other types of flavonoids [12–14], also against HIV.
2. Results and Discussion
2.1. Synthesis of B-Ring Modified Protoapigenone Analogs
First, we prepared the 1′-O-alkyl substituted protoapigenone derivatives from apigenin (1),
following our previously described procedure [7]. Oxidative dearomatization of the B-ring of apigenin
was achieved by a hypervalent iodine reagent, [bis(trifluoroacetoxy)iodo]benzene, and the solvent
was 10% v/v of water or alcohol in acetonitrile depending on the substituent to be coupled at C-1′.
This allowed for us to obtain compounds 2–8 as potential intermediates for further transformations,
among which 6 was already a compound of interest for this study due to its very weak cytotoxicity
when compared to the others.
As detailed above, the function that is dominantly responsible for the cytotoxicity of protoflavones
is the symmetric dienone moiety on the B-ring, conferring pro-oxidant and Micheal-acceptor properties
to the compound. While considering this, we employed two different targeted synthetic strategies for
eliminating cytotoxicity: (i) Saturation of the double bonds through hydrogenation or deuteration and
(ii) substituting the 4′-oxo group with an oxime function. Scheme 1 shows synthetic routes.
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Scheme 1. Semi-synthetic routes employed for the preparation of tetrahydro-, tetradeutero- or
4′-oxime analogs of protoapigenone and its 1′-O-alkyl ether derivatives. Oxime derivatives 21–28
were t ined as racemates, how ver, for simplicity only o e enantiomer is shown. Reaction conditions:
(a) CH3CN/RO —9: , ◦ , 1 ; (b) H-Cube®, 9–14: H2, 5% Pd/C or 15−20: D2, 5%
Pd/BaSO4; (c) NH2OH· Cl (3 equiv.), Me , fl , 24 h; and, (d) NH2OH·HCl (4 equiv.), MeOH,
reflux, 3 h.
The hydrogenation of protoflavonoids’ dienone moiety might result various products.
Following our previously published procedure, the saturation of the protoflavone B-ring was achieved
with high selectivity under mild reaction conditions while utilizing a modified H-cube® continuous
flow hydrogenation reactor [11]. Employing this device has several advantages when compared to
traditional batch hydrogenation, i.e., the ease of handling of the explosive gas, precise control over
the reaction conditions, instrumentally controlled gas pressure, sustainability, and safe applicability.
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During this process, hydrogen gas was in situ generated by an electrolytic cell fueled with high
purity water, and forwarded to interact with the substrate’s solution. The mixture was then passed
through a stainless-steel tube that was filled with the catalyst, where the triphasic reaction took place.
During each transformation, the catalyst bed was placed in a thermostat to assure temperature control.
Products of the reactions were collected into glass vials and subsequently purified by RP-HPLC to
obtain tetrahydroprotoapigenone analogs 9–14 in high purity (Scheme 1).
Deuterium is applied in organic chemistry for several purposes. It is employed as a tracer in
studies that aim to follow the reaction routes or as a reference for determining the influence of isotope
effects on the development of a reaction during kinetic studies. Isotope labeling is a versatile technique
that can be used many ways, including e.g., metabolomic studies, and the importance of deuterium in
isotope labeling is increasing as new applications emerge [15,16].
Deuterium can also be of potential interest for discovery, since it can significantly influence
bioactivity of a compound due to the so-called isotope effect [17,18]. Several methods are available for
the synthetic preparation of deuterium containing compounds. The conventional batch synthesis of
deuterated molecules suffers from similar drawbacks as hydrogenation, such as the lack of sustainability
and the low purity and high price of D2 gas. Therefore, we used a previously established continuous-flow
method in this current work [19–21], during which the required deuterium gas was in situ generated
from high-purity D2O with H-Cube®. The reaction was performed in an aprotic solvent, ethyl acetate,
to ensure that no hydrogen-deuterium exchange occurs during the transformation. For the same
reason, we chose barium sulfate as the catalyst carrier, since activated charcoal might contain protic
contaminations on its surface. In all other aspects of the synthesis, we followed the same procedure as
in the case of hydrogenation, to obtain tetradeuteroprotoapigenone derivatives 15–20 (Scheme 1).
Several studies underline that the preparation of flavonoid oxime derivatives can be a simple
yet effective synthetic option for enhancing certain biological effects of the parent compound, e.g.,
antimicrobial [22], antioxidant [23], and antitumor [24] properties. Compounds with different B-ring
saturation and/or 1′-O-substituents (6–9 and 14) were selected for the preparation of 4′-oximes to
further increase chemical and consequential pharmacological diversity (Scheme 1).
Our preliminary small-scale test reactions indicated that oxime formation of protoflavones is
regioselective at the 4′-keto group, and under the synthetic conditions applied, we did not observe
the formation of 4-oxime nor 4,4′-dioxime side products. On the other hand, the solvent appeared to
play a crucial role in the possible outcome of the transformation. Pyridine, ethanol, and acetonitrile
are probably among the most commonly used solvents in oxime synthesis. However, none of these
worked in our case and, finally, we found methanol to be the best solvent for reacting protoflavones
with hydroxylamine. The yields appeared to vary greatly, depending on the substrate’s concentration
in the reaction solution, and we obtained the best yields with ca. 2–2.5 mg/mL concentrations; both
lower and higher concentrations could significantly decrease the efficiency of the transformation.
Regioselective transformation of the tetrahydroprotoflavone analogs 9 and 14 to their
corresponding 4′-oximes 27 and 28 was straightforward. However, in the case of protoflavones 6–8, each
transformation was accompanied by a regioselective Michael addition of methanol at C-2′, forming a
methoxy group and saturating one of the double bonds to yield 2′-methoxy-2′3′-dihydroprotoapigenone
4′-oxime derivatives 21–26. The orientation of the methoxy group was apparently random, since the
1′,2′-cis and trans derivatives were formed in a ca. 1:1 ratio. When assigning the relative configuration
of the 1′,2′-carbon atoms, we could not observe diagnostic NOESY cross-peaks between the 2′-methoxy
and the 1′-O-alkyl substituents for any of these compounds. Therefore, cis-trans isomers were assigned
based on the characteristic coupling constant patterns that were observed between H-2′ and H-3′a
or H-3′b. To achieve this, structures were optimized by the MMFF94x force field in CCG-MOE,
the H2′-C2′-C3′-H3′a, and H2′-C2′-C3′-H3′b dihedral angles were measured, and theoretical 1H-1H 3J
coupling constants were calculated by means of the Bothner-By equation. The experimental coupling
constants showed good agreement with the calculated values, unambiguously assigning compounds
21–23 as the 1′,2′-trans, and 24–26 as the 1′,2′-cis isomers. Nevertheless, while each compound was
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obtained as racemate, the newly formed oxime took a defined orientation in all of them. This suggests
that the solvent addition took place to an intermediate of the reaction in a way that it determined
the final orientation of the oxime. We considered compounds 27 and 28 as internal references, since
the exact data of the ∆δ syn-anti parameters were not available this way, which provided us with the
chemical shifts for both neighbouring methylenes of the oxime. In these compounds, C-3′ (syn) and
C-5′ (anti) gave 13C NMR chemical shifts at ca. 18.8 and 26.2 ppm, respectively. The 13C NMR signals of
the 3′-CH2 moieties of compounds 21–26 appeared within the range of 22.7–23.7 ppm, which strongly
suggests that the oxime is present in E-orientation in each of these compounds while also taking the
effect of the electron-rich neighbouring OCH3 group into account.
2.2. Biological Activities
2.2.1. Antiretroviral Activity
Compounds 2, 6–14, and 21–28 were tested against HIV-1 while using a pseudotype virus assay
allowing only one cycle of viral replication and being more sensitive for compounds targeting the early
steps of HIV replication, such as reverse transcription and integration [25]. Tetrahydroprotoapigenone
(9) was found to inhibit viral infection by ca. 50% at the non-cytotoxic concentration of 100 µM (see
Supplementary Materials, Table S1). While this represents a rather weak activity, it might still be of
interest, since this compound was not cytotoxic on the host cells at as high as 500 µM concentration.
2.2.2. Antiviral Activity against EBV
Compounds 2 and 6–28 were tested for their activity on the EBV lytic cycle. To assess this,
the P3HR1 cells were treated with sodium butyrate and TPA for 24 h. As expected, lytic protein Rta
was expressed after lytic induction. As a first screening, the cells were treated with protoapigenone (2),
used as a positive control, or compounds 6–28 at the induction of lytic cycle for 24 h. The concentration
selected for screening was 0.25 µM, where protoapigenone (2) was previously found to exert a strong
activity [10]. The results indicated that three of the analogs, 6, 7, and 8 can inhibit EBV lytic cycle at
this concentration. These compounds were then tested for the dose dependency of their effect on the
expression of Rta; Figure 2 shows the results.
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Figure 2. Inhibition of the expression of Epstein–Barr Virus (EBV) Rta by protoapigenone (2) and its
analogs 6–8. The cells were treated with the compounds at the time of lytic induction with SB and
TPA. Cell lysates were harvested at 24 h after lytic induction. Proteins in the lysate were detected by
immunoblotting using anti-Rta and anti-α-tubulin antibodies. Calculated IC50 values for 2, 6, 7, and 8
were 0.127, 0.467, 0.208, and 0.285 µM, respectively.
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We found that, similarly to protoapigenone (2), compounds 6, 7, and 8 also caused a marked
reduction in the Rta levels at 0.50, 0.25, and 0.50 µM, respectively, and the IC50 values were calculated
as 0.467, 0.208, and 0.285 µM, respectively. The positive control protoapigenone (2) acted with an IC50
value of 0.127 µM, which was in good agreement with our previous findings [10]. Subsequently, we
conducted MTT assay to evaluate the cytotoxicity of these compounds to P3HR1 cells; Figure 3 shows
the results.
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Compounds 7 and 8 were similarly active as protoapigenone, as expected from our previously
published structure-activity relationship (SAR) study on the effect of 1′-O-alkyl substituents on the
cytotoxic activity of protoflavones [7] (2), and the isopropyl-ether derivative 6 was much weaker in
this regard. Selectivity of the anti-EBV vs. cytotoxic effect of these compounds, expressed as a ratio
of the corresponding IC50 values, could therefore be calculated, as follows: 2 (30.1), 6 (73.0), 7 (9.80),
and 8 (17.3). This means that compound 6 demonstrated a relevant, ca. 2.6-times increase in selectivity
when compared to protoapigenone. It needs to be stressed that this selectivity increase is due to the
much weaker cytotoxic activity of compound 6 as compared to protoapigenone, and it does not refer
to a stronger anti-EBV activity. While this successfully fulfills our objectives that were set for this
study, it might be worthy to further explore SAR regarding the role of the 1′-O-alkyl chain in the future.
For example, when considering that the 1′-O-butyl derivative compound 7 exerted an over two-fold
stronger anti-EBV activity than the 1′-O-isopropyl compound 6, it might be a relevant strategy to study
further analogs with a longer branching side-chain coupled at C-1′, such as i-butyl, i-pentyl, etc.
It is also worth noting that it was also found to be possible to shift the bioactivity profile of
protoflavones to the other direction, i.e., increasing cytotoxicity and decreasing anti-EBV activity, by
appropriate modifications of the B-ring. As compared with protoapigenone (2), compound 7 was less
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effective against EBV and more cytotoxic, i.e., ca. three-times less selective in this regard. Therefore,
the SAR of protoflavonoids might be explored towards various therapeutic targets, and this is certainly
a need to evaluate their real value concerning drug discovery.
3. Materials and Methods
3.1. Synthesis and Chromatographic Purification
Reagents were purchased from Sigma (Merck KGaA, Darmstadt, Germany) and the solvents were
obtained from Macron Fine Chemicals (Avantor Performance Materials, Center Valley, Pennsylvania,
USA). The reactions were monitored by TLC on Kieselgel 60F254 silica plates purchased from Merck
(Merck KGaA, Darmstadt, Germany), and characteristic spots of compounds were examined under
UV illumination at 254 and 366 nm. Chromatographic purification of components was carried out
in one or two steps, depending on the complexity of protoflavone product mixtures. For flash
chromatography, a CombiFlash® Rf+ Lumen apparatus (TELEDYNE Isco, Lincoln, NE, USA) was
utilized that was equipped with ELS and diode array detectors. Components were separated on
commercially available RediSep NP-silica flash columns (TELEDYNE Isco, Lincoln, NE, USA) or
manually filled polyamide columns. The mobile phase eluents consisted of mixtures of n-hexane—ethyl
acetate or dichloromethane—methanol, modified according to the polarity of the analytes. To determine
the composition of sample mixtures or to evaluate the purity of compounds, RP-HPLC analysis was
performed on a Kinetex XB-C18 250 × 4.6 mm, 5 µm or a Kinetex Biphenyl 250 × 4.6 mm, 5 µm column
(Phenomenex Inc., Torrance, CA, USA) at 1 mL/min. flow rate, while using a dual pump (PU-2080)
Jasco HPLC instrument (Jasco International Co. Ltd., Hachioji, Tokyo, Japan) that was equipped with
an MD-2010 Plus PDA detector to collect data in a detection range of 210–400 nm. For preparative
purposes, an Armen Spot Prep II integrated HPLC purification system (Gilson, Middleton, WI, USA)
with dual-wavelength detection was applied, operating at 230 and 300 nm. Preparative separations
were performed on the corresponding Kinetex XB-C18 or Biphenyl 250 × 21.2 mm, 5 µm columns with
adequately chosen eluents of acetonitrile–water, and the flow rates were 15 mL/min.
3.1.1. Preparation of Protoapigenone Derivatives 2–8
Protoapigenone and its 1′-O-alkyl ether analogs were synthesized while following our previously
described procedures [7]. Briefly, apigenin (1 mg/mL) was dissolved in a 9:1 v/v ratio mixture
of acetonitrile and H2O or the alcohol to be coupled at C-1′. Under stirring, two equivalents of
[bis(trifluoroacetoxy)iodo]benzene was added slowly to the solution and the reaction was left to
develop for 1 h at 80 ◦C. After completion, the solvent was evaporated on a rotary evaporator and the
residue was purified by flash chromatography, allowing for obtaining the corresponding protoflavones
in pure form.
3.1.2. Preparation of Tetrahydroprotoapigenone Derivatives 9–14
Selective hydrogenation of protoflavones was carried out based on our previous strategy [11] that
relied on the application of an H-Cube® continuous flow hydrogenation system (ThalesNano Inc.,
Budapest, Hungary). The applied catalyst cartridge was a stainless-steel column (internal dimensions:
50 mm × 4.6 mm) containing approximately 200 mg of 5% Pd/C catalyst. The cartridge was inserted
into an external thermostat (Jetstream 2 plus, Jasco International Co. Ltd., Hachioji, Tokyo, Japan) set
to 25 ◦C. A standard HPLC pump (Well-Chrom K-120, Knauer GmbH, Berlin, Germany) was used to
provide continuous stream. In each case, the flow rate was set to 1 mL/min., and 40 bar pressure was
applied in the system.
For each reaction, 20 mg of the corresponding protoflavone was dissolved/suspended in 20 mL
of HPLC grade ethyl acetate and homogenized by sonication. The catalyst bed was washed with
the solvent for 15 min. to ensure reproducibility between each reaction. Following transformations,
preparative RP-HPLC was utilized for chromatographic purification.
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3.1.3. Preparation of Tetradeuteroprotoapigenone Derivatives 15–20
The selective deuteration of the protoflavone B ring was performed similarly to that described for
hydrogenation with only slight modifications. In this case, approximately 400 mg of 5% Pd/BaSO4
was used as a catalyst, and the reservoir of the instrument was filled up with high purity heavy water
(D2O). The obtained compounds 15–20 were purified by preparative RP-HPLC.
3.1.4. Preparation of Protoflavone 4′-oxime Derivatives 21–26
An aliquot of 150 mg of compound 6, 7, or 8 was dissolved in methanol in a concentration of
2.5 mg/mL (50 mL). Following this, three equivalents of hydroxylamine hydrochloride were added
to the solution, and the mixture was refluxed for 24 h at 70 ◦C. Silica gel (3–5 g) was added to the
solution and the solvent was evaporated to prepare for dry loading separation. The dried residue was
applied to flash chromatography, and products were pre-purified by a gradient separation program
starting with n-hexane, and the ratio of ethyl acetate was gradually increasing 90%, v/v, in 15 min.
Following this, cis- and trans-isomeric racemate pairs (21 and 24, 22 and 25, 23, and 26, respectively)
were separated by means of preparative RP-HPLC to obtain racemates 21–26.
3.1.5. Preparation of Tetrahydroprotoflavone 4′-oxime Derivatives 27–28
An aliquot of 60 mg of tetrahydroprotoflavone 9 or 14 was dissolved in methanol in a concentration
of 2.5 mg/mL (25 mL). Four equivalents of hydroxylamine hydrochloride were added to the mixture
and the solution was stirred at 70 ◦C for 3 h. Following this, solvent was evaporated on a rotary
evaporator and brine (40 mL) was added to the residue. Extraction was performed with EtOAc
(3 × 40 mL), and the organic fractions were then combined and dried over Na2SO4. The drying agent
was removed through filtration, and the solution was evaporated under reduced pressure. Eventually,
preparative RP-HPLC was applied to obtain oxime derivatives 27 and 28.
3.2. Structure Elucidation
NMR and MS techniques characterized the compounds. NMR spectra were recorded at 25 ◦C on
a Bruker Avance DRX 400 MHz (Bruker Co., Billerica, MA, USA) or on a Bruker Avance NEO 500 MHz
spectrometer that was equipped with a Prodigy BBO 5 mm CryoProbe with the use of TMS as an
internal standard. Typically, 5–10 mg of the corresponding protoflavone was dissolved in DMSO-d6
and transferred to NMR tubes for recording spectra. The data report and spectra analysis were carried
out with MestReNova v6.0.2-5475 software (Mestrelab Research S.L., Santiago de Compostela, Spain).
1H and 13C NMR chemical shifts are listed below; residual hydrogen signals of the B-rings of deuterated
compounds 15–20 are marked with an asterisk. Mass spectra were recorded on an API 2000 triple
quadrupole tandem mass spectrometer (AB SCIEX, Foster City, CA, USA) that was equipped with
ESI ion source that was used in the negative ionization mode. 1H and 13C (JMOD) spectra of the
new compounds are provided as Supplementary Materials, Figures S1–S36, and their mass spectra as
Figures S37–S54.
Compound 10: Pale yellow solid, Isolated yield: 25.2% (5.1 mg); RP-HPLC purity: 97%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.93 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.34 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.22 (3H, s), 2.56 (2H, m), 2.35 (2H, m), 2.18–2.22 (4H, m). 13C NMR (125 MHz, DMSO-d6):
208.9, 181.7, 168.9, 164.5, 161.4, 157.8, 107.5, 103.9, 99.0, 94.1, 75.7, 51.0, 2 × 35.8, 2 × 30.8. ESI-MS (m/z):
303.4 [M-H]−.
Compound 11: Pale yellow solid, Isolated yield: 70.5% (15.5 mg); RP-HPLC purity: 98%. 1H NMR
(500 MHz, DMSO-d6): 12.66 (1H, s), 10.94 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.40 (2H, q, J = 6.9 Hz), 2.55 (2H, m), 2.34 (2H, m), 2.16–2.22 (4H, m), 1.16 (3H, t, J = 6.9 Hz).
13C NMR (125 MHz, DMSO-d6): 209.0, 181.7, 169.6, 164.5, 161.4, 157.7, 107.1, 103.8, 99.0, 94.0, 75.5, 58.6,
2 × 35.9, 2 × 31.3, 15.5. ESI-MS (m/z): 317.7 [M-H]−.
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Compound 12: Pale brown solid, Isolated yield: 30.1% (6.1 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.97 (1H, br s), 6.38 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.30 (2H, t, J = 6.4 Hz), 2.56 (2H, m), 2.36 (2H, m), 2.16–2.22 (4H, m), 1.55 (2H, m), 0.89 (3H,
t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6): 209.0, 181.7, 169.3, 164.6, 161.4, 157.7, 107.3, 103.8, 99.0,
94.0, 75.2, 64.5, 2 × 35.9, 2 × 31.2, 22.8, 10.7. ESI-MS (m/z): 331.3 [M-H]−.
Compound 13: Pale yellow solid, Isolated yield: 44% (8.9 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.62 (1H, s), 10.99 (1H, br s), 6.42 (1H, s), 6.39 (1H, d, J = 1.9 Hz), 6.20 (1H, d,
J = 1.9 Hz), 3.82 (1H, septet, J = 6.1 Hz), 2.55 (2H, m), 2.42 (2H, m), 2.13–2.21 (4H, m), 1.02 (6H, d,
J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 209.2, 181.7, 169.0, 164.8, 161.4, 157.5, 108.0, 103.9, 99.1,
93.9, 75.0, 66.1, 2 × 36.1, 2 × 31.6, 2 × 24.0. ESI-MS (m/z): 331.4 [M-H]−.
Compound 15: Pale yellow solid, Isolated yield: 63.1% (12.6 mg); RP-HPLC purity: 98.9%.
1H NMR (500 MHz, DMSO-d6): 12.73 (1H, s), 6.41 (1H, s), 6.38 (1H, d, J = 1.9 Hz), 6.18 (1H, d, J = 1.9 Hz),
6.08 (1H, br s), 2 × 2.26 * (d, J = 4.7 Hz), 2 × 2.17* (d, J = 4.7 Hz). 13C NMR (125 MHz, DMSO-d6):
209.6, 182.0, 174.3, 164.5, 161.4, 157.6, 104.7, 103.6, 98.9, 94.0, 70.2, 2 × 35.7, 2 × 33.7. ESI-MS (m/z):
293.5 [M-H]−.
Compound 16: White solid, Isolated yield: 40.5% (8.2 mg); RP-HPLC purity: 95%. 1H NMR
(500 MHz, DMSO-d6): 12.65 (1H, s), 10.96 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.34 (1H, s), 6.20 (1H,
d, J = 1.9 Hz), 3.21 (3H, s), 2.52* (br d, J = 6.1 Hz) 2.33* (br d, J = 6.1 Hz), 2 × 2.18* (m). 13C NMR
(125 MHz, DMSO-d6): 209.1, 181.7, 168.9, 164.6, 161.4, 157.8, 107.6, 103.8, 99.0, 94.1, 75.7, 51.0, 2 × 35.4,
2 × 30.4. ESI-MS (m/z): 307.4 [M-H]−.
Compound 17: Pale pink solid, Isolated yield: 60.6% (12.1 mg); RP-HPLC purity: 96%. 1H NMR
(500 MHz, DMSO-d6): 12.66 (1H, s), 10.94 (1H, br s), 6.39 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.21 (1H, d,
J = 1.9 Hz), 3.40 (2H, q, J = 6.9 Hz), 2.54* (br d, J = 6.0 Hz), 2.32* (br d, J = 6.0 Hz), 2 × 2.17* (m), 1.16
(3H, t, J = 6.9 Hz). 13C NMR (125 MHz, DMSO-d6): 209.1, 181.7, 169.5, 164.6, 161.4, 157.7, 107.1, 103.8,
99.0, 94.0, 75.4, 58.6, 2 × 35.5, 2 × 30.9, 15.5. ESI-MS (m/z): 321.3 [M-H]−.
Compound 18: White solid, Isolated yield: 51.4% (10.4 mg); RP-HPLC purity: 98%. 1H NMR
(500 MHz, DMSO-d6): 12.64 (1H, s), 10.97 (1H, br s), 6.38 (1H, d, J = 1.9 Hz), 6.32 (1H, s), 6.20 (1H, d,
J = 1.9 Hz), 3.30 (2H, t, J = 6.3 Hz), 2.53* (br d, J = 6.1 Hz), 2.34* (br d, J = 6.1 Hz), 2 × 2.17* (m), 1.55
(2H, m), 0.88 (3H, t, J = 7.3 Hz). 13C NMR (125 MHz, DMSO-d6): 209.6, 182.1, 169.7, 165.1, 161.9, 158.2,
107.8, 104.3, 99.5, 94.5, 75.5, 64.9, 2 × 35.9, 2 × 31.3, 23.2, 11.1. ESI-MS (m/z): 335.5 [M-H]−.
Compound 19: White solid, Isolated yield: 55.8% (11.3 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.62 (1H, s), 11.01 (1H, br s), 6.42 (1H, s), 6.39 (1H, d, J = 1.9 Hz), 6.21 (1H,
d, J = 1.9 Hz), 3.81 (1H, septet, J = 6.1 Hz), 2.53* (br d, J = 5.9 Hz), 2.39* (br d, J = 5.9 Hz), 2.17* (m),
2.13* (m), 1.01 (6H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 209.4, 181.7, 169.0, 164.8, 161.4,
157.5, 108.0, 103.8, 99.1, 93.9, 75.0, 66.0, 2 × 35.7, 2 × 31.2, 2 × 24.0. ESI-MS (m/z): 335.5 [M-H]−.
Compound 20: White solid, Isolated yield: 73.5% (14.7 mg); RP-HPLC purity: 99%. 1H NMR
(500 MHz, DMSO-d6): 12.64 (1H, s), 10.98 (1H, br s), 6.37 (1H, d, J = 1.7 Hz), 6.32 (1H, s), 6.19 (1H, d,
J = 1.7 Hz), 3.33 (2H, overlap with H2O signal, J = 5.7 Hz), 2.53* (br d, J = 6.1 Hz), 2.34* (br d, J = 6.1 Hz),
2 × 2.17 * (m), 1.52 (2H, m), 1.36 (2H, m), 0.85 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6):
209.2, 181.6, 169.3, 164.7, 161.4, 157.7, 107.4, 103.8, 99.1, 94.0, 75.1, 62.5, 2 × 35.5, 31.6, 2 × 30.8, 18.9, 13.8.
ESI-MS (m/z): 349.8 [M-H]−.
Racemate 21: Pale brown solid; Isolated yield: 24.3% (41.67 mg); RP-HPLC purity at 241 nm:
99.5%. 1H NMR (500 MHz, DMSO-d6): 12.69 (1H, s), 11.45 (1H, s), 6.50 (1H, d, J = 10.1 Hz), 6.35 (1H, s),
6.34 (1H, d, J = 1.8 Hz), 6.32 (1H, d, J = 10.1 Hz), 6.20 (1H, d, J = 1.8 Hz), 3.91 (1H, septet, J = 6.1 Hz),
3.71 (1H, dd, J = 10.0 and 4.4 Hz), 3.18 (3H, s), 3.01 (1H, dd, J = 16.7 and 4.4 Hz), 2.43 (1H, dd, J = 16.7
and 10.0 Hz), 1.11 (3H, d, J = 6.1 Hz), 1.07 (3H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 181.5,
169.9, 164.6, 161.5, 157.6, 152.3, 130.1, 129.9, 108.4, 103.9, 99.1, 94.0, 79.0, 77.9, 67.6, 57.3, 24.03, 24.02,
23.6. ESI-MS (m/z): 374.7 [M-H]−.
Racemate 22: Pale brown solid; Isolated yield: 27.8% (47.43 mg); RP-HPLC purity at 247 nm:
99.9%. 1H NMR (500 MHz, DMSO-d6): 12.68 (1H, s), 11.43 (1H, br s), 6.48 (1H, d, J = 10.0 Hz), 6.33 (1H,
Int. J. Mol. Sci. 2019, 20, 6269 10 of 13
d, J = 2.0 Hz), 6.29 (1H, d, J = 10.0 Hz), 6.25 (1H, s), 6.21 (1H, d, J = 2.0 Hz), 3.76 (1H, dd, J = 10.1 and
4.7 Hz), 3.43 (2H, m), 3.18 (3H, s), 3.03 (1H, dd, J = 16.8 and 4.7 Hz), 2.45 (1H, dd, J = 16.8 and 10.2 Hz),
1.50 (2H, m), 1.32 (2H, m), 0.85 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz, DMSO-d6): 181.4, 168.5, 164.5,
161.5, 157.8, 152.2, 130.1, 129.7, 108.2, 103.9, 99.1, 94.0, 78.6, 77.7, 64.1, 57.5, 31.8, 23.7, 18.8, 13.7. ESI-MS
(m/z): 388.0 [M-H]−.
Racemate 23: Pale brown solid; Isolated yield: 25.1% (43.11 mg); RP-HPLC purity at 248 nm:
99.8%. 1H NMR (500 MHz, DMSO-d6): 12.67 (1H, s), 11.52 (1H, s), 6.52 (1H, d, J = 10.0 Hz), 6.33 (1H, d,
J = 1.9 Hz), 6.32 (1H, s), 6.29 (1H, d, J = 10.0 Hz), 6.21 (1H, d, J = 1.9 Hz), 4.27 (1H, dd, J = 15.7 and
2.3 Hz), 4.18 (1H, dd, J = 15.7 and 2.3 Hz), 3.80 (1H, dd, J = 10.2 and 4.7 Hz), 3.46 (1H, t, J = 2.3 Hz),
3.18 (3H, s), 3.07 (1H, dd, J = 16.7 and 4.7 Hz), 2.43 (1H, dd, J = 16.7 and 10.2 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 167.8, 164.5, 161.5, 157.7, 152.1, 130.8, 128.7, 108.4, 104.0, 99.1, 94.1, 80.5, 78.33, 78.31,
77.5, 57.4, 53.3, 23.7. ESI-MS (m/z): 370.3 [M-H]−.
Racemate 24: Pale brown solid; Isolated yield: 29.6% (50.76 mg); RP-HPLC purity at 246 nm:
97.3%. 1H NMR (500 MHz, DMSO-d6): 12.66 (1H, s), 11.38 (1H, s), 6.47 (3H, m, overlapping signals),
6.36 (1H, d, J = 1.9 Hz), 6.21 (1H, d, J = 1.9 Hz), 3.84–3.92 (2H, m, overlapping signals), 3.12 (1H, dd,
J = 12.3 and 4.2 Hz), 3.10 (3H, s), 2.52 (1H, dd, J = 3.4 Hz; partially overlapped with DMSO signal),
1.04 (3H, d, J = 6.1 Hz), 0.97 (3H, d, J = 6.1 Hz). 13C NMR (125 MHz, DMSO-d6): 181.5, 168.7, 164.7,
161.5, 157.4, 151.1, 130.1, 127.3, 108.9, 103.9, 99.1, 93.8, 78.2, 76.6, 66.6, 56.9, 24.4, 23.8, 22.7. ESI-MS (m/z):
374.7 [M-H]−.
Racemate 25: Pale brown solid; Isolated yield: 33.2% (56.64 mg); RP-HPLC purity at 247 nm:
99.7%. 1H NMR (500 MHz, DMSO-d6): 12.65 (1H, br s), 11.39 (1H, s), 10.92 (1H, br s), 6.48 (1H, d,
J = 10.3 Hz), 6.42 (1H, s), 6.36 (1H, d, J = 10.3 Hz), 6.32 (1H, d, J = 2.1 Hz), 6.21 (1H, d, J = 2.1 Hz), 3.90
(1H, br t, J = 4.3 Hz), 3.45 (1H, m), 3.28 (1H, m), 3.15 (3H, s), 3.02 (1H, dd, J = 17.4 and 5.1 Hz), 2.61
(1H, dd, J = 17.4 and 3.9 Hz), 1.45 (2H, m), 1.30 (2H, m), 0.82 (3H, t, J = 7.4 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 168.0, 164.5, 161.5, 157.5, 151.1, 130.1, 127.6, 108.7, 103.9, 99.1, 93.8, 78.0, 77.3, 62.8,
57.2, 31.6, 23.3, 18.7, 13.6. ESI-MS (m/z): 388.2 [M-H]−.
Racemate 26: Pale brown solid; Isolated yield: 31.8% (54.62 mg); RP-HPLC purity at 248 nm:
97.3%. 1H NMR (500 MHz, DMSO-d6): 12.65 (1H, s), 11.48 (1H, s), 6.53 (1H, d, J = 10.3 Hz), 6.44 (1H, s),
6.40 (1H, d, J = 10.3 Hz), 6.34 (1H, d, J = 1.9 Hz), 6.20 (1H, d, J = 1.9 Hz), 4.21 (1H, dd, J = 15.8 and
2.3 Hz), 4.15 (1H, dd, J = 15.8 and 2.3 Hz), 3.93 (1H, dd, J = 4.6 and 3.6 Hz), 3.39 (1H, t, J = 2.3 Hz),
3.14 (3H, s), 3.04 (1H, dd, J = 17.4 and 4.6 Hz), 2.57 (1H, dd, J = 17.4 and 3.6 Hz). 13C NMR (125 MHz,
DMSO-d6): 181.5, 167.1, 164.6, 161.5, 157.5, 151.0, 131.1, 126.0, 109.0, 104.0, 99.1, 93.9, 80.3, 77.9, 77.6,
77.4, 57.2, 52.1, 23.1. ESI-MS (m/z): 370.2 [M-H]−.
Racemate 27: Pale white solid; Isolated yield: 48.3% (30.5 mg); RP-HPLC purity at 247 nm: 96.1%.
1H NMR (500 MHz, DMSO-d6): 12.75 (1H, s), 10.34 (1H, s), 6.37 (1H, d, J = 1.9 Hz), 6.36 (1H, s), 6.18
(1H, d, J = 1.9 Hz), 5.84 (1H, br s), 3.08 (1H, br d, J = 14.2 Hz), 2.45 (1H, td, J = 13.4 and 4.9 Hz), 2.21 (1H,
m), 2.06 (1H, m), 1.98 (1H, td, J = 12.9 and 4.6 Hz), 1.80–1.89 (3H, m, overlapping signals). 13C NMR
(125 MHz, DMSO-d6): 182.1, 174.9, 164.4, 161.4, 157.6, 155.4, 104.5, 103.6, 98.9, 94.0, 71.2, 34.6, 33.3, 26.3,
18.8. ESI-MS (m/z): 304.4 [M-H]−.
Racemate 28: Pale white solid; Isolated yield: 42.1% (26.4 mg); RP-HPLC purity at 250 nm: 96.6%.
1H NMR (500 MHz, DMSO-d6): 12.66 (1H, s), 10.36 (1H, s), 6.38 (1H, d, J = 1.9 Hz), 6.27 (1H, s), 6.19
(1H, d, J = 1.9 Hz), 3.28 (2H, t, J = 6.1 Hz), 3.05 (1H, br d, J = 14.4 Hz), 2.33 (1H, td, J = 13.9 and 5.4 Hz),
2.16–2.23 (3H, m, overlapping signals), 1.98 (1H, td, J = 13.6 and 5.1 Hz), 1.87 (1H, td, J = 14.2 and
4.3 Hz), 1.78 (1H, td, J = 13.3 and 4.6 Hz), 1.49 (2H, m), 1.35 (2H, m), 0.84 (3H, t, J = 7.4 Hz). 13C NMR
(125 MHz, DMSO-d6): 181.7, 170.0, 164.5, 161.4, 157.7, 155.0, 107.1, 103.8, 99.0, 94.0, 76.0, 62.2, 31.8, 31.6,
30.6, 26.2, 18.9, 18.8, 13.8. ESI-MS (m/z): 360.5 [M-H]-.
3.3. Cell Lines and Viruses
The U373-CD4-CCR5 cell line was obtained from the AIDS Research and Reagent Program, NIAID.
Cells were cultured according to the protocol of the provider with 10% heat-inactivated fetal bovine
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serum (Lonza, Maastricht, The Netherlands) supplemented with 2 mM l-glutamine, 100 units/mL of
penicillin, and 100 µg/mL streptomycin (Invitrogen, Merelbeke, Belgium). Pseudotyped viral particules
bearing the ADA HIV Env were produced, as described previously [25].
EBV-positive BL cell line P3HR1 cells were cultured in RPMI 1640 medium [26,27]. Culture media
were supplemented with 10% fetal calf serum. P3HR1 cells were treated with 3 mM sodium butyrate
and 30 nM 12-O-tetradecanoylphobol-13-actetae (TPA) to induce the EBV lytic cycle [26,27].
3.4. Anti-HIV Testing
Antiviral activity was assessed while using a Pseudotype Virus Assay, allowing for one cycle of viral
replication [25]. The U373-CD4-CCR5 cells were infected by pseudotyped virus pNL4.3∆envLuc-ADA
8 using spinoculation at 1200 g during 2 h in the presence of compounds and cultured for two
consecutive days in the presence of the compounds. After 48 h, luciferase activity expressed as Relative
Light Units was measured (Luciferase System kit, Promega, The Netherlands). Drug cytotoxicity was
evaluated while using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma,
Belgium) 48 h after incubation with the compounds by measuring A540 and A690 using a POLARstar
Omega Plate Reader (BMG Lab Technologies, Belgium) after 48 h of incubation with the compounds.
The value of OD540–OD690 was calculated.
3.5. Immunoblot Analysis of EBV Rta Protein
P3HR1 cells were lysed in mRIPA buffer (50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM EDTA,
0.5% Triton X-100, 0.5% NP-40) [26,27]. Approximately 5% of the lysate was loaded to a gel and
then separated by electrophoresis in 10% SDS-PAGE. The proteins in the gel were electroblotted
onto a polyvinylidene difluoride (PVDF) blotting membrane while using a Hoefer transfer system.
Rta was detected while using mouse anti-Rta monoclonal antibody (Argene, Verniolle, France).
α-Tubulin was detected using mouse anti-α-tubulin monoclonal antibody (Abcam, Cambridge, UK).
Primary antibodies were detected using horseradish peroxidase-conjugated secondary antibodies
(Cell Signaling Technology, Danvers, MA, USA) and then visualized using SuperSignal West Pico
Chemiluminescent substrate (Thermo Fisher Scientific, Waltham, MA, USA).
3.6. Cytotoxicity Assay
P3HR1 cells (5 × 104) were seeded in wells of a 96-well plate and then cultured for 24 h in 100 µL
of RPMI 1640 medium containing protoapigenone or its analogs. Subsequently, 1% Triton X-100 was
added as a negative control. Cytotoxicity was determined by Cell Proliferation Kit I (Roche, Basel,
Switzerland). An aliquot of 10 µL of the MTT labeling reagent was added to each well and the plate
was incubated for 4 h at 37◦C. Afterwards, 100 µL solubilization solution was added to each well to
dissolve insoluble formazan and was incubated overnight. Optical density was measured at 595 nm
and 650 nm.
4. Conclusions
As a result of this work, the chemical space of non-cytotoxic protoflavonoids was significantly
extended through the preparation of derivatives without the symmetric dienone moiety, such as
saturated (hydrogenated or deuterated) B-ring and/or 4′-oxime containing protoflavones. Compound 9
was found to exert a weak antiretroviral activity that, due to the extremely low cytotoxicity
of this compound, might still be of interest. Further, three compounds, the isopropyl-, butyl-,
and propargyl-ether derivatives of protoapigenone were identified to act as potent anti-EBV agents
at similar, medium-low nanomolar concentration range as their parent compound 2. Importantly,
protoapigenone 1′-O-isopropyl ether demonstrated an order of magnitude lower cytotoxic effect when
compared to protoapigenone, which makes compound 6 ca. 2.6-times more selective anti-EBV agent.
Therefore, this compound can serve as a possible new lead for the development of safe and effective
protoflavone derivatives against the lytic cycle of EBV.
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Altogether, as a result of this work, it might also be concluded that targeted chemical modifications
of the protoflavone B-ring to decrease cytotoxicity represent a valid strategy towards the discovery of
new bioactive compounds against pathologies other than cancer.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6269/s1.
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